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ABSTRACT 
 
SHANA HARRINGTON:  Comparison of Shoulder Kinematics, Flexibility, Strength, 
and Function between Breast Cancer Survivors and Healthy Participants 
(Under the direction of Dr. Darin A. Padua) 
 
 
The present study compared shoulder kinematics, flexibility, strength, and 
function between breast cancer survivors and healthy, matched participants.  Twenty four 
breast cancer survivors and twenty four matched controls completed the Disabilities of 
Arm, Shoulder, and Hand (DASH) and the Pennsylvania Shoulder Score (PSS) outcome 
measure questionnaires.  Clinical measures of shoulder active (AROM) and passive 
(PROM) range of motion, cervical AROM, and shoulder strength were analyzed. 
Participants also had scapular kinematics assessed during the elevation phase of three 
tasks: flexion, scaption, and reaching.  The results indicated statistically significant 
differences with the breast cancer survivors demonstrating decreased scores on the 
DASH and  PSS, decreased  AROM and PROM flexion and 90° ER, decreased AROM 
extension, and decreased strength for the  measures of scapula abduction and upward 
rotation, scapula depression and adduction, shoulder flexion, shoulder adduction, 
shoulder internal and external rotation, and scaption.  Kinematic analysis revealed a main 
effect for group during the scaption task for protraction/retraction with the breast cancer 
survivors demonstrating greater protraction throughout arm elevation.  Correlation 
analyses revealed a relationship with the DASH to AROM flexion, PROM flexion and 
90° ER, strength measures of scapula abduction and upward rotation, scapula depression 
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and adduction, shoulder flexion, shoulder adduction, shoulder internal, and scaption, and 
cervical spine AROM left rotation.  The PSS was found to correlate with AROM flexion, 
PROM flexion and 90° ER, strength measures of shoulder flexion, shoulder adduction, 
shoulder internal, and scaption, and cervical spine AROM left sidebending, left rotation, 
and right rotation.  The results demonstrate the ROM measures of humeral flexion and 
humeral ER at 90º appear to be affected in the breast cancer survivor population.  All 
seven of the strength measures assessed in this study were found to be decreased in the 
breast cancer survivor cohort.  Finally, increased scapula protraction is another key 
finding.  The results from this study provide preliminary evidence to suggest that 
clinicians focus on these particular ROM and strength measures when treating a breast 
cancer survivor who has recently completed their primary treatment.  Results from this 
study also show women who have recently completed their primary breast cancer 
treatment appear to have function deficits as revealed in this study when using outcome 
measures such as the DASH and PSS.   
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CHAPTER I 
INTRODUCTION 
1.1 Breast Cancer 
Breast cancer accounts for approximately 1/3 of all cancers diagnosed in American 
women.1  In the United States, breast cancer is the most common non-skin cancer and the 
second leading cause of cancer related death in women.2  The overall breast cancer death 
rate has dropped steadily since the early 1990’s, although the breast cancer diagnosis rate 
has increased.2  The National Cancer Institute estimates that more than $8 billion is spent 
each year in the United States on the treatment of breast cancer.2  It has also been 
estimated that the number of cancer patients receiving treatment will increase threefold 
over the next 30 years, causing many to speculate that oncology may soon exceed 
cardiology as the most costly medical field in the United States.3  Because of the 
increased number of women diagnosed with breast cancer, which can be most likely be 
attributed to improved technology and early detection, approximately 2.5 million women 
in the United States who have been diagnosed with and treated for breast cancer.4  
Approximately 89% of women diagnosed with breast cancer survive for 5 years or 
longer.4  These statistics draw attention to the number of women experiencing, as well as 
surviving breast cancer.   While survival rates continue to improve, the focus on 
survivorship issues and quality of life related to breast cancer treatment has now gained 
significantly more attention.5  Therefore, it is imperative that these women be afforded 
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the best possible care to manage the after effects of breast cancer treatment in order to 
restore function and live a healthy life. 
1.2 Breast Cancer Treatment and Side Effects 
 Women diagnosed with breast cancer can be treated in a variety of ways 
depending upon several factors such as age, stage of cancer, location of tumor, size of the 
tumor, lymph node status, estrogen/progesterone receptors, and her-2-neu receptors.  The 
most common types of breast cancer treatment include surgery, hormone therapy, 
chemotherapy, and/or radiation.  Due to these treatments, many women experience 
secondary complications not only from the disease of breast cancer itself but because of 
its treatments.  These secondary complications include decreased quality of life, weight 
gain, poor body image, fatigue,6  increased risk for osteoporosis, cardiovascular disease, 
premature menopause, and lymphedema.7 More specifically a loss of energy, pain, 
muscular weakness, a decrease in lean mass, and a reduction in total body flexibility and 
agility can contribute to the decrease in general activities of daily living, impacting an 
individual’s overall quality of life.3  Many of the side effects from cancer treatment are 
often debilitating and leave the individual with the inability to function at their pre-cancer 
level.3 
Traditionally, management of breast cancer often primarily focuses on tumor 
response to treatment and survival rate.9  However, there has been a recent interest in 
examining the physical morbidities associated with breast cancer survivorship.8  In a 
study conducted by Isaksson and Feuk, 21% of the 45 breast cancer survivors in the study 
reported restricted arm/shoulder movements and 23% reported upper extremity pain six 
months after surgery, while 1 – 2 years after surgery, 13% reported weakness, 9% 
3 
 
complained of restricted arm/shoulder movements, and 9% described pain in their upper 
extremity.9  Higher prevalence levels of reported weakness, restricted arm/shoulder 
movements, and pain in the upper extremity have been reported in other studies 
examining breast cancer survivors.10  Among 233 women with newly diagnosed breast 
cancer, 82% stated having at least one arm problem, 55% reported pain, 40% complained 
of stiffness, 32% had limited arm movements, and 26% reported weakness 3 months after 
surgery, with little change 15 months later.10  While some research has demonstrated that 
arm-related complaints usually decrease within three months of treatment11, these 
complaints may become chronic to the extent that the arm dysfunction related to breast 
cancer is often underestimated.12  Many of the studies examining upper extremity 
dysfunction in breast cancer survivors incorporate a broad selection of inclusion criteria 
making it impossible to determine what aspects of breast cancer treatment contribute to 
impairments.  Therefore, the limited amount of research and conflicting results warrants 
that continued research should be undertaken to determine the factors contributing to 
these impairments in breast cancer survivors. 
1.3 Limitations in Previous Breast Cancer Research 
Given the significant impact that breast cancer has on individuals, it is evident 
that the breast cancer care continuum should include evidence based supportive 
therapeutic services to help the individual limit fatigue, deconditioning, and upper 
extremity dysfunction during and following treatment.3  While arm disability appears to 
be a problem in breast cancer survivors, there is little known regarding shoulder function.  
Two aspects regarding breast cancer research have not been established as of this date.  
These include, 1) understanding what differences occur due to breast cancer and its 
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treatment and 2) understanding the role of scapula and clavicle kinematics in these 
individuals.  Specifically, it is important rehabilitation professionals have an appreciation 
of the following clinical variables:  affected shoulder girdle strength, shoulder active 
ROM, shoulder passive ROM, and cervical ROM.  These variables are imperative for 
rehabilitation professionals to recognize clinically in order to better understand what may 
be driving the upper extremity dysfunction that has been recognized recently in the breast 
cancer survivor population.  Preliminary evidence suggests weakness in previous study 
designs involving breast cancer survivors.  There have been no studies that have 
compared breast cancer survivors to healthy age, matched, and gender controls in order to 
establish baseline data of the exact deficits these women experience regarding range of 
motion, strength, and upper extremity function.  Furthermore, no one has examined what 
differences may be occurring with regards to scapula and clavicle kinematics in breast 
cancer survivors.  Research has demonstrated individuals with shoulder impairments such 
as subacromial impingement syndrome demonstrate altered scapula kinematics when 
compared to healthy controls.13-20  Scapula motions are key components of shoulder 
function, and understanding what scapula and clavicle kinematic differences may exist in 
this population could provide clinicians with an enhanced understanding of the role the 
scapula and clavicle might have regarding pain and function, as well as prevention of 
dysfunction, in the breast cancer population.  Results from this study hope to add to the 
body of knowledge for rehabilitation professionals who work with breast cancer 
survivors experiencing arm disability that affects function.  Therefore, the primary 
purpose of this study was to examine differences that may exist between breast cancer 
survivors and healthy age, matched, and gender controls for upper extremity function, 
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strength, shoulder active ROM, shoulder passive ROM, cervical active ROM, and 
scapula and clavicle kinematics during humeral elevation tasks of reaching, elevation in 
the sagittal plane, and elevation in the scapula plane (30 anterior to the frontal plane of 
the thorax) on the affected side.  A secondary purpose of this study was to assess if 
relationships exist in the breast cancer survivor population between functional scores on 
the DASH and PSS with affected active shoulder ROM, affected passive shoulder ROM, 
cervical active ROM, and affected shoulder girdle strength. 
1.4 Research Questions 
RQ1. Are there significant differences between breast cancer survivors and matched 
controls on shoulder function (DASH and PSS)? 
a. Function  
a. Disabilities of the Arm, Shoulder, and Hand (DASH) Scores 
b. University of Pennsylvania Shoulder (PSS) Scores 
RQ2. Are there significant differences between breast cancer survivors and matched 
controls on shoulder girdle strength, shoulder active ROM, shoulder passive ROM, 
cervical ROM, and 3D kinematics? 
a. Affected shoulder girdle strength 
a. Scapula abduction and upward rotation 
b. Scapula depression and adduction 
c. Humeral flexion 
d. Humeral IR 
e. Humeral ER 
f. Shoulder Scaption 
g. Shoulder horizontal adduction 
b. Affected shoulder girdle active shoulder ROM 
a. Supine flexion 
b. Supine ER at 0 
c. Supine ER at 90 
d. Supine IR at 0 
e. Prone extension 
c. Affected extremity passive shoulder ROM 
a. Supine flexion 
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b. Supine ER at 0 
c. Supine ER at 90 
d. Supine IR at 0 
e. Prone extension 
d. Cervical spine Active ROM 
a. Flexion 
b. Extension 
c. Left side bending 
d. Right side bending 
e. Left rotation 
f. Right rotation 
e. 3D kinematic variables 
a. Scapula anterior/posterior tipping 
b. Scapula upward/downward rotation 
c. Scapula internal/external rotation 
d. Clavicle elevation/depression 
e. Clavicle protraction/retraction 
 
RQ3. Is shoulder active shoulder ROM, passive shoulder ROM, shoulder girdle strength, 
or active cervical ROM correlated to scores on the DASH in breast cancer survivors? 
a. Active shoulder ROM 
b. Passive shoulder ROM 
c. Shoulder girdle strength 
d. Active cervical ROM 
 
RQ4. Is shoulder active shoulder ROM, passive shoulder ROM, shoulder girdle strength, 
or active cervical ROM correlated to scores on the PSS in breast cancer survivors?  
a. Active shoulder ROM 
b. Passive shoulder ROM 
c. Shoulder girdle strength 
d. Active cervical ROM 
1.5 Research Hypotheses 
RH1. There will be significant differences between breast cancer survivors and matched 
controls on shoulder function. 
a. Breast cancer survivors will demonstrate the following differences when 
compared to matched controls: 
a. Function 
7 
 
i. Increased DASH Scores 
ii. Decreased PSS Scores 
 
RH2.  There will be significant differences between breast cancer survivors and matched 
controls on shoulder girdle strength, shoulder active ROM, shoulder passive ROM, active 
cervical ROM, and 3D kinematics.  
a. Breast cancer survivors will demonstrate the following differences when 
compared to matched controls: 
a. Shoulder girdle strength 
i. Decreased scapula abduction and upward rotation 
ii. Decreased scapula depression and abduction 
iii. Decreased humeral flexion 
iv. Decreased humeral internal rotation 
v. Decreased humeral external rotation 
vi. Decreased shoulder scaption 
vii. Decreased shoulder horizontal adduction 
b. Active shoulder ROM 
i. Decreased supine flexion 
ii. Decreased supine ER at 0° 
iii. Decreased supine ER at 90° 
iv. Decreased supine IR at 90° 
v. Decreased prone extension 
c. Passive shoulder ROM 
i. No differences in supine flexion 
ii. No differences in supine ER at 0° 
iii. No differences in supine ER at 90° 
iv. No differences in supine IR at 90° 
v. No differences in prone extension 
d. Active cervical ROM 
i. Decreased flexion 
ii. Decreased extension 
iii. Decreased left side bending 
iv. Decreased right side bending 
v. Decreased left rotation 
vi. Decreased right rotation 
e. Scapula kinematics 
i. Increased scapula anterior tipping 
ii. Increased scapula upward rotation 
iii. Increased scapula internal rotation 
iv. Increased clavicle elevation 
v. Decreased clavicle protraction  
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RH3.  There will be a significant negative relationship between active shoulder ROM, 
shoulder passive ROM,  shoulder girdle strength, and active cervical ROM to scores on 
the DASH in breast cancer survivors. 
a. Variables of Interest 
a. DASH 
b. Active shoulder ROM 
c. Passive shoulder ROM 
d. Shoulder girdle strength 
e. Active cervical ROM 
 
RH4.  There will be a significant positive relationship between active shoulder ROM, 
shoulder passive ROM,  shoulder girdle strength, and active cervical ROM to scores on 
the PSS in breast cancer survivors. 
b. Variables of Interest 
a. PSS 
b. Active shoulder ROM 
c. Passive shoulder ROM 
d. Shoulder girdle strength 
e. Active cervical ROM 
 
1.6 Operational Definitions 
Affected side:  The side, right or left, that the breast cancer was diagnosed and treated. 
Ascending phase:  Humeral motion from baseline (resting position) until the participant’s 
maximum humeral elevation angle is achieved. 
Scapula plane:  Defined as 30 anterior to the frontal plane of the thorax 
Humeral elevation task of reaching:   The participants imagined that they were holding a 
soup can while placing their ulna styloid at a target that was positioned perpendicular to 
the affected AC joint on a shelf with the hand held in neutral rotation.  The shelf was 
positioned so that the goal for the task was to move the arm from a height equal to the 
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participant’s greater trochanter to a shelf at a height which allowed for extension of the 
elbow.  A standard goniometer was used to ensure the humeral elevation relative to each 
participant’s trunk was greater than 120 and that the elbow was comfortably extended. 
Humeral elevation in the frontal plane:  The participant was standing and a pole 
constructed of PVC pipe served as a guide in order for participants to maintain the proper 
plane of movement during the glenohumeral elevation task in the sagittal plane.  This 
guide was placed in the sagittal plane in line with the affected side acromion and 
participants began with their arm at rest by their side and proceeded to full humeral 
elevation.  The participants were asked to maintain a neutral hand position in which the 
palm of their hand lightly touched the PVC guide during the elevation task while their 
thumb was pointed towards the ceiling. 
Humeral elevation in the scapula plane (30 anterior to the frontal plane of the thorax):  
The participant was standing and a pole constructed of PVC pipe served as a guide in 
order for participants to maintain the proper plane of movement during the glenohumeral 
elevation task in the scapula plane.  This guide was placed 30 anterior to the frontal 
plane of the thorax, where a piece of tape was placed on the ground, and was confirmed 
using a standard goniometer.  Participants began with their arm at rest by their side and 
proceeded to full humeral elevation.  The participants were asked to maintain a neutral 
hand position in which the palm of their hand lightly touched the PVC guide during the 
elevation task while their thumb was pointed towards the ceiling. 
Baseline humeral elevation:  The angle of humeral elevation when the arm is at rest 
beside the participant. 
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Ascending phase of motion:  Humeral motion from baseline humeral elevation until the 
participant’s maximum humeral elevation angle 
Beginning of phase:  Defined as the point when the humeral elevation angle is greater 
than the baseline humeral elevation angle for 10 consecutive frames. 
End of phase:  Defined as the point when the humeral elevation angle is equal to the 
baseline humeral elevation angle for 10 consecutive frames. 
Shoulder girdle strength:  Represents the peak force during a 5 second muscle 
contraction, measured in pounds (lbs.) 
Active range of motion:  Defined as the amount of joint motion attained by a participant 
during unassisted voluntary joint motion, measured in degrees. 
Passive range of motion:  Defined as the amount of motion attained by the principal 
investigator without assistance from the participant. 
Scapula anterior/posterior tipping:  Scapula motion that occurs about an axis through the 
scapula spine.  Posterior tipping rotates so that the anterior acromion moves upwards 
during humeral elevation and reverses this path during descending humeral elevation. 
Scapula upward/downward rotation:  Scapula motion that occurs about an axis 
approximately perpendicular to the scapula.  Upward rotation moves toward a position so 
that the glenoid faces superiorly during humeral elevation and downward rotation moves 
toward a position where the glenoid faces inferiorly during the descending phase of 
humeral elevation. 
Scapula internal/external rotation:  Scapula motion that occurs about the long axis of the 
scapula.  Internal motion is motion which moves toward a position where the glenoid 
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faces anteriorly and external rotation moves toward a position where the glenoid faces 
posteriorly. 
Clavicle elevation/depression:  Clavicle motion that occurs along the joints anterior-
posterior axis. 
Clavicle protraction/retraction:  Clavicle motion that occurs along the joints vertical axis. 
1.7 Assumptions/Limitations 
The following limitations and assumptions apply to this study: 
1.  Participants self-reported information was both honest and unbiased. 
2. Kinematic data obtained from the skin mounted sensors on the scapula and 
humerus were representative of the true motion of these segments 
3.  Participants provided a true maximal voluntary isometric contraction during 
strength data collection 
4. Participants performed to the best of their ability on all functional tasks and 
ROM measures 
5. No subject randomization 
6. No blinding of the researcher 
1.8 Delimitations 
The following delimitations apply to this study: 
1. Forty-eight participants (24 breast cancer survivors and 24 healthy, matched, 
controls) were recruited from the University and the Chapel Hill surrounding 
community. 
2.  All control participants had no history of shoulder and neck injury in the past 6 
months prior to data collection. 
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3. Kinematic data was collected from the thorax, scapula, and humerus using an 
electromagnetic tracking system. 
1.9 Independent Variables 
Four independent variables were used in this study: 
1. Group 
a. breast cancer survivors  
b. healthy, matched controls 
 
2. Phase of humeral elevation   
a. ascending  
 
3. Humeral elevation angle  
a. 0 (start)  
b. 30  
c. 60 
d. 90 
e. max (reaching task only) 
 
 4. Functional task 
  a. Humeral elevation task of reaching 
  b. Humeral elevation in the sagittal plane 
  c. Humeral elevation in the scapula plane 
 
1.10 Dependent Variables 
Seven categories of dependent variables were used in this study: 
 
1. Function  
a. DASH Scores 
b. PSS Scores 
 
2. Affected shoulder girdle strength 
a. Shoulder abduction and upward rotation 
b. Scapula depression and adduction 
c. Humeral flexion 
d. Humeral IR 
e. Humeral ER 
f. Shoulder scaption 
g. Shoulder horizontal adduction 
3. Affected active shoulder ROM 
a. Supine flexion 
b. Supine ER at 0° 
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c. Supine ER at 90° 
d. Supine IR at 90° 
e. Prone extension 
4. Affected passive shoulder ROM 
a. Supine flexion 
b. Supine ER at 0° 
c. Supine ER at 90° 
d. Supine IR at 90° 
e. Prone extension 
5. Cervical active ROM 
 a. Cervical forward bending 
 b. Cervical backward bending 
 c. Cervical left side bending 
 d. Cervical right side bending 
 e. Cervical left rotation 
 f. Cervical right rotation 
 
6. Scapula Kinematics 
 a. Scapula anterior/posterior tipping 
 b. Scapula upward rotation/downward rotation 
 c. Scapula internal/external rotation 
 
7. Clavicle Kinematics 
 a. Clavicle elevation/depression 
 b. Clavicle protraction/retraction 
 
1.11 Significance 
The overall goal of this study was to compare function, affected shoulder girdle 
strength, affected active shoulder ROM, affected passive shoulder ROM, cervical active 
ROM, and 3D scapula and clavicle kinematics between breast cancer survivors and 
matched controls.  The secondary goal of this study was to assess if any relationships 
exist in the breast cancer survivor population between functional scores on the DASH 
and PSS with affected shoulder girdle strength, affected active shoulder ROM, affected 
passive shoulder ROM, and cervical active ROM.  These goals were accomplished by 
comparing 24 individuals who have a known diagnosis of breast cancer to 24 individuals 
who were considered healthy, matched controls.  Selected scapula and clavicle kinematic 
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variables were compared between the groups during three humeral elevation tasks.  This 
is a unique study because there have been no prior comparisons of breast cancer survivors 
who have completed their treatment measuring upper extremity strength, shoulder 
AROM, shoulder PROM and cervical AROM to healthy, matched controls.  Also, no 
studies have examined breast cancer survivors’ scapula and clavicle kinematics during 
functional tasks.  Understanding what differences exist with regards to function, affected 
shoulder girdle strength, affected active shoulder ROM, affected passive shoulder ROM, 
cervical active ROM, and scapula and clavicle kinematics between breast cancer 
survivors and matched controls will provide rehabilitation professionals with evidence 
based data that may assist clinicians in providing the best care possible when treating 
breast cancer survivors who present with shoulder dysfunction.  This study has the ability 
to answer two significant missing pieces in the research literature regarding breast cancer 
survivors who have recently completed (within the past 6 months) their primary treatment 
of surgery, chemotherapy/and or radiation. The information from this study could help 
with future endeavors in reducing the impact of shoulder dysfunction for this group of 
women to provide them with the ability to return to a normal level of function. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
Introduction 
 There are over 2.5 million women in the United States who are either living with 
or who have battled breast cancer.21  Research has shown that these women may suffer 
from both psychological and physical long term consequences from not only the 
diagnosis of the breast cancer, but also the treatments these women receive.  Because of 
this, there is a need to provide these women with the best possible care to allow them to 
return to their prior level of function before the initial diagnosis of breast cancer. 
This literature review will provide a background on what is breast cancer, 
common treatments women who have been diagnosed with breast cancer receive, and 
how these treatments affect function, pain, shoulder girdle strength, shoulder range of 
motion (ROM), and quality of life.  Since no studies to date have examined scapular 
kinematics in breast cancer survivors, the current understanding of scapular kinematics 
will be discussed in other populations who suffer from shoulder dysfunction.  This review 
will also examine the current limitations in breast cancer research in order to provide 
supportive rationale for conducting this research study. 
2.1 What is Cancer 
Cancer is the universal name for a group of more than 100 diseases in which cells 
in a part of the body begin to grow out of control.  All cancers start because atypical cells 
grow out of control. If left untreated, cancer can cause serious illness and even death.  In 
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a healthy individual, normal body cells grow, divide, and die in an orderly fashion. 
During the early years of a person's life, normal cells divide more quickly until the person 
becomes an adult. As a person ages, cells in most parts of the body divide only to replace 
depleted or dying cells and to repair injuries.  Cancer cells often develop because of 
damage to deoxyribonucleic acid (DNA). DNA is in every cell and directs all of the cell's 
processes. In most cases, when DNA becomes damaged, either the cell dies or is able to 
repair the DNA, however, in cancer cells; the damaged DNA is not repaired.  
2.2 What is Breast Cancer 
It is believed that the Egyptians were the first to diagnosis breast cancer around 1600 
B.C. 22  Today, breast cancer is defined as a malignant tumor that starts from cells of the 
breast.  Breast cancers can begin in the cells that line the ducts, known as ductal cancer or 
in the lobules, known as lobular cancer and is classified as either non-invasive or 
invasive.  Non-invasive (or “in situ”) breast cancer is limited to the ducts or lobules and 
do not spread to the surrounding tissues of the body.  Whereas invasive breast cancer is 
when the cancer has started to spread through the normal breast tissue barriers and 
invades surrounding areas.   
In some instances breast cancer may be found in other tissues of the breast. 
2.2.1  Breast Cancer Cost and Incidence  
In 2007, according to the National Institute of Health, cancer cost the United States 
an estimated $219 billion.23  The Center for Disease Control estimates that each year, 
breast cancer treatment costs nearly $7 billion.23  Other than skin cancer, breast cancer is 
the most common cancer in women in the United States.24  After lung cancer, it is the 
second leading cause of cancer death in women.  It is estimated that in the year 2008, 
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182,460 women will be diagnosed with some form of invasive breast cancer in the United 
States.24  Of those, it is estimated that 40,480 will die of this disease.24 The chance of a 
woman being diagnosed in her lifetime with invasive breast cancer is 1 in 8 and the 
chance of a woman dying from invasive breast cancer is 1 in 35.24  Currently in the 
United States there are over 2.5 million breast cancer survivors.24  
2.2.2  Breast Cancer Staging and Survival Rates 
Understanding each stage of breast cancer is important in order to provide the best 
type of treatment to each individual survivor.  Also, breast cancer staging is useful for the 
clinician because of its ability to estimate prognosis.22  Breast cancer is most often 
classified using the tumor-node-metastasis (TNM) system that was developed by Pierre 
Denoix in 1942.22  This system attempts to classify cancer based on the major 
morphological attributes of malignant tumors that were thought to influence disease 
prognosis: size of the primary tumor (T), presence and extent of regional lymph node 
involvement (N), and presence of distant metastases (M).22  In 1977, the American Joint 
Committee on Cancer (AJCC) published a breast cancer staging system based on the 
TNM.22    Since then, regular revisions have been made to reflect advances in diagnosis 
and treatment.22 
 Breast cancer is expressed as a Roman numeral beginning with stage 0 and further 
staged from I through IV.  Some stages are sub-divided using the letters A, B, and C.   In 
general, the lower the number, the less the cancer has spread and the higher the number, 
such as stage IV, means more advanced cancer.  All non-invasive breast cancers such as 
DCIS and LCIS are described as Stage 0.24  Women who have been diagnosed with Stage 
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0 breast cancer have a 5-year relative survival rate of 100%. 24  Breast cancers staged 
from I through IV.   
Stage I breast cancer can be described as having a tumor that measures up to 2 
centimeters and has no lymph node involvement.24  The 5-year relative survival rate for 
this stage is also 100%.24 
Stage II breast cancer is often subdivided into two categories known as IIA and IIB.  
Stage IIA breast cancer has no tumor that can be found in the breast, but cancer cells are 
found in the axillary lymph nodes, or the tumor measures 2 centimeters or less and has 
spread to the axillary lymph nodes, or the tumor is larger than 2 centimeters, but not 
larger than 5 centimeters and has not spread to the axillary lymph nodes.24  Ninety-two 
percent of these women have a 5-year relative survival rate.24  Stage IIB breast cancer is 
described as having a tumor larger than 2 but no larger than 5 centimeters and has spread 
to the axillary lymph nodes, or the tumor is larger than 5 centimeters but has not spread to 
the axillary lymph nodes.24  The 5-year relative survival rate of women in this stage of 
breast cancer is 81%.24 
Stage III breast cancer can be subdivided into three further categories known as IIIA, 
IIIB, and IIIC.  Stage IIIA has no tumor found in the breast.  The cancer in this stage is 
found in the axillary lymph nodes, or the tumor is 5 centimeters or smaller and has spread 
to the axillary lymph nodes, or the tumor is larger than 5 centimeters and has spread to 
the axillary lymph nodes.24  The 5-year relative survival rate of these women is 67%.24  
Stage IIIB describes breast cancer in which the tumor may be any size and has spread to 
the chest wall and/or skin of the breast, and may have spread to axillary lymph nodes.  
Inflammatory breast cancer is considered at least to be a stage IIIB.24  Approximately 
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fifty-four percent of women diagnosed with stage IIIB with survive 5 years.24  With 
breast cancer stage IIIC, there may be no sign of cancer in the breast or, if there is a 
tumor, it may be any size and may have spread to the chest wall and/or the skin of the 
breast and the cancer has spread to lymph nodes above or below the collarbone, and the 
cancer may have spread to the axillary lymph nodes or to lymph nodes near the breast 
bone.24  Survival rates for stage IIIC have not been established because this is a relatively 
new defined stage.24  
 Stage IV breast cancer has spread to other organs of the body, most often the 
lungs, liver, bone or brain.24  The term “metastatic” is used meaning that the breast cancer 
has spread beyond the breast and nearby lymph nodes, despite this being the first 
diagnosis of breast cancer.24  This is because the primary breast cancer was not found 
when it was only inside the breast.  All stage IV breast cancers are metastatic and have a 
5-year relative survival rate of 20%.24 
2.3 Breast Cancer Treatment 
Breast cancer is treated by a variety of combinations of treatment.  These include 
surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy.  
Treatment selection depends on a variety of factors that include age, menopausal status of 
the patient, stage of breast cancer, histologic and nuclear grade of the primary tumor, 
estrogen-receptor (ER) and progesterone-receptor (PR) status, measures of proliferative 
capacity, and HER2/neugene amplification.25  The majority of women who have been 
diagnosed with breast cancer will undergo intensive treatment, often involving multiple 
modalities that are described below.25  What continues to remain unknown are the effects 
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these modalities have on breast cancer survivors.  This is because it is almost impossible 
to tease out the effect of one modality from another.  
2.3.1 Biopsies 
Women who are diagnosed with breast cancer will often undergo one of two types of 
procedures both of which can be performed to identify cancer specifically in the lymph 
nodes.  These two procedures are the Axillary Lymph Node Dissection (ALND) and the 
Sentinal Lymph Node Biopsy (SLNB). 
The status of axillary lymph nodes is an important prognostic factor in breast cancer 
staging and often guides further treatment.26  During an ALND, anywhere from ten to 
forty lymph nodes are removed and then examined under a microscope for cancer.26  
Removal or resection of the pectoral muscles may occur depending on the level of ALND 
which also could involve the surrounding pectoral nerves.26  This procedure is often 
performed in conjunction with a radical or modified radical mastectomy, or 
lumpectomy.26  The presence of cancer cells in the axilla indicates that the cancer has 
spread beyond the breast, thereby worsening the prognosis.27  Despite the advantages of 
ALND negative long-term effects have been found to include pain10, 28-33, numbness10, 28-
30, 32, 33, swelling10, 29, 30, 32-35, weakness10, 29, 30, 32, 33, 36, and decreased sweat production.37  
Furthermore, research has shown that patients who undergo an ALND are 10 times more 
likely to report upper arm complaints.26 
 Due to the considerable arm morbidity often associated with ALND, physicians 
have developed the SLNB within the last decade.26  The SLNB procedure removes fewer 
nodes then the ALND.26  A sentinel node is the first lymph node into which a tumor 
drains.26  These nodes are the ones most likely to contain cancer cells if the cancer has 
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started to spread.26  During a SLNB a small incision is made in the axillary region that is 
approximately ½ inches.38  Following a SLNB, some women may experience pain, nerve 
damage, and/or lympedema.38  If cancer has been found during the SLNB, the next step is 
usually to perform an ALND.  Purushotham et al. conducted as study assessing quality of 
life (QOL) immediately after surgery in 298 women who were diagnosed with early 
breast cancer (tumors 3 cm or less on ultrasound examination).39  Results revealed that 
those who had an ALND had significantly decreased QOL scores when compared to 
those who had a SLNB immediately after surgery.39 
2.3.2 Local Treatment - Radiation 
Localized treatment involves treating a tumor at the site of the cancer without 
affecting the rest of the body.  Examples of localized treatment include surgery and 
radiation.  Radiation therapy is a type of breast cancer treatment using high-energy rays 
or particles that destroy cancer cells.40  Radiation can be administered in two ways: 
through an external beam radiation and brachytherapy.40   The most common type of 
radiation for women with breast cancer is external beam radiation.40  The extent of 
radiation depends on the type of surgical procedure performed and whether lymph nodes 
are involved.40  Brachytherapy is known as “internal radiation”.  This procedure involves 
radioactive seeds or pellets being placed directly into the breast tissue next to the cancer.  
A meta-analysis of 78 randomized controlled trials including approximately 
42,000 women with breast cancer was conducted to determine the effects of 
radiotherapy.41   Results show that radiation after either breast conserving surgery (BCS) 
or mastectomy in women with early breast cancer decreases both 5-year recurrence and 
15-year mortality rates.41  Radiotherapy after mastectomy can reduce the risk of a local 
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recurrence by approximately 2/3 and remains an important component of management 
for breast cancer.40  
Although the beneficial effect of postoperative radiotherapy for breast cancer is 
well documented, there are a number of complications associated with this treatment that 
might affect patients’ QOL and possibly survival.  Long-term radiation complications 
may include cardiac and lung damage, impaired shoulder mobility, and chronic pain.42  
Many studies have found axillary radiation to be a predictive factor for the development 
of shoulder morbidity.43, 44  This is due to the fact that radiation may cause injury to 
normal tissues resulting in changes of the vascular network causing ischemia, ultimately 
affecting the efficacy of muscle contraction.37, 45, 46  The muscles that are most commonly 
affected by radiation are the pectoralis major,47, 48  serratus anterior, and lattisimus 
dorsi.36  Radiation has been shown to cause subcutaneous fibrosis of the pectoralis 
muscles which in turn could be a factor causing shoulder pain and restriction.49, 50  Chest 
wall adhesion may also be a side effect and can lead to increased risk of pain and 
reduction in ROM of the shoulder on the involved side as well as postural dysfunction.51  
Furthermore, soft tissue changes have been reported from the beginning of radiotherapy 
to as late as 3 years after the start.47, 48 
2.3.3 Surgical Procedures 
Most women who have been diagnosed with breast cancer will undergo some type 
of surgical procedure.  The two categories of surgical procedures include breast 
conserving surgery (BCS) and mastectomy.  Breast conserving surgery can be subdivided 
into lumpectomy, quadrantectomy, and partial mastectomy procedures.  A lumpectomy 
removes only the breast lump that contains the cancer cells and a surrounding margin of 
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normal tissue.52  After a lumpectomy is performed, a seroma, or clear fluid trapped in the 
wound, often fills the surgical cavity.38  Several months following a lumpectomy, the 
seroma is replaced by scar tissue.38  The final result may vary from person to person 
depending on such factors as the location of the mass, its initial size, and the type of 
incision used.38  A quadrantectomy is the removal of one quarter, or a quandrant of the 
breast.2  A partial or segmental mastectomy is removal of the cancer, as well as some of 
the breast tissue around the tumor and the lining over the chest muscles below the tumor.2 
 A mastectomy involves removal of all of the breast tissue.  Mastectomy 
procedures can be further subdivided into simple or total mastectomy, modified radical 
mastectomy, and radical mastectomy.  A simple or total mastectomy is when the entire 
breast is removed, including the nipple.52  However, the axillary lymph nodes and muscle 
tissue from beneath the breast is not removed.52  In contrast, a modified radical 
mastectomy does involve removing some of the axillary lymph nodes along with removal 
of the entire breast.52  Two common types of modified radical mastectomy procedures are 
the Patey and Madden.  In the Patey procedure, the pectoralis minor muscle is often 
removed, but the pectoralis major is spared.53   In contrast, the Madden procedure 
preserves both the pectoralis minor and major.54  A radical mastectomy is a very 
extensive operation that removes the entire breast, axillary lymph nodes and the pectoral 
muscles.52  This surgical procedure used to be very common; however it is rarely 
performed today because research has demonstrated that performing a modified radical 
mastectomy is just as effective.52   
 Even today, many physicians do not refer patients who have undergone43, 55 
mastectomies to physical therapy.  This is most likely due to a lack of scientific evidence 
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detailing the benefits of physical therapy in breast cancer survivors.  Physicians also fear 
side-effects, such as lymphedema, may occur from rehabilitation programs that could 
hinder healing from breast cancer surgery and treatment.  Fortunately, there is a recent 
increased interest in the rehabilitation of breast cancer survivors.  In a recent study 
conducted by Cinar et al., fifty-seven women were randomly assigned to either a 
treatment group or a home exercise group.55  The purpose of this study was to evaluate 
the effectiveness of an early rehabilitation program in women who had undergone a 
modified radical mastectomy.55  After removal of each subject’s drain, the treatment 
group participants attended fifteen sessions of individualized rehabilitation.55  Range of 
motion (ROM) of the shoulder, upper extremity circumferential difference, and 
functional status, which was devised by Wingate (1985), were assessed preoperatively 
and then postoperatively at the fifth day, first, third, and sixth months.55  Results 
demonstrated statistically significant improvements in ROM of shoulder flexion, 
abduction, and adduction, as well as improvements in the functional questionnaire scores 
for the treatment group.55  Also, there was no statistical difference in the development of 
lymphedema or reported postoperative complications in either group.55  Continued 
research, such as the study conducted by Cinar et al., needs to be performed in order to 
dispel any fear from the medical community about potential negative side-effects that 
could arise from participating in a rehabilitation program for breast cancer survivors who 
have undergone mastectomies. 
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2.3.4 Systemic Treatment 
Systemic treatment refers to drugs that can be administered orally or directly into 
the blood stream to target cancer cells anywhere in the body.  Examples of systemic 
treatment include chemotherapy, hormonal therapy, and targeted therapy. 
2.3.4a  Chemotherapy 
 Chemotherapy is a type of cancer treatment in which drugs are administered 
intravenously or by mouth.  Chemotherapy is given in cycles in which the treatment is 
followed by a period of rest.52  Chemotherapy cycles generally last anywhere from 3 – 6 
months.52  Breast cancer chemotherapy is considered to be either adjuvant or 
neoadjuvant.52   
 Adjuvant chemotherapy is given to cancer patients after surgery in which there is 
no evidence that the cancer has spread.52  Adjuvant chemotherapy is often administered 
after BCS or mastectomy to reduce the recurrence of breast cancer.52  Neoadjuvant 
chemotherapy is chemotherapy that is administered before surgery.52  Two benefits of 
having chemotherapy before surgery include the ability to shrink large cancers so they 
are small enough to be removed by a lumpectomy instead of mastectomy and physicians 
are able to see how the tumor responds to chemotherapy.52  Currently there is no evidence 
as to whether providing neoadjuvant chemotherapy improves survival rates in women 
with breast cancer.52 
 Patients with cancer who are receiving chemotherapy may experience a variety of 
side effects including hair loss, nausea, pain, weight changes, vomiting, anxiety, and 
fatigue.56  One of the most common reported breast cancer-related side-effect is fatigue.  
Fatigue has been shown to increase significantly after the start of chemotherapy.56  
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Fatigue is a  multidimensional and complex concept involving subjective feelings of 
tiredness, weakness, and/or a lack of energy.57-59  Research has shown that fatigue can 
often be debilitating affecting daily activities for a long period of time after a cancer 
diagnosis.60   
Sitzia and Huggins conducted a study on fifty-two breast cancer patients who were 
receiving 6 cycles of chemotherapy.61  Questionnaires revealed that the incidence of 
fatigue was approximately 90% with the severity of fatigue remaining stable throughout 
the chemotherapy treatment cycles.61  A longitudinal study conducted by Bower et al. 
surveyed 763 breast cancer survivors 1 – 5 and 5 – 10 years after diagnosis.60  
Approximately 34% of the breast cancer survivors in this study reported significant 
fatigue at 5 – 10 years after diagnosis.60  What is not known is whether factors such as 
pain and impaired function causes fatigue or vice versa in breast cancer survivors.  
Therefore, it is important for clinicians to evaluate the effects of chemotherapy, 
specifically fatigue, on function in breast cancer survivors. 
2.3.4b  Hormone Therapy 
 Hormone therapy is another type of systemic treatment often administered to 
breast cancer survivors.  For more than 100 years, hormone therapy has been known to be 
effective in treating breast cancer.62  This type of treatment is most often used as an 
adjuvant to decrease cancer recurrence after surgery.62  The hormone estrogen plays an 
important role in this type of adjuvant treatment.  Estrogen functions as the primary 
female sex hormone and is produced by a woman’s ovaries up until menopause.62  It has 
been discovered that the estrogen hormone promotes the growth of 2 out of 3 breast 
cancers – the estrogen receptor positive (ER+) and progesterone receptor positive (PR+) 
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breast cancers.62  Because of these two hormones, several pharmacological agents that 
block and/or decrease estrogen levels are used to treat ER+ and PR+ breast cancers.   
Commonly used drugs to treat ER+ and PR+ breast cancers are Tamoxifen, 
Femara, Arimidex, and Aromasin.  Tamoxifen is the most often used anti-estrogen drug 
that is taken daily in pill form for 5 years after breast cancer diagnosis.  In 1998 a study 
was conducted by Fisher et al. on 13,388 women who had taken Tamoxifen.63   Results 
showed that there was a 49% reduced risk of developing invasive and noninvasive breast 
cancer 69 months after taking Tamoxifen63.  Taking Tamoxifen may produce side effects 
such as a higher risk of endometrial cancer, venous thrombotic events, cataracts, fatigue, 
hot flashes, and decreased quality of life.52, 64  
Femara, Arimidex, and Aromasin are classified as Aromatase Inhibitors (AIs).52  
These types of drugs stop estrogen production in postmenopausal women52.  Aromatase 
inhibitors work by blocking the enzyme aromatase which is responsible for making small 
amounts of estrogen in postmenopausal women.52  It is important to understand that this 
classification of drug cannot stop the ovaries in premenopausal women from making 
estrogen.52  Common side effects that may occur when taking AIs include nausea, 
vomiting, diarrhea, rashes, and arthralgia.65  Currently, there is no study that has reported 
a difference in overall survival rates between breast cancer survivors who take an AIs or 
Tamoxifen.66   
 Due to the many side-effects that breast cancer survivors may have a result of 
hormonal therapy, it is important that clinicians who are treating women who are taking 
this type of medication recognize the potential side-effects.  More specifically, how these 
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side-effects influence function and activities of daily living, especially on the affected 
upper extremity.   
2.3.4c  Targeted Therapy 
Targeted therapies are newer drugs that specifically target genes in cells and are 
often used along with chemotherapy.  One of these genes is the human epidermal growth 
factor receptor-2 (HER2).  This gene has been found to be an important prognostic and 
predictive marker for women with breast cancer.67  The HER2 gene is present in small 
amounts on the surface of breast cancer cells.67  If there is too much of this protein, breast 
cancer tends to grow and spread more aggressively.52  Approximately 20% to 25% of 
women diagnosed with breast cancer have the HER2 gene amplified and the HER2 
protein overexpressed resulting in a poor prognosis and shortened survival.68  Therefore, 
women who have breast cancer as well as the HER2 gene amplification will most often 
have a more aggressive clinical course.67   
 One drug that is commonly used in combination with chemotherapy is 
Trastuzumab® (Herceptin).  Herceptin was approved in 1998 by the U.S. Food and Drug 
Administration (FDA) for treatment of women who had been diagnosed with metastatic 
breast cancer.67  This drug works to slow the growth of breast cancer cells along with 
stimulating the immune system to more effectively attach the cancer.52  Herceptin is 
given as an injection intravenously 1 time a week for approximately 3 weeks.52  Research 
is ongoing to determine the optimal length of time to administer this type of treatment.52  
Side effects from this treatment include fever, chills, weakness, nausea, vomiting, cough, 
diarrhea, and headache.52  More serious side effects of taking Herceptin include the 
development of clinically manageable left ventricular systolic dysfunction and 
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occasionally advanced congestive heart failure (CHF).67  Risks for cardiac complications 
can be as high as 27% depending upon the combination of treatment used with 
Herceptin.69  
 When women who have been diagnosed with HER2+ breast cancer become no 
longer helped by chemotherapy and Herceptin, Lapatinib® (Tykerb) is another drug that 
targets the HER2 protein.  Side effects experienced when taking Tykerb include nausea, 
diarrhea, vomiting, rash, hand foot syndrome, and in rare instances a decrease in heart 
function.52  Symptoms of hand foot syndrome include tingling, redness, swelling, and 
discomfort of the hands and feet.52  In a study conducted by Burris et al., sixty-seven 
patients with metastatic tumors were treated with Tykerb.70  The two most common side 
effects were diarrhea (42%) and skin rash (31%).70 
New biologic therapies have been developed that specifically target growth factor 
receptor signaling pathways.  The vascular endothelial growth factor (VEGF) signal 
transduction pathway is one such pathway that plays a key role in new blood vessel 
formation.71  One of the monoclodal antibodies that targets VEGF, which is one of the 
central growth factors responsible for tumor angiogenesis is Bevacizumab® (Avastin).71  
Avastin can be used when treating metastatic breast cancer in combination with 
chemotherapy.52  Common side effects reported when taking Avastin include 
hypertension, headaches, loss of appetite, dyspnea, asthenia, and myalgia.52, 71 
 Targeted therapies are new treatments for those diagnosed with breast cancer.  
Because of this, not much is known regarding the side-effects resulting from these 
treatments.  Despite this, it is important that clinicians understand what types of targeted 
30 
 
therapies are often provided to these women and monitor the effects of these treatments 
on function and quality of life. 
 Breast cancer can be a confusing topic to not only those diagnosed, but for 
rehabilitation clinicians as well.  For clinicians who treat women with breast cancer, it is 
our responsibility to understand what is breast cancer, staging of breast cancer, and the 
many types of treatments that may be prescribed for these women.  It is also important 
that clinicians have an understanding of the common side effects that may arise from 
these treatments in order to provide the best care as well as modify treatment programs 
when needed to improve each breast cancer survivor’s quality of life and function.  The 
most common side-effects of these treatments include pain, fatigue, and weakness.  It is 
essential for clinicians who work with breast cancer survivors to understand what 
treatments these women receive, as well as their common side effect to provide the best 
possible care to return these women to their level of function prior to the diagnosis of 
breast cancer.  Furthermore, it is imperative to understand that because of the myriad of 
treatments described above that breast cancer survivors may receive, these women are 
more likely to protect their affected side and use their arm less to avoid pain due to the 
many side effects of these treatments.72  Protection of the affected side may lead to 
potential disuse problems that include limits in ROM and surrounding muscle weakness. 
2.4 Function in Breast Cancer Survivors 
It is estimated that approximately 89% of women diagnosed with breast cancer 
survive for 5 years or longer.73  These statistics draw attention to the number of women 
experiencing, as well as surviving breast cancer.  Traditionally, management of breast 
cancer often primarily focuses on tumor response to treatment and survival rate.74  
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However, with improved survivorship there is also a recent increased awareness of 
complications that may arise from breast cancer treatment.  Challenges associated with 
breast cancer survivorship are now widely recognized to have a long-term impact on a 
significant proportion of those affected by breast cancer.75  These include decreased 
shoulder range of motion (ROM), decreased shoulder strength, pain, decreased quality of 
life (QOL) and function, and lymphedema.  In one study, breast cancer participants 
reported their most distressing problem in association with their breast disease was “arm 
symptoms” (29%); even more stressful than the “fear for cancer recurrence” (22%).76  
Many researchers have studied these impairments relative to the type of treatment77, 78 
and type of surgery, ALND27, 79-81, or a combination of these.9, 82-85  However, many 
studies incorporate a broad selection of inclusion criteria making it impossible to 
determine what aspects of breast cancer treatment contribute to impairments.  Therefore, 
the limited amount of research and conflicting results warrants that continued research 
should be undertaken to determine the factors contributing to these impairments in breast 
cancer survivors.86 
2.4.1 Upper Extremity Range of Motion 
The shoulder is a complex joint that has an incredible amount of ROM and mobility 
with many degrees of freedom.87  This mobility is needed to complete several different 
tasks in daily life.87  For example, a study conducted by Magermans et al. investigated 
how 24 healthy female subjects performed ADL’s and the glenohumeral and scapular 
joint angles needed to perform these tasks.87   When these women combed their hair an 
average of 90 of glenohumeral frontal plane elevation, 59 of glenohumeral flexion in 
the scapular plane, and 34 of scapular external rotation was used.87  Eating with a spoon 
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required an average of 121 of glenohumeral frontal plane elevation, 60 of glenohumeral 
flexion in the scapular plane, and 26 of scapular external rotation.87  Washing the axilla 
required and average of 53 of glenohumeral frontal plane elevation, 100 of 
glenohumeral flexion in the scapular plane, and 29 of scapular external rotation.87  When 
these subjects lifted a 4kg bag from the ground to the front of their body, subjects’ 
average motion utilized was 64 of glenohumeral frontal plane elevation, 79 of 
glenohumeral flexion in the scapular plane, and 23 of scapular external rotation.87  
Understanding what is considered to be “normal” glenohumeral and scapular ROM in 
healthy individuals is imperative in being able to define ROM deficits in those with 
dysfunction. 
Decreased ROM has been recognized as a potential impairment after breast cancer 
treatment.88-90  Research has shown that having less than 100-120 of ROM for shoulder 
abduction or flexion is often associated with reduced functional use of an upper 
extremity.91  Incidence of impaired shoulder movements in breast cancer survivors 
reveals a lot of variability, ranging from 1.5% to as high as 50% 9, 76, 81, 92-94  
 In a retrospective study, 396 breast cancer survivors were examined using a self-
report questionnaire and a clinical ROM examination of shoulder flexion and abduction 
performed by a physical therapist.76  Results showed that 55.4% had limited shoulder 
abduction (>10 difference) and 30% had limited forward flexion.76.  Those subjects who 
did have limitations in ROM revealed a mean restriction of 21 for abduction and 12 for 
forward flexion when compared to the contralateral arm.76 
 Thomas – Maclean et al. conducted a research study on 347 women to examine 
shoulder abduction and external rotation active ROM in women with breast cancer 6 – 12 
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months after surgery.75  Fifty – nine percent of the women in this study had limited 
abduction (defined as < 170) and 46% had limited external rotation (< 80).75  When 
defining disability as a difference of >10 between the affected and non-affected side, 
41% showed differences with abduction and 28% had external rotation differences.75  
Surprisingly, 66% of the women in this study who experienced decreased ROM on their 
affected side had not discussed treatment options for this problem with a healthcare 
professional.75  Researchers asked open-ended questions to try and determine why these 
women did not seek treatment for these ROM restrictions.  Reasons given were many 
women expressed that their symptoms were “not that bad”, a lack of awareness of 
treatment options, and the perception that the symptoms would diminish over time75.   
 It is apparent that decreased shoulder ROM can be a deficit during and following 
breast cancer treatment as evidenced by the above research studies.  It is important that 
clinicians who work with breast cancer survivors provide appropriate assessments of 
shoulder ROM to identify deficits that may be present.  If ROM deficits occur as a result 
of breast cancer treatment and are not addressed, future problems might arise when 
performing functional activities and could possibly lead to shoulder dysfunctions such as 
adhesive capsulitis. 
2.4.2 Shoulder Girdle Strength 
Cancer and cancer treatments can potentially cause a loss of lean tissue and 
abnormalities in the metabolic system, as well as cardiac and skeletal muscle, resulting in 
a loss of muscle strength in cancer survivors.95   The loss of lean muscle mass occurs due 
to a decline in protein synthesis in combination with enhanced protein catabolism.96  The 
major adaptations that occur as a result of a decline in protein synthesis and protein 
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degradation include:  1) a decrease in muscle and muscle fiber cross-sectional area as a 
result of a loss of myofibrils and myofilaments, 2) a loss of muscle extensibility, and 3) a 
decrease in proteins necessary for metabolism, especially the oxidative enzymes in the 
Krebs cycle and electron transport chain, leading to a decrease in the muscles’ oxidative 
potential.97  In a healthy population, researchers98-100 have found decreases in muscular 
endurance after only 2 weeks of physical inactivity and reductions (~60%) in oxidative 
enzymatic activity within 3 months of physical inactivity.   
There is a need to examine upper extremity strength to determine the differences 
that may occur during and after breast cancer treatment.  In a study conducted by 
Isaksson and Feuk, approximately 13% of breast cancer survivors experienced weakness 
even 2 years after their surgery.9  In other studies, muscle weakness in the upper 
extremity has been found among 18 - 23% of breast cancer survivors.76, 81, 84  
In 2007, Merchant et al. conducted a study on 40 women to determine whether 
muscle strength, power, and endurance at the affected shoulder were reduced in breast 
cancer survivors.101  Dynamic concentric strength was measured at one repetition 
maximum (1RM), endurance at 90% 1RM, and power through a range of 40 – 100% 
1RM for the shoulder protractors, retractors and, extensors.101  Additionally, strength and 
endurance were measured for shoulder flexors.  Results showed that the affected side was 
significantly weaker than the unaffected side for shoulder protractors, retractors, and 
extensors.101  Also, power was significantly less in the affected arm than the unaffected 
arm although endurance of the affected arm was not consistently poorer than the 
unaffected arm.101  The results from this study also revealed that self-reported weakness 
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correlated poorly with the clinical measures of muscle strength.101  Therefore, women 
who did not report weakness demonstrated a decrease in muscle strength when assessed. 
 It may be difficult to draw conclusions about upper strength in breast cancer 
survivors because subjective measures may differ than the objective measures.  
Therefore, when assessing strength in breast cancer survivors, it is of value to ask the 
person if they feel strength deficits and also objectively measure strength as well. 
 2.4.3 Pain  
Pain is a subjective term that is both difficult to describe and define.  This is due to 
a wide variation from individual to individual about the perception and tolerance to 
pain.102  Essentially, pain is the way the brain interprets information about a particular 
sensation a person’s body is experiencing.102  Since everyone feels pain differently, it is 
often difficult to define objectively.   
 Persons diagnosed with cancer may have pain for many different reasons.103  Pain 
may be caused by the cancer itself, especially when it has spread into soft tissues such as 
muscle or connective tissue.103  Treatment related pain may also be present and possibly 
caused by radiation therapy, chemotherapy, surgery, and/or other types of treatment such 
as hormone therapy.103  Pain can be one of the most distressing symptoms of cancer104 
and has been recognized as impacting all facets with regard to quality of life.105-107 
The prevalence of pain in breast cancer survivors continues to remain unclear.108  
Some recent studies have reported approximately 50% of breast cancer survivors 
complain of chronic pain years after treatment.32, 109-112  According to the particular study 
analyzed, along with how pain is measured, pain prevalence in breast cancer survivors 
varies greatly from about 20%113, 114 to more than 70% in selected groups.115, 116  The 
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variability in reported pain by breast cancer survivors may reflect differences in the 
selection of breast cancer survivors and the wide variety of treatments these women 
receive.108   
In 2008, a study was conducted by Peuckmann et al. investigating self-reported 
chronic pain in 1316 women who had survived for at least 5 years after their primary 
breast cancer surgery without recurrence.108  Results from this study revealed the total 
prevalence of chronic pain in these women to be 42%.108  Women who received 
radiotherapy had a greater prevalence of pain 36%, versus those who did not 26%.108  
Interestingly, women who received a lumpectomy reported a higher prevalence of pain 
34%, when compared to those who received a mastectomy 27%.108  The highest 
prevalence of reported pain were the areas of the axilla (20%), arm (20%), shoulder/neck 
(12%), and chest (9%).108     
 In another study, a telephone survey was administered to 148 breast cancer 
survivors to examine self-reported pain.8  The mean age was 57.2 years and more than 
two-thirds of the participants had a lumpectomy (69%), while 25% had a total 
mastectomy, and the remainder underwent a modified radical mastectomy procedure.8  
Approximately 14% reported moderate to severe pain in the affected arm, chest 
wall/breast tissue area, and axillary area.8  In 2005, a prospective study was conducted on 
ninety-six breast cancer survivors.117  The purpose of the study was to describe the 
impairments of upper body and limb functions, the impact of these impairments on 
activity limitations, and participation restrictions experienced at work, in the home, and 
in leisure 6 and 12 months after breast cancer surgery.117  Data were collected using a 
questionnaire that included both closed and open-ended questions.  At both 6 and 12 
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months after surgery one of the most limiting impairment reported was neck and shoulder 
pain 6 months (38.5%) and 12 months (40.6%) after surgery.117 
While the definition of pain varies from person to person, untreated, pain has the 
potential to have a strong impact on factors such as quality of life and function.75  More 
studies need to be conducted on women who experience pain during and after their breast 
cancer treatment in order to help these survivors, along with their clinicians, provide 
improved treatment options. 
2.4.4 Quality of Life and Function 
Quality of life (QOL) is a subjective, multidimensional term, which consists of 
different domains such as physical functioning, social functioning, and psychological 
well-being .118  The World Health Organization74, 119 defines QOL as a person’s 
perception about his or her life position in cultural context in relation to his or her aims, 
expectations, and concerns.  Furthermore, QOL is a complicated model that incorporates 
a person’s physical health, psychological status, level of independence, beliefs, and social 
and personal relationships.74, 119  As there has been an increase in breast cancer survivors 
due to earlier detection and advances in medical care, it has become increasingly vital to 
assess these survivors perspective of their symptoms and their impact on the daily life. 
(Kuroi et al 2007)   Evaluating QOL can provide clinicians a tool for determining 
treatment and a means to assess the outcome of a chosen treatment.120 Only a few studies 
have been published over the past 20 years investigating prevalence of the upper 
extremity disability in relation to daily activities and QOL in breast cancer survivors.43  
Rietman et al. conducted a retrospective study on 55 breast cancer survivors who 
underwent a modified radical mastectomy or a segmental mastectomy with ALND.121  
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The aim of this study was to assess impairments, disabilities, and health related QOL 
after treatment of breast cancer and to analyze the relationship between treatment 
modalities, impairments, disabilities, and health related QOL.121  The impairments 
assessed were shoulder ROM, grip strength, arm volume, pain using a visual analog scale 
(VAS), disability assessed by the Shoulder Disability Questionnaire (SDQ), and health 
related QOL measured by means of the RAND 36-item Health Survey (RAND-36).121  
Results of this study showed that pain, explained 61% of the variance, followed by ROM 
(12%), were the most important factors when impairments are used to predict health 
related QOL.121   
 The European Organization for Research and Treatment of Cancer Breast Cancer 
(EORTC BR 23) questionnaire was utilized in a study by Albert et al. to assess QOL in 
389 women 1 year after they were diagnosed with primary breast cancer.  The EORTC 
BR 23 is a questionnaire that contains three items related to arm morbidity (pain, swollen 
arm, difficulty to raise).  In this particular study, manually scoring these three items were 
aggregated into a single score.122  Results from this study showed that approximately 
20% of the breast cancer survivors experienced considerable impairment in arm 
functioning even one year after their initial diagnosis.122  A significant limitation of this 
study is the use of the EORTC BR 23, specifically the fact that this QOL questionnaire 
has only 3 items that address upper extremity/arm function. 
The Disabilities of Arm, Shoulder, and Hand Questionnaire (DASH) has been 
utilized in a few studies to specifically address shoulder/arm disability and how it is 
related to activities of daily living and function in breast cancer survivors.  The DASH is 
a 5-level Likert scale with 21 items addressing the ability of a person to perform daily 
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activities relating to functional use of the involved shoulder, arm, and hand within the 
past week.  Five questions assess activity related pain, weakness, and stiffness.  Four 
questions examine the effects of social activities, work, sleep, and psychological impact.  
Scores on the DASH range from 0 – 100, with 0 reflecting no disability (good function) 
and 100 representing extensive disability (poor function). 
One study utilizing the DASH, examined 347 breast cancer survivors 6 – 12 
months after surgery.75  Pain (r = 0.468) and active ROM restrictions, specifically 
abduction (r = -.493), were found to be associated with disability.75  The strongest 
correlations (r > 0.30) were performing heavy household chores, gardening and doing 
yard work, making a bed, carrying a shopping bag or briefcase, carry and object heavier 
than 10 lbs, and putting on a pullover sweater.75  A second study administered the DASH 
to assess changes in upper-body disability over time, from pre to post-intervention, and 6 
to 12 months post-diagnosis, in women receiving two community interventions as well as 
a non-intervention group.5  Sixty-seven breast cancer survivors participated in the two 
community interventions with a common goal of restoration of upper-body strength and 
flexibility, and general support after breast surgery.  One program was termed DAART 
which was administered by physiotherapists in a patient’s home.  The program consisted 
of education and a tailored exercise program for self-management lasting 1 hour for 6 
weeks.5  The second community intervention, named STRETCH, was administered by 
exercise physiologists delivered in group sessions providing education and discussion of 
psychosocial issues lasting 1-2 hours for 8 weeks.  Results of this study revealed that 6 
months post diagnosis the mean DASH scores were: DAART 13.4, STRETCH 12.4, and 
non-intervention 7.3.  Although the authors concluded “overall, mean DASH scores 
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suggest women have relatively little disability”.5  Several limitations regarding this study 
exist. First, there is no mention of what stage of breast cancer these participants were 
diagnosed and secondly, whether the breast cancer survivors affected arm was their 
dominant arm.5    Hayes et al. utilized the DASH to survey 258 unilateral breast cancer 
survivors.86  DASH scores ranged from 0 – 71.7 on the affected side with approximately 
50% of the respondents reporting scores > 12.86    These results reflect a wide range of 
DASH scores, however, once again, a significant limitation in this study was that there 
was no mention of how many of these 258 breast cancer survivors were affected on their 
dominant arm.  A significant limitation when administering the DASH is that it is not 
specific to a patient’s affected limb.123 Therefore, when research studies are conducted on 
those with upper extremity disability such as breast cancer survivors and limb dominance 
is not discussed; results and interpretations of the DASH may not be a true representation 
of the disability and therefore be skewed.  
While there have been a few research studies utilizing the DASH to examine 
function and quality of life in breast cancer survivors, no study to date has used to PSS in 
this manner.  The PSS provides additional information that cannot be found in the DASH.  
The PSS contains three portions, the first contains 20 questions regarding function, the 
second portion has three questions regarding pain, and the final portion asks one question 
about a person’s satisfaction with their current level of shoulder function.  Because the 
PSS has different domains than the DASH, valuable added information can be obtained 
when using this outcome questionnaire to assess function and quality of life in a 
pathologic population.  
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 Examining QOL as an outcome is as challenging as it is dynamic, and may even 
change as a breast cancer survivor adapts to living with cancer.124  There appears to be no 
standard or consensus in the research and rehabilitation communities as to what is the 
best way to assess arm morbidity with relation to function and QOL in breast cancer 
survivors.  Furthermore, little is known about what specific assessments for breast cancer 
survivors are commonly used in rehabilitation settings and what predictive factors they 
may have in order to improve function and QOL.  Additional research needs to be 
conducted in order to determine the most appropriate assessment instrument to explain 
how upper extremity morbidity affects function and QOL in this group of individuals.  
2.5  Lymphedema 
Lymphedema is the most recognized form of arm morbidity in breast cancer 
survivors.75  Although lymphedema is not a primary outcome measure in this study, it 
warrants discussion because of its potential effects on arm function.  Lymphedema in the 
upper limb results from an excessive accumulation of interstitial fluid due to an 
obstruction or interruption of the lymph system.125, 126  Lymphedema may range from 
mild to severe, be chronically swollen, unappealing, and cause functional impairment of 
the arm.127  Lymphedema may occur immediately after breast cancer treatment or up to 
20 years after initial treatment.127, 128 Among women treated for early stage breast cancer, 
lymphedema prevalence rates are estimated to range from 2.7% 129 to 37%.130  
Lymphedema can progress to cause pain, psychological distress, body image alterations, 
impairments in mobility, strength, and function if left untreated.34, 131   
There appears to be no standardized definition of breast cancer-related lymphedema 
and therefore it may go underreported.132  The most widely used strategy to diagnose 
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upper extremity lymphedema is circumferential upper extremity measurements using 
specific anatomical landmarks.133  Petryk and colleagues have tried to create a 
measurable, clinical definition of lymphedema by stating it to be a “2-cm difference 
between the surgical-side upper extremity and the contralateral upper extremity”.134   
 Women who have been treated for breast cancer have traditionally been advised 
to avoid strenuous or repetitive activities that require effort with the affected arm because 
these activities were thought to initiate or exacerbate lymphedema.135  Risk factors for 
lymphedema in breast cancer survivors have been poorly characterized.128  There are 
clinicians who believe factors such as arm infection, injury, tumor stage, nodal status, 
radiotherapy to the breast and/or axilla, and elevated body mass may cause 
lymphedema.29, 136-139  Even though leisure and occupational activities are thought to be 
risk factors for lymphedema, it is believed that no form of physical activity has been 
associated with lymphedema in prospective research.137 
 Several studies have been conducted showing that using the affected upper 
extremity in a repetitive manner, mostly with exercise activities, does not cause a 
significant increase in lymphedema in breast cancer survivors.  A study was conducted by 
Ahmed et al. examining the effects of a supervised upper and lower-body weight training 
on the incidence and symptoms of lymphedema in 45 breast cancer survivors.128  Twenty-
three of these women participated in the treatment group while 22 served as controls.  
The intervention was conducted twice a week over a 6 month period.128  Lymphedema 
was monitored by measuring the circumference of each arm and by self-report of 
symptoms and clinical diagnosis.128  None of the intervention-group participants 
experienced a change in arm circumference ≥ 2.0 cm after performing the 6 months of 
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prescribed exercise.128  Therefore, this study concluded that during the 6 month exercise 
trial, there was no incidence or onset of lymphedema symptoms in either the intervention 
or control group participants.128  A study was conducted by Turner et al. utilizing 10 
breast cancer survivors who had completed their surgical treatment and adjuvant 
chemotherapy.6  This pilot study was conducted to determine the impact of a mixed-type, 
moderate-intensity exercise program on the presence of physical measures such as 
lymphedema, fatigue, fitness and body composition, and quality of life.6  The exercise 
program was conducted once per week over 8 consecutive weeks.6  The initial weeks 
consisted of aerobic-based exercise, such as low-impact aerobics and ergometery.6  
During weeks 4 and 5, the women performed water-based exercise and during the final 
weeks, moderate resistance exercise using free and machine weights were incorporated 
into the program.6  Lymphedema was assessed using total sum of arm circumference, as 
well as bio-electrical impedance.  Measures were taken at intake, at the completion of the 
8 week program, as well as at a 6 week and 3 month follow-up.6  No statistically 
significant changes were observed for the presence of lymphedema.6  This is another 
study that shows promise explaining the minimal effects upper extremity exercise has on 
lymphedema in breast cancer survivors, although the limitations of this study need to be 
considered.  These include a small sample size (n=10), no control group, and an exercise 
program that was only performed 1 time a week. 
There have been several studies examining the effects of exercise on 
lymphedema, however, in all of these studies, none of the breast cancer subjects had 
measurable lymphadema at baseline.  There has been one study conducted that examined 
the effects on lymphedema on women who had measurable lymphedema from breast 
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cancer.  The goal of this study was to determine whether these women would experience 
any changes in arm volume if they performed a regular exercise routine.140  Fourteen 
breast cancer survivors with unilateral lymphedema were randomly assigned into either 
an exercise (n=7) or a control group (n=7).140  The exercise group followed a progressive, 
8-week upper-body exercise program consisting of resistance training plus aerobic 
exercise using an arm ergometer while wearing a professionally fitted compression 
sleeve140  The control group was given no specific exercise instruction.  Lymphedema 
was measured in two manners; using arm circumference and measurement of arm volume 
by water displacement.140  Upper extremity volume and circumference were measured on 
all subjects at baseline and every 2 weeks after for the 8 week duration.140  Results 
showed that there were no changes in arm circumference or arm volume as a result of 
participating in the exercise program.140  As well as no significant change in either the 
control or exercise groups over time.140  Although this study does have a small sample 
size (n=14), important conclusions can be drawn regarding whether women who have 
measurable lymphedema following breast cancer treatment should participate in an 
exercise program.  As these results show, performing a progressive, controlled upper-
body exercise program did not significantly affect the volume of the upper extremities in 
women with lymphedema after breast cancer treatment. 
 Factors such as shoulder ROM, strength, and even function may not be addressed 
after breast cancer treatment out of concern that these measures may cause 
lymphedema.133, 141  However, this may be changing due to several recent studies that 
have been conducted measuring the effects of exercise and lymphedema in women with 
breast cancer.  These studies have provided scientific evidence to suggest that exercise 
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for breast cancer survivors is safe, although continued monitoring of lymphedema should 
be conducted in any exercise program on breast cancer survivors.1  
2.6  Other Factors 
There appears to be other factors that necessitate consideration when treating a 
breast cancer survivor from those mentioned above. A study was conducted by Hayes et 
al. describing associations between upper body function and certain personal and 
treatment characteristics six months following treatment for unilateral breast cancer.86  
Objective measures were defined as upper body strength and endurance, upper body 
flexibility, and hand grip strength.86  Subjective measures were scores on the Disability of 
Arm, Shoulder, and Hand (DASH) and Functional Assessment of Cancer Therapy, Breast 
(FACT-B+4).86  Two important conceptual findings emerged from the study relating to 
the limited correlation between various objective and subjective measures on upper body 
function and the relevance of dominance of the treated side when considering upper body 
function.86  Specifically, treatment on the dominant side was associated with better upper 
body function compared to those treated on the non-dominant side.86  However, 
subjective upper body function was reduced when treatment occurred on the dominant 
side.86  The results show that those women who were treated on their dominant side may 
demonstrate higher upper body strength and endurance; however, being treated on the 
dominant side may potentially cause more disruption in their lives that may be perceived 
as more burdensome and thus hinder function and quality of life.86    
Optimal upper body function is essential for maintaining independent living, 
performing daily routine activities, returning to work, performing tasks requiring physical 
strength, and for general quality of life.142  The above research demonstrates that in order 
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to achieve optimal upper body function in breast cancer survivors, many aspects of care 
need to be considered and well understood in these women.  These aspects of care 
include understanding the types of biopsies, effects of radiation, types of surgical 
procedures, effects of chemotherapy, hormonal treatment, and targeted therapy, upper 
extremity ROM and strength limitations, quantifying pain, evaluating QOL, and 
assessing function. 
2.7 Shoulder Anatomy 
Kinematics can be defined as the “description of time-dependent aspects of motion in 
terms of displacement, velocity, and acceleration without dealing with the forces causing 
the motion”.143  Shoulder joint kinematics consists of coordinated movements of the 
clavicle, scapula, and humerus.  To better appreciate shoulder and scapular kinematics, it 
is essential to understand the basic anatomy of the shoulder region.   
The clavicle, scapula, and humerus form the bony structures of the shoulder 
region.144  The clavicle extends laterally and horizontally across the root of the neck.145  
The clavicle has three functions; to act as a strut for holding the upper limb free from the 
trunk so it may have maximum freedom of action, to provide attachments for muscles, 
and to transmit forces from the upper limb to the axial skeleton.145  The scapula is a 
triangular flat bone that lies on the posterolateral aspect of the thorax, overlying the 2nd 
through 7th ribs.145  In what is thought of as a normal erect standing and relaxed position, 
with the arm dependent, the superior angle of the scapula lies at the level of the second 
thoracic vertebra.  The root of the scapular spine is at the level of the third thoracic 
spinous process and the inferior angle is at the level of the spinous process of the seventh 
or eighth thoracic vertebra.146  The plane of the scapula is approximately at right angles to 
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the plane of the glenoid147 and lies obliquely between the frontal and sagittal planes, 30 - 
45 anterior to the coronal plane.148-150  Motions of the scapula include: 
elevation/depression, abduction/adduction, and depression and downward 
rotation/abduction and upward rotation.151  The humerus is the largest bone in the upper 
extremity.145  The proximal portion is smooth, ball-shaped, and articulates with the 
glenoid cavity of the scapula.145 The distal portion consists of the medial and lateral 
epicondyles. 
The joints of the shoulder region include the sternoclavicular (SC), acromioclavicular 
(AC), and glenohumeral (GH).  Together, these articulations provide the shoulder with a 
range of motion (ROM) that exceeds any other joint in the body.  In order to achieve full 
mobility of the shoulder, coordinated and synchronous motion in all of these joints is 
required.144          
The SC joint is a plane synovial joint which is dependent on the disc, strong capsule, 
and three ligaments for stability.144  The SC joint functions as a ball-and-socket joint, 
although the articular surfaces are saddle-shaped.152, 153  This joint has three degrees of 
freedom, the first elevation and depression of the clavicle, occurs between the medial end 
of the clavicle and disc.154  The second, protraction and retraction occur between the disc 
and the sternum. 148, 154, 155  The third degree of freedom, rotation, occurs about the 
clavicles longitudinal axis.148, 153, 155, 156   
The AC joint is also a plane synovial joint.157  The stability of this joint is dependent 
on the superior and inferior acromioclavicular ligaments that reinforce a weak joint 
capsule.153  The AC joint permits movement of the scapula on the clavicle in three 
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planes.144  The movement of rotation occurs about the coronal, sagittal, and vertical 
axes.144   
The GH joint is a synovial ball-and-socket joint that lies between the glenoid fossa of 
the scapula and humeral head.144  This particular joint is inherently unstable due to the 
shallowness of the glenoid fossa and the disproportionate size and lack of congruency of 
the articular surfaces.144  Stability of the GH joint is primarily dependent upon the 
osseous morphology, glenoid labrum, capsuloligamentous mechanism, intra-articular 
pressure, and musculotendinous cuff.144  The biomechanics of the GH joint rely on the 
interaction of both static and dynamic stabilizing structures.158  The static stabilizing 
structures include the bony anatomy, negative intra-articular pressure, the glenoid 
labrum, and the GH ligaments along with the joint capsule.158  The dynamic-stabilizing 
structures include the rotator cuff and scapulothoracic muscles.158   
2.7.1  Shoulder Stability 
The upper limb is not often involved in weight bearing, therefore its stability has 
been sacrificed to gain mobility.145  The glenohumeral joint is distinct because it 
maintains stability despite having few restraints.158   These restraints consist of the static 
and dynamic components.  Bony, cartilaginous, capsular, and ligamentous structures all 
function to provide static stability of the glenohumeral joint.159   The musculature 
surrounding the shoulder composes what is known as the dynamic stabilizers.158    
Although the static stabilizers of the upper limb have an important role, it is 
imperative to understand the influence of the dynamic stability provided to the shoulder 
in order to fully appreciate mobility and function of this region.  The dynamic stability is 
primarily the result of neuromuscular control between the scapulothoracic musculature 
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and the rotator cuff (RC) muscles.158   This dynamic stability can be described further as 
scapulohumeral balance.  Scapulohumeral balance refers to the theory that the humeral 
head is balanced in the glenoid if the net joint reaction force passes through the fossa.160  
Therefore, the glenohumeral joint will remain stable, as long as the scapula is positioned 
so that the glenoid fossa encloses the net forces acting on the humeral head.160  It is 
essential that the RC and scapulothoracic musculature work in a synchronous manner so 
the resultant compressive force across the joint falls within a stable arc provided by the 
glenoid concavity.160  If these muscles do not work together efficiently, deficits may arise 
which could lead to shoulder dysfunction such as impingement syndrome. 
When assessing the upper extremity, it is essential to understand the function of the 
surrounding musculature.  The rotator cuff’s primary function is to guide and stabilize the 
GH joint.161, 162  The RC muscles help to strengthen the GH joint in every direction 
except inferiorly and are well positioned to resist GH shear stresses in order to prevent 
pathologic translation.145, 158, 161   The RC consists of the supraspinatus, infraspinatus, 
teres minor, and subscapularis.   Each of the individual muscles of the rotator cuff along 
with the biceps brachii originate on the scapular body and insert onto the humeral head, 
thus pulling the humerus closer to the glenoid cavity upon activation.  Simultaneous 
contraction of these 5 muscles creates a compression effect of the humeral head into the 
glenoid cavity.  As the rotator cuff and biceps brachii musculature contract to pull the 
humeral head downward and inward, this humeral head compression is coupled by the 
upward and outward pull of the anterior, middle, and posterior deltoid musculature.  This 
mechanism is commonly referred to as the glenohumeral force couple, and, when in 
balance, functions to center the humeral head in the glenoid cavity. 
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 The interaction of the RC muscles works in combination with other muscles in the 
shoulder girdle to provide stability.  Another classification of dynamic stabilizing 
structures in the upper extremity is known as the scapulothoracic muscles.  Several 
research studies have established the importance of a coordinated, synchronous action of 
the glenohumeral and scapular muscles.17, 163-165  The muscles included in the 
scapulothoracic region that provide this dynamic stability are the: latissimus dorsi, 
serratus anterior, pectoralis major, rhomboid major and minor, and the upper, middle, and 
lower trapezius.  These muscles are capable of producing large torques about the shoulder 
joint because of their cross-sectional anatomy and distance from the joint center of 
rotation.158   
 When discussing the dynamic stability of the shoulder joint provided by the 
scapulothoracic region, it is important to discuss the scapula force couple.  The scapula 
force couple refers specifically to the stability and balance provided to the 
scapulothoracic region by the upper trapezius, lower trapezius, rhomboid major, 
rhomboid minor, levator scapulae, and serratus anterior.166  It is important to understand 
how contraction of each of these muscles effect movement of the scapula.  Contraction of 
the upper trapezius creates scapular upward rotation, elevation, and retraction.145  When 
the lower trapezius is contracted, it causes scapular upward rotation, depression, and 
retraction.145  When the rhomboid major and minor are fired, both muscles produce 
scapular retraction, downward rotation, and depression.145  Activation of the serratus 
anterior creates scapular protraction and upward rotation.145    
There is a need to understand the intricate relationships between the static and 
dynamic stabilizing structures at the shoulder when evaluating and treating this region. 
51 
 
Research has shown that even the smallest alteration in performance and coordination of 
the muscles surrounding the shoulder has the potential to lead to dysfunctions and 
compensations that could compromise normal joint function and lead to disabilities,17 
resulting in inactivity,167and lower quality of life.168  As mentioned previously in the 
literature review, muscle weakness in the upper extremity has been found among 18-23% 
of breast cancer survivors and this weakness may be present even up to 2 years after their 
surgery.76, 81, 84  Breast cancer treatments appear to effect a percentage of these survivors 
upper extremity strength, specifically around the scapulothoracic region.  Therefore, 
weakness of the upper extremity must be evaluated when a breast cancer survivor has 
complaints of either pain and/or loss of function when using their upper extremity.  It is 
important that clinicians understand the function of the scapulothoracic muscles, effects 
breast cancer treatments may have on this region, and are able to assess weakness 
appropriately.  In summary, when clinicians develop rehabilitation programs for breast 
cancer survivors to correct dysfunction at the shoulder, it is necessary to break down this 
complex region into its various components in order to discover the fundamental 
principles that may be the underlying cause of the problem. 
2.7.2 Shoulder and Cervical Mobility 
 Understanding what is considered to be “normal” active ROM of the shoulder in 
the healthy population is essential when assessing those who present with upper 
extremity dysfunction.  The mobility of the glenohumeral joint can be described as 
having three degrees of freedom: flexion/extension, abduction/adduction, and 
internal/external rotation.144  Full ROM of the shoulder involves humeral, scapular, and 
clavicle motion at the GH, SC, AC, and scapulothoracic joints.147 The American 
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Academy of Orthopaedic Surgeons (AAOS) and the American Medical Association 
(AMA) values for mean ROM at the glenohumeral joint are as follows: flexion 150-
180, extension 50-60, abduction 180, internal rotation 70-90, and external rotation 
90.169, 170 What is unknown about the above recommendations from the AAOS and 
AMA are the age, gender, and number of subjects that were measured to obtain these 
values.147  Another study was conducted on 109 males to assess AROM using a clinical 
goniometer.171  Males ranging from 20 – 54 years of age demonstrated mean values of 
shoulder AROM: flexion 166.7±4.7, extension 62.3±9.5, abduction 184±7.0, 
internal rotation 68.8±4.6, and external rotation 103.7±8.5.171 Limitations of the 
above study include only utilizing males as subjects and the fact that no one was studied 
over the age of fifty-four.   
 As mentioned previously, decreased ROM has been recognized as a potential 
impairment after breast cancer treatment.88-90  The incidence of impaired shoulder motion 
in breast cancer survivors is quite variable, ranging from 1.5% to as high as 50%.76, 81, 89, 
92-94  Two research studies has found the greatest deficits in ROM of breast cancer 
survivors appears to be during the motions of forward flexion, shoulder abduction, and 
shoulder external rotation.75, 76  The results of these studies appear to correlate with other 
pathologic populations, such as adhesive capsulitis and shoulder impingement syndrome, 
in regards to limitations in active shoulder ROM.   A study was conducted by Ardic, et al. 
on 59 patients with diagnosed impingement syndrome.172  Although the exact 
methodology of how shoulder active ROM was not discussed, results revealed an average 
of 139.2±24.5 of flexion, 53.0±21.6 of external rotation, and 50.7± of internal 
rotation.172  A similar study was conducted on 65 patients with idiopathic adhesive 
53 
 
capsulitis.172  Measures of active shoulder forward elevation and external rotation were 
measured in a seated position using a goniometer.172  Results showed that the average 
active ROM for flexion was 102 and 17 for external rotation.172  Both of these 
pathologic populations demonstrate reductions in active ROM, when compared to 
normative values.  Continued studies need to be conducted to gain a better understanding 
of the effects of breast cancer treatment on shoulder active ROM and function. 
 There has been some initial evidence to suggest that impairments of the cervical 
spine may contribute to shoulder pain and disability.173  Neck pain appears to have a 
variable definition as apparent in several research studies.174, 175  The term “neck pain” 
has been used to describe pain in the area between the occiput and the upper back.175 
Because of the ambiguity of the term “neck pain” it can be difficult to obtain an exact 
diagnosis and is it possible that shoulder and neck pain may coexist and overlap.175  In 
one research study, neck pain was described as a referred pain syndrome originating in 
the shoulder.175  In this study, a retrospective review was conducted on 34 patients with 
neck pain.175  Eighty-eight percent of these 34 patients had a positive referred shoulder 
impingement test, with relief of their neck pain five minutes after injection in the 
shoulder.175  The authors go on to conclude that “shoulder impingement is a previously 
undescribed cause of chronic neck pain along the medial border of the scapula”.175  The 
results of this study demonstrate that a thorough examination should be performed on 
both the shoulder and cervical spine by clinicians who are evaluating persons who 
present with decreased upper extremity function and disability. 
As of this date, there have been no studies to examine cervical spine active ROM 
in the breast cancer population.  Despite this, it is important to understand what has been 
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described as “normal ROM of the cervical spine” for gender and age, in order to examine 
if cervical ROM deficits exist in populations such as breast cancer survivors.  In 1992, 
Youdas et al. examined cervical active ROM measurements on 337 subjects whose ages 
ranged from 11 to 97 years.176  A CROM was used to measure the 6 cervical active ROM 
measures and of these 337 subjects, 171 were females.176  The results revealed that for 
females who range in age of 40-69 years (n=62) demonstrate an average extension ROM 
from 65.2 to 77.5, left side bending 34.4 to 40.8, right side bending 32.7 to 42.5, 
left rotation 59.7 to 64.0, and right rotation 65.2 to 70.2.176  This study also revealed 
that the active ROM measures of extension, left and right side bending, and left and right 
rotation were significantly correlated to age.176  Furthermore, the number of degrees of 
motion lost per year did not differ between genders, but female subjects started with a 
higher degree of active ROM, which appears to be maintained with increasing age.176  
Since neck flexion did not differ between male and female subjects, the range of 41.0 to 
49.5 was found in both males and females who range in age of 40-69 years (n=122).176 
2.8 Normal Scapular Kinematics 
 In order for normal shoulder motion to occur, coordinated movements of the 
clavicle, scapula, and humerus must occur.  In particular, scapular motion is a key 
component of shoulder function, and a comprehensive understanding of scapular 
biomechanics may provide clinicians with better knowledge that can be applied when 
assessing and treating shoulder dysfunctions.  The capability of the scapula to move 
about the trunk while maintaining glenohumeral alignment and proper angulation of the 
humerus with the trunk, enables the scapula to provide a stable base of support between 
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the humerus and trunk.177  This allows for the high degree of movement observed in the 
shoulder that is needed for upper extremity function.177 
 Cathcart was the first to describe the scapulothoracic contribution for normal 
shoulder kinematics.178  He described the scapula moving on the thorax throughout 
humeral elevation.178  Recent three-dimensional (3-D) studies have expanded Cathcart, as 
well as Inman and colleagues’ original description of “scapulohumeral rhythm” to 
include three rotations and two translations.179, 180  Scapulohumeral rhythm is often 
defined as the ratio of scapular upward rotation relative to humeral elevation. (Codman 
1934)  Scapulohumeral rhythm is further described as a 2:1 ratio of humeral to scapular 
movement.181  Stookey was the first to specifically investigate scapulohumeral rhythm, 
defining three distinct phases of humeral elevation: 0-60°, 60-115°, and 115° to maximal 
shoulder elevation.182  During the initial phase of elevation from 0-60°, large variations in 
the amount of scapular upward rotation were observed.182  But the middle phase, 60-
115°, had less variation in the amount of movement and is what is often used to describe 
the typical 2:1 ratio of scapulohumeral rhythm.  Therefore, as humeral elevation 
increases, the scapula rotates in an upward manner one degree for every two degrees of 
humeral abduction.183  There has been variability in defining scapulohumeral rhythm, 
ranging from 1.25:1 to 3:2 depending on the plane of humeral elevation (frontal, scapular, 
or sagittal), and the arc of elevation evaluated.184  Furthermore, the differences in 
methodology of these studies make it difficult to compare results and to understand why 
such discrepancies in the scapulohumeral rhythm exist.  Despite these difference, there 
does appear to be a consensus in the literature to support a non-linear pattern of scapular 
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upward rotation relative to glenohumeral elevation progressing from 2:1 in the early 
phases (30-100°) and 3:2 (100° to max) in successive phases.185 
The three rotations of the scapula include upward/downward rotation, 
internal/external rotation, and anterior/posterior tipping.  More specifically, rotation about 
an axis perpendicular to the plane of the scapula is defined as upward/downward rotation, 
whereas scapular rotation around an axis roughly parallel to the scapular spine has been 
termed anterior/posterior tipping.147  Scapular motion around a vertical axis has been 
defined as internal/external rotation.179 The two translations occurring with scapular 
motion are protraction/retraction and elevation/depression. 
 Scapular motion has been studied for over 60 years, beginning with two-
dimensional (2D) methods such as radiography,180 goniometry,180, 186 and Moire’ 
topography..187  These techniques have been used to describe humeral elevation in the 
scapular and frontal planes.  Recent advances in technology have afforded the ability to 
examine scapular motion from a three-dimensional (3D) non-invasive perspective.  With 
the development of electromagnetic tracking devices in the late 1980’s188 and their 
validation for application to the shoulder region189, 190 a substantial improvement has 
occurred regarding the accessibility of scapula kinematic research.191  An electromagnetic 
tracking system consists of a transmitter and receivers.  Within the past 10 years, the 
development of the extended range transmitters has enabled a larger operating space 
allowing for advances in the study of shoulder kinematics. 
Before understanding the effects of motion on the scapula, one must understand 
the normative data regarding the resting position of the scapula.  Recognizing what is 
considered to be a normal resting position of the scapula can aid a clinician in identifying 
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scapular abnormalities which may lead to identifying the underlying causes of 
dysfunction in the shoulder region.   In 1998, Meskers et al. examined static scapula 
positions in steps of 10 using a six-degree-of-freedom electromagnetic tracking device 
in 3 elevation planes: forward flexion (90 angle with the frontal plane), elevation in the 
scapular plane (30), and elevation in the frontal plane (0).192  The resulting resting 
position of the scapula was upward rotation 3, internal rotation 30, and posterior tipping     
-12.192 Similar results regarding the resting position of a healthy scapula have been 
found by several other authors with the resting scapula being positioned from -1.7 - 3 
of upward rotation, 30.2 - 37.4 of internal rotation, and -8 - -20.6 of posterior 
tipping.144, 179, 193  
   Three-dimensional kinematics has been described for shoulder motion during 
elevation in the frontal, scapular, and sagittal planes.14, 179, 194  Several studies have found 
that as the humeral angle is increased, the scapula demonstrates a pattern of progressive 
upward rotation and movement from an anterior to a posterior tipped position.17, 179, 190, 
192, 193, 195  The most variable scapular motion appears to be internal/external rotation, 
either decreasing, increasing, or staying relatively unchanged.17, 18, 192, 196  These 
discrepancies regarding scapular internal/external rotation appear to be due to the 
definition of the local axis systems, choice of Euler angle rotations, arc of elevation, and 
plane of humeral elevation evaluated.195 
 Several previous studies have shown that healthy subjects use a reproducible and 
complex pattern of scapular kinematics with a large ROM during arm elevation..194, 197  
Most studies examining scapular kinematics in healthy individuals appear to analyze 
subjects moving in what is known as the “scapular plane”.17, 19, 179, 196, 197  Researchers 
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believe that arm elevation during functional activities occurs in this scapular plane that 
can have variations in its definition, but is most often described as 30 anterior to the 
frontal (sagittal) plane of the thorax.141, 179, 193  In 1996, Ludewig et al. examined 3D 
scapular orientation in 25 asymptomatic subjects (19-37 years old) during humeral 
elevation in the scapular plane.179  The results of this study showed that at 90° of humeral 
elevation, the scapula demonstrated averages of 21°of upward rotation, 28° of internal 
rotation, and 2° of anterior tipping.179  At the higher elevation angle of 140°, the scapula 
demonstrated averages of 36° of upward rotation, 20° of internal rotation, and 7° of 
posterior tipping.179  A similar study examining elevation in the scapular plane was 
conducted on 26 healthy construction workers.17  At 60° of humeral elevation, the 
scapula averaged values of 22° of upward rotation and 8° of posterior tipping.17  Similar 
scapular angles were found in another study conducted by Borstad and Ludewig during 
humeral elevation in the scapular plane.196  The scapula progressively moved into greater 
upward rotation during humeral elevation from 22.5° at 60°, 29.1° at 80°, 35.3° at 100°, 
and 40.7° at 120°.196  The scapula also moved into a slightly more anterior position by 3° 
during humeral elevation from 11° at 60°, 12° at 80°, 13° at 100°, and 14° at 120°.196  
Finally, the scapula moved progressively into a more internally rotated position during 
the humeral elevation task from 40.5° at 60°, 42° at 80°, 44° at 100°, and 44° at 120°.196  
More recently in 2007, 17 healthy subjects performed 5 repetitions of scapular plane 
elevation reporting averages of the 5 trials of scapular motion at 60°, 90°, and 120°.198   
As humeral elevation increased, so did scapular upward rotation from 26° at 60°, 36° at 
90°, and 49° at 120°.198  The scapula moved into a greater anterior position during the 
humeral elevation task from 10° at 60°, 14° at 90°, and 18° at 120°.198  Finally, the 
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scapula demonstrated small changes of moving into greater internal rotation  from 45° at 
60°, 46° at 90°, and 49° at 120°.198   Although slight differences in methodology were 
used for the above studies, the results appear to be similar demonstrating that during a 
humeral elevation task in the scapular plane in healthy individuals, the scapula moves 
progressively into greater upward rotation, posterior tipping, and internal rotation. 
Two studies have examined humeral elevation in the sagittal plane.  A study 
conducted by Fayad and colleagues examined 30 healthy subjects performing two 
repetitions of arm elevation in the sagittal plane.197  Results revealed small changes with 
the scapula moving into a slightly more anterior position by 3° when moving from 60°, 
90°, and 120° (-8°, -9°, and -5°).197  The scapula also moved into greater upward rotation 
during sagittal plane flexion when moving from 60°, 90°, and 120° (22°, 38°, and 49°).197  
McClure and colleagues examined 3D scapular kinematics in 45 healthy subjects during 
3 cycles of active elevation in both the sagittal and scapular planes.19 Result of this study 
show that during the sagittal plane motion, the scapula moved into progressive upward 
rotation from 28°, 38°, and 53° when moving from 60°, 90°, and 120°.19 Small changes 
were seen in this plane, showing the scapula moving into a more posterior position from 
2°, 3°, and 4° when moving from 60°, 90°, and 120°.19  Two degree changes were 
observed moving from 60°, 90°, and 120° (41°, 43°, and 43°) regarding scapular internal 
rotation.  During the task of humeral elevation in the scapular plane in this study, similar 
results were seen as presented above.17, 179, 196, 198  Result of this study show that during 
the scapular plane motion, the scapula moved into progressive upward rotation from 26°, 
36°, and 50° when moving from 60°, 90°, and 120°.19  Small changes were seen in this 
plane, showing the scapula moving into a more posterior position from 3°, 3.5°, and 4° 
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when moving from 60°, 90°, and 120°.19 Two degree changes were observed when 
moving from 60°, 90°, and 120° (37°, 37.5°, 35°) demonstrating the scapula moving into 
more internal rotation.19  
   In order to understand if there are differences in scapular kinematics in the breast 
cancer survivor population, an understanding of what is considered to be “normal” 
kinematics in healthy populations needs to be understood.  Although all of the above 
studies utilized different methodology and subject characteristics, during either a humeral 
task of elevation in the sagittal or scapular plane, the scapula demonstrates a pattern of 
progressive upward rotation. 17, 18, 179, 190, 192, 193, 195, 196  Movement of the scapula was 
slightly variable regarding tipping, although the variability was small ranging from 1° - 
3°.17, 18, 179, 190, 192, 193, 195, 196  Internal and external rotation of the scapula continues to be 
variable in these studies. 172, 191,195   
2.8.1  Alterations in Scapular Kinematics 
 The scapular component of shoulder movement patterns is thought to play a key 
role in the understanding of shoulder dysfunction.17, 18, 136, 185, 187, 197, 199 Alterations in 
scapular kinematics in one or all planes are believed to contribute to shoulder pain and 
pathology.179, 200-202  Changes in scapular resting position and motion have been seen in 
subjects with impingement syndrome,13-20 rotator cuff tears,185, 203, 204 frozen shoulder,198, 
205-207 and glenohumeral instability.185, 187, 208-211  It is believed that factors such as muscle 
weakness or shortening, trauma, repetitive overhead work conditions, or pain may 
potentially disrupt muscular control and lead to scapular motion abnormalities. 
It is important to understand scapular kinematics in other populations who suffer 
from shoulder dysfunction to formulate a basis for examining scapular kinematics in 
61 
 
breast cancer survivors.  Alterations in scapular motion may cause increase stress on the 
muscular, ligamentous, and capsular structures, placing the shoulder at risk for 
dysfunction.20  The historical emphasis on clinical evaluation of scapular motion patterns 
during an assessment of the shoulder should be used to guide treatment in those with 
shoulder dysfunction.181, 202  Understanding abnormalities that exist in populations such 
as persons diagnosed with impingement syndrome and frozen shoulder could help 
provide a foundation for pursuing such research on breast cancer survivors.   
Shoulder impingement appears to be the most common studied pathology with 
regards to scapular kinematics.  This is most likely due to the high prevalence (16-40%) 
of shoulder complaints consistent with impingement in occupations and those who 
perform repetitive work that is above 60° of elevation in any plane.212-216  Several studies 
have examined 3D scapular kinematics in those with shoulder impingement syndrome.  
The general consensus from research on persons with impingement syndrome 
demonstrates that this population presents with decreased posterior tipping, decreased 
upward rotation, and increased internal rotation when compared to healthy subjects.14, 17, 
18, 217  One study conducted by Ludewig and Cook analyzed glenohumeral and 
scapulothoracic kinematics in a group of male construction workers with symptoms of 
shoulder impingement (n = 26) relative to a group of subjects without symptoms of 
shoulder impingement (n = 26) during humeral elevation in the scapular plane.17  The 
results revealed that those subjects with symptoms of shoulder impingement 
demonstrated decreased upward rotation during the first 60 of humeral elevation and a 
more anteriorly tipped position as elevation progressed when compared to the subjects 
without symptoms of shoulder impingement.17  Some researchers believe that a decrease 
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in the amount of scapular posterior tilt may decrease the size of the subacromial space, 
potentially causing greater compressive forces to the RC tendons.18  
Another study conducted by McClure et al. compared 3D scapular kinematics in 
male and female subjects with (n = 45) and without (n = 45) primary shoulder 
impingement syndrome during active elevation in both the sagittal and scapular planes, as 
well as during external rotation with the arm at 90 of elevation in the frontal plane.19  
Results revealed that upward rotation was greater during the flexion task in those subjects 
with shoulder impingement when compared to those who did not have impingement.19   
These results contrast those found by Ludewig and Cook, regarding the upward rotation 
component, but may be explained in part by differences in the subject population and 
measurement methods.  Another study found similar results regarding upward rotation as 
McClure et al.  Karduna and colleagues studied the effects of scapular orientation on 
contact forces in the subacromial space using cadavers.136  The researchers found that 
posterior tilt and external rotation did not affect subacromial space, but that upward 
rotation did.136  Specifically, an increase in scapular upward rotation was found to 
decrease subacromial clearance.  Results of this particular study should be read 
cautiously and seem to differ regarding upward rotation which could be due to the very 
low number of subjects, 8, the use of cadavers, and the muscle forces were simulated by a 
man made “mechanical testing machine”. 
It is important to understand the clinical significance of scapular kinematic 
alterations in those with shoulder dysfunction such as impingement.  Result of many of 
the above studies show that a decrease in the amount of scapular posterior tilt may 
decrease the size of the subacromial space, potentially causing greater compressive forces 
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to the RC tendons.18  The results of the above studies disagree as to what role upward 
rotation contributes to shoulder impingement, but what the results show that there are 
differences between healthy individuals and those with shoulder impingement regarding 
upward rotation.  The kinematic differences found between pathologic populations and 
healthy controls may represent scapulothoracic compensatory strategies for glenohumeral 
weakness loss of motion.  As clinicians it is our responsibility to evaluate these 
differences in the shoulder region to provide the best possible care for individuals who 
present with such dysfunction. 
 The second most common shoulder dysfunction analyzed with 3D scapular 
kinematics is frozen shoulder, also known as adhesive capsulitis or idiopathic loss of 
shoulder ROM.  This shoulder dysfunction is often characterized by a pattern of limited 
external rotation, abduction, forward flexion, and internal rotation.207  With frozen 
shoulder, abnormal motion of the scapula is thought to exist, although it has been difficult 
to describe and measure clinically.   
Vermeulen and colleagues examined 10 patients with unilateral frozen 
shoulder.207  Scapular kinematics on both the affected and unaffected upper extremities in 
3 planes: humeral elevation in the sagittal plane, elevation in the scapular plane and 
abduction in the frontal plane, were recorded.207 The researchers analyzed the 3D 
kinematic data using curves showing scapular movement in relation to glenohumeral 
movement, as opposed to the most common practice of reporting the three scapular 
rotations at angles.  However, the results from this study showed that the affected upper 
extremity showed earlier and more scapular movement in relation to the curves on the 
unaffected side.207  Clinically, the authors believe this early and excessive scapular 
64 
 
motion is to compensate for the lack of glenohumeral joint mobility.207  Rundquist 
examined 3D scapular kinematics in seventeen subjects with frozen shoulder (impaired) 
and 17 subjects with normal shoulder ROM (unimpaired).  Subjects performed 5 
repetitions of bilateral humeral elevation in the scapular plane (40 anterior to the coronal 
plane).198   Results showed that the impaired subjects’ involved side demonstrated a 
significant greater upward rotation (7.7) at peak scapular plane elevation than their non-
involved side.198  Although 7.7 may not seem like a large difference, it did represent 
23% of the total scapular motion during upward rotation excursion.198  The authors 
suggest that the upward rotation differences may be attributed to scapulothoracic 
compensation in order to overcome a loss of glenohumeral motion.198  Clinically, this 
may allow subjects with frozen shoulder complete activities of daily living despite 
glenohumeral ROM restrictions.  
 A more recent study was conducted to examine 3D scapular kinematics in 32 
patients with a “stiff shoulder”, 16 with GH joint osteoarthritis and 16 with frozen 
shoulder.197  These subjects performed 2 repetitions of maximal arm elevation in the 
sagittal and frontal planes on both the affected and unaffected side.197  Results of this 
study showed that patients with either GH osteoarthritis or frozen shoulder had increased 
scapular external rotation during both planes of movement.197  Similar to Rundquist and 
colleagues, the authors of this study suggest that the increase in scapular external rotation 
may be an adaptation that enables patients to perform activities of daily living requiring 
humeral elevation.197   
 The results of these studies illustrate that alterations exist for scapular kinematics 
in several shoulder dysfunction classifications when those individuals are compared to 
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matched controls or their unaffected side.  What remains unclear is whether scapular 
dysfunction is a contributing factor or a compensatory mechanism for shoulder 
pathology.  Despite this, understanding what scapular kinematic differences exist in 
pathologic populations such as shoulder impingement and frozen shoulder, along with 
breast cancer survivors, could provide clinicians with an enhanced understanding of the 
role the scapula might have regarding pain and function.  Although the long term 
consequences of altered scapular kinematics are uncertain, having an understanding of 
what alterations exist in pathologic populations such as breast cancer survivors, could 
provide clinicians with evidenced based rehabilitation techniques to improve function and 
disability. 
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CHAPTER III 
METHODS 
3.1 Research Design 
 A case-control design was used to compare breast cancer survivors and a control 
group of healthy, matched participants.  The following dependent variables were 
measured on the affected arm and compared between the two groups: 1) shoulder active 
and passive range of motion (ROM); 2) cervical active ROM; 3) shoulder girdle strength; 
and 4) three-dimensional scapula kinematics during humeral elevation tasks (sagittal 
plane flexion, scapula plane elevation, and reaching).  Functional outcome measures were 
also recorded using the Disabilities of the Arm, Shoulder, and Hand (DASH), and The 
University of Pennsylvania Shoulder Score (PSS). 
3.2 Procedures 
3.2.1 Recruitment and Population 
 The breast cancer survivor (BCS) group consisted of women who had been diagnosed 
with breast cancer in the Raleigh-Durham-Chapel Hill region and had completed all of 
their systemic and/or surgical treatment no greater than six months prior to testing date.  
The BCS group was recruited through the Get Real and Heel Program at UNC-CH and 
by word of mouth.  The eligibility criteria were: 1) a diagnosis of stage I-III breast 
cancer, 2) female age between 25 and 75 years, 3) no history of shoulder or neck surgery, 
and 4) no known neuromuscular dysfunctions or taking medications that may influence 
neuromuscular performance.  The control (CON) group served as the comparison group 
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and was matched by gender, age, and body mass index to those participants in the BCS 
group.  Participants will be matched by gender, (all were female), ages within 5 years, 
and a BMI within 3 kg/m2.  Eligibility criteria for the comparison group were:  1) 
female age between 25 and 75 years, 2) no history of upper extremity or neck pain within 
the last 6 months, 3) no previous history of shoulder or neck injury, 4) no known 
neuromuscular dysfunctions or taking medications influencing neuromuscular 
performance, and 5) no previous diagnosis of breast cancer.   
3.3 Instrumentation 
3.3.1 Shoulder Function 
Shoulder function was measured using the Disabilities of the Arm, Shoulder and 
Hand (DASH) and the University of Pennsylvania Shoulder Score (PSS) functional 
outcome instruments. (Appendix C)  Both of these outcome measures are self-report 
questionnaires that assess upper extremity function. 
3.3.2 Scapular kinematics 
Kinematics was assessed using the miniBIRD® (model 800, Ascension 
Technologies, Inc., Burlington, VT) 3D electromagnetic motion analysis system 
controlled by the MotionMonitor software (Innovative Sports Training, Inc. Chicago, 
IL) software, Version 6).  The electromagnetic motion analysis system consists of a 
transmitter and six miniature receivers, which are all hardwired to the system’s main 
computer unit.  The transmitter emits a low-frequency electromagnetic field, which was 
detected by the receivers. Each receiver was able to calculate linear motion within 3 
planes, rotational motion around 3 axes, and translational motion around 2 axes, thus 
allowing six degrees of freedom to be measured. The receivers entered and were moved 
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throughout the electromagnetic field and relayed the relative orientation and position of 
the receiver within the field to the computer. Once the information was received by the 
main computer, the data was processed and displayed using the MotionMonitor 
motion-capture software.  
The miniBIRD® system has been shown to be accurate demonstrating a Root Mean 
Squared (RMS) of 1.8mm for position and .5 for orientation.218   Three-dimensional 
angular data was recorded in degrees for the three scapula rotations of anterior/posterior 
tipping in the sagittal plane, upward/downward rotation in the scapula plane, and 
internal/external rotation in the transverse plane.  Three-dimensional data was recorded in 
degrees for the two scapula translations of elevation/depression in the sagittal plane and 
protraction/retraction in the transverse plane. 
3.3.3 Shoulder Active and Passive Range of Motion 
Active and passive ROM was measured in degrees on the affected extremity using 
a digital inclinometer (The Saunders Group, Inc., Chaska, MN).  Measures included 
shoulder flexion, extension, external rotation at 0 and 90 of shoulder abduction, and 
internal rotation at 90 of shoulder abduction. 
3.3.4 Shoulder Girdle Strength 
Strength was measured by means of a maximal voluntary isometric contraction 
(MVIC) using the Lafayette manual muscle tester (Lafayette Instrument®, Lafayette, IN).  
Bilateral peak muscle force in pounds was assessed for scapula abduction and upward 
rotation, scapula depression and adduction, shoulder flexion, shoulder internal rotation, 
shoulder external rotation, shoulder scaption, and shoulder horizontal adduction. 
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3.3.5 Cervical Active Range of Motion 
Cervical active ROM was measured using the CROM (Cervical Range of Motion 
Instrument) (Performance Attainment Associates, Lindstrom, MN).  ROM was measured 
for cervical flexion, extension, left side bending, right side bending, left rotation, and 
right rotation.    
3.4 Testing Procedures 
The method for data collection was the same for both groups (BCS and CON).  
Participants reported for a single testing session lasting approximately 90 minutes.  
Participants wore athletic attire including a tank top or camisole and a shirt that was 
removed so that the shoulders and neck were appropriately exposed for the measurements 
to be taken.  Prior to data collection all participants read and signed an informed consent 
form approved by the University of North Carolina at Chapel Hill Biomedical 
Institutional Review Board.  Participants then completed two self-report questionnaires, 
the DASH and PSS.  Next, participants underwent a series of physical tests.  The first 
consisted of three trials of shoulder active range of motion (ROM) followed by three 
trials of shoulder passive range of motion (ROM) on the affected side for flexion, 
external rotation at 0 of abduction, internal rotation at 90 of abduction, external rotation 
at 90 of abduction, and extension.  To assess scapula kinematics, participants were asked 
to perform ten repetitions of each of the 3 tasks: 1) reaching, 2) humeral elevation in the 
frontal plane, and 3) humeral elevation in the scapula plane without a limb load.  The 
order of tasks was randomized by having each participant choose three pieces of paper 
out of a cup.  After 3D kinematics were collected, three trials of strength measures on the 
affected side for scapula abduction and upward rotation, shoulder flexors, adductors, 
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shoulder internal and external rotators, and scaption positions were measured with the 
order of these strength testing positions randomized.  The final assessment included three 
trials of cervical AROM for flexion and extension, left and right side bending, and left 
and right rotation.    
3.4.1 Functional Questionnaires 
3.4.1a  Disabilities of Arm, Shoulder, and Hand 
 The Disabilities of the Arm, Shoulder, and Hand (DASH) is a 30-item self-report 
questionnaire appropriate for those with upper extremity musculoskeletal conditions.219, 
220  The American Academy of Orthopaedic Surgeons and the Institute for Work & 
Health developed this tool to assess “upper extremity-related symptoms and measure 
functional status at the level of disability”.221  All questions asked in the DASH require 
the use of the upper extremity.  The DASH questionnaire is the most validated measure 
of upper extremity function in upper extremity disorders.219   The average time it takes to 
complete the DASH is 6 minutes and it can be scored in less than 5 minutes.220 
 The DASH consists of two components, the disability/symptom section containing 30 
items and the high performance sport/music or work section containing 4 items, both 
sections are scored from 1-5.222   For purposes of this study, only the disability/symptom 
section was administered.  Each item in this section was scored on a 5 point scale ranging 
from 1 “no difficulty” to 5 “unable”.  The DASH has a maximum score of 100, where a 
higher score is a sign of greater disability.219  For a score to be calculated, at least 27 of 
the 30 items must be answered. To make the score on the DASH easier to compare to 
other measures, the score is then transformed to a score out of 100 by subtracting 1 and 
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multiplying by 25.222   The equation to calculate a score on the DASH is as follows, 
where n is the number of completed responses:  
[(sum of n responses) – 1] * 25 n 
 The DASH has been shown to be a valid and reliable measure for reporting outcome 
of patients with a variety of shoulder disorders.223   The DASH psychometric properties 
have been evaluated and have revealed relative reliability to be excellent with ICC’s 
varying from 0.82 – 0.98.224-236 
3.4.1b  University of Pennsylvania Shoulder Score 
 The University of Pennsylvania Shoulder Score (PSS) is a 100-point shoulder-
specific self-report questionnaire that first became available in 1999. 223  The PSS 
consists of 3 subscales:  pain, satisfaction, and function.223  Higher scores on each 
subscale indicate increased function. 
 The pain subscale comprises of 3 pain related questions that address pain at rest, with 
normal activities, and with strenuous activities.  The pain related questions are based on a 
10-point numeric rating scale with 0 = “no pain” and 10 = “worst pain”.  For calculating 
points in this portion, each item circled is subtracted from 10.  Therefore, 30 points 
represents a complete absence of pain, whereas 0 points means the arm is not able to be 
used.  
 The function subscale of the PSS is based on a sum of 20 items, each with a 4-point 
Likert scale.  The response options are: can’t do at all (0), much difficulty (1), with some 
difficulty (2), and no difficulty (3).  If all activities can be performed with no difficulty a 
total of 60 points is calculated.  There is an option to respond “did not do before injury” 
for those questions who are not applicable.  When this option is answered, for scoring 
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purposes, the total possible points for the function subscale is reduced by 3.  Scoring of 
the function subscale is based on a percentage of the total possible points.  For example, 
when a total score of 24 points of this subscale is calculated and he or she responded “did 
not do before injury” for 1 question, the total possible points would be 57 (60 – 3).  The 
final function score would be calculated 24  57 = 0.42, then 0.42 x 60 = the function 
subscale score of 30 points, equaling a 25.2/30. All three of the subscales, pain, 
satisfaction, and function were examined in this study. 
 The PSS has been found to be a valid and reliable measure for reporting outcome of 
patients with a variety of shoulder disorders.223  The PSS psychometric properties have 
been evaluated and has revealed a test-retest ICC2, 1 of 0.94 (95% CI, 0.89 – 0.97).223  
Internal consistency has been found to be a Cronbach's alpha of 0.93 with a standard 
error of measurement of ± 8.5 scale points (based on a 90% CI).223 
3.4.2 Measurement of Scapular kinematics 
Three electromagnetic tracking sensors were attached using double sided carpet 
tape (Scotch®, 3M, St. Paul, MN) and were affixed using Transpore (3M Health Care, 
St. Paul, MN) surgical tape to: 1) the thorax over the spinous process of C7, 2) the 
affected (or matched) shoulder over the broad flat surface of the scapula acromion, and 
pre-wrap (Cramer® Products, Inc. Gardner, KS ) was additionally used over 3) the 
posterior one third of the affected upper arm with the sensor over the area of least muscle 
mass to minimize potential sensor movement.  A fourth receiver was secured to a stylus 
for digitization of landmarks.177, 237   Figure 1 represents the electromagnetic tracking 
sensor placement. 
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To assess scapula kinematics, reconstruction of the bony segments were 
performed by following the International Society of Biomechanics-Shoulder Group 
Recommendations that have been used in previous studies.136  The bony landmarks were: 
T12, medial and lateral epicondyle of the humerus, T8, xyphoid process, C7, sternal notch, 
spine of the scapula at the medial border, posterior-acromion of the scapula, inferior 
angle of the scapula, and the glenohumeral joint rotation center.  The glenohumeral joint 
center was defined as the point that moves least with respect to the scapula when the 
humerus is passively moved through short arcs of mid-range glenohumeral motion (< 
45) for a total of  20 positions during glenohumeral circumduction in approximately 20 
seconds.238   The glenohumeral joint was moved by the researcher in three different 
directions: abduction-adduction, flexion-extension, and internal-external rotation while 
trying not to apply a dislocating force to the joint, or to press the humerus against the 
glenoid.  As a result of this passive motion, regression equations as published by Meskers 
and colleagues were used to determine the ultimate position of the glenohumeral rotation 
center.192  The mean error when using this system will vary from 8mm to 16.5mm.238 
 The electromagnetic transmitter was positioned on a custom stand allowing for 
the establishment of a global reference system.  The global reference system axes were 
defined such that the Y-axis was designated as positive in the superior direction, the 
positive X-axis was designated as anterior, and the Z-axis was designated as positive to 
the right, all relative to the participant.  The local axes systems were aligned with the 
reference axes of the electromagnetic system to simplify data reduction.  
Once the participants were set up on the miniBIRD® system, they completed three 
different tasks of glenohumeral elevation in a randomized order: reaching, glenohumeral 
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elevation in the sagittal plane, and glenohumeral elevation in the scapula plane (30 
anterior to the frontal plane of the thorax).  Randomization was accomplished by having 
each participant choose 3 pieces of numbered papers, one at a time, out of a cup.   
Before the beginning of each task, participants stood upright with both arms 
hanging beside their body in a resting position (palms facing body) with their feet at a 
comfortable width apart and their eyes fixed forward.  Participants elevated the affected 
(or matched) upper extremity to the terminal end point of their available ROM while 
maintaining a neutral hand position throughout the entire ROM.  Movement velocity was 
maintained by asking participants to sustain a speed that was set to the beat of a 
metronome at 60 beats per minute, approximately 1 beat every second.  This allowed the 
participants to move at a two count during the elevation phase and a two count during 
lowering phase.  Before recording each task, the participants completed three practice 
trials to become familiar with the movement and velocity.  Participants were then asked 
to complete 10 continuous repetitions of each elevation task.  After completing 10 
repetitions of each task, the participants were allowed a two-minute rest interval before 
testing of the next task. 
Description of Each Elevation Task 
 All of the elevation tasks were performed with each participant’s affected (or 
matched) side while the arm was unloaded (or without holding a weight).  During all of 
the tasks, the participants were asked to maintain a neutral hand position in which the 
palm of their hand can lightly touch the PVC guide during the elevation task while their 
thumb is pointed towards the ceiling. 
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The reaching task required the participants to imagine that they were holding a 
soup can while placing their ulna styloid at a target that was positioned perpendicular to 
the affected AC joint on a shelf with the hand held in neutral rotation,.  A standard 
goniometer was used to ensure the humeral elevation relative to each participant’s trunk 
was greater than 120 and that the elbow was comfortably extended.  This task has been 
used in previous studies examining scapula kinematics.237  Figures 2 and 3 refers to 
examples of how the reaching task was performed.   
For the glenohumeral elevation task in the sagittal plane, a pole constructed of PVC 
pipe was used to serve as a guide in order for participants to maintain the proper plane of 
movement.  This guide was placed in the sagittal plane in line with the affected side 
acromion.  The sagittal plane was defined as the plane perpendicular to a line through 
each participant’s fifth metatarsal head.  Participants elevated their arm greater than 120° 
and elevation was visually confirmed with a goniometer.  Figures 4 and 5 demonstrate 
the humeral elevation task in the sagittal plane.  
During the elevation task in the scapula plane (scaption), a PVC pipe was also used 
as a guide.  This guide was placed 30 anterior to the frontal plane of the thorax, where a 
piece of tape was placed on the ground, and was confirmed using a standard goniometer. 
Once again, participants elevated their arm greater than 120° and elevation was visually 
confirmed with a goniometer as depicted in Figure 6.   
3.4.3  Shoulder active ROM and passive ROM 
 Participant’s upper extremity active ROM was assessed in the following order: 
supine flexion, supine ER at 0 of abduction, supine ER at 90 of abduction, supine IR at 
90 of abduction, and prone extension.  Three trials of active ROM were performed 
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followed by three trials for passive ROM on the affected extremity.  Participants 
practiced each active ROM one time before measures were recorded.  Each measurement 
was taken three times and the average was used for data analysis.  All active and passive 
ROM measures were performed according to Norkin and White.147  Intratester reliability 
has been established during pilot data for active ROM (ICC2,1 .84 – 1.0 ) and passive 
ROM (ICC2,1 .97 – 1.0) and is shown in Table 1. 
Supine flexion 
 The participant was supine with the knees flexed.  The shoulder was positioned at 
0 of abduction, adduction and rotation.  The forearm was positioned in 0 of supination 
and pronation so that the palm of the hand faced the body.  Stabilization was provided at 
the scapula to prevent elevation, posterior tipping, and upward rotation.  The participant 
was asked to “move your shoulder, keeping your elbow straight from the table to your ear 
until you can go no further without substituting”.  The participant held this position while 
the digital inclinometer was placed parallel to the long axis of the posterior humerus 
displaying the flexion angle and is depicted in Figure 7.   
Supine ER at 0 
The participant was supine with the knees flexed and the arm being tested at 0 of 
shoulder abduction.  The forearm was perpendicular to the supporting surface and was in 
0 of supination and pronation so that the palm of the hand was facing their other arm.  
The full length of the humerus rested on the supporting surface while the elbow was not 
supported.  Stabilization was provided at the distal end of the humerus to keep the 
shoulder in 0 of abduction.  Stabilization was provided at the scapula to prevent 
posterior tipping.  The participant was asked to “rotate the arm as if you are bringing the 
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back of your hand to the floor, while keeping your elbow by your side, until you can go 
no further without substituting”.  Figure 8 demonstrates how the participant held this 
position while the digital inclinometer was placed parallel to the long axis of the forearm 
displaying the flexion angle.  
Supine ER at 90 
The participant was supine with the knees flexed and the arm being tested in 90 
of shoulder abduction.  The forearm was perpendicular to the supporting surface and was 
in 0 of supination and pronation so that the palm of the hand faced the feet.  The full 
length of the humerus rested on a supporting surface while the elbow was not supported.  
Stabilization was provided at the distal end of the humerus to keep the shoulder in 90 of 
abduction.  Stabilization was also provided to the scapula to prevent posterior tipping.  
The participant was asked to “rotate the arm as if you are bringing the back of your hand 
to the floor until you can go no further without substituting”.  The participant held this 
position while the digital inclinometer was placed parallel to the long axis of the forearm 
displaying the flexion angle as portrayed in Figure 9. 
Supine IR at 90 
The participant was supine with the knees flexed and the arm being tested in 90 
of shoulder abduction.  The forearm was perpendicular to the supporting surface and was 
in 0 of supination and pronation so that the palm of the hand faced the feet.  The full 
length of the humerus rested on a supporting surface while the elbow was not supported.  
Stabilization was provided at the distal end of the humerus to keep the shoulder in 90 of 
abduction.  Stabilization was also provided to the scapula to prevent elevation and 
anterior tipping.  The participant was asked to “rotate the arm as if you are bringing the 
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palm of your hand to the floor until you can go no further without substituting”.  Figure 
10 reveals how the participant held this position while the digital inclinometer was placed 
parallel to the long axis of the forearm displaying the flexion angle.   
 
Prone extension 
 The participant was prone, with the head facing away form the shoulder being 
tested without a pillow.  The shoulder was positioned in 0 of abduction and rotation.  
The elbow was positioned in slight flexion so the tension in the long head of the biceps 
brachii muscle did not restrict the motion.147  The forearm was positioned in 0 of 
supination and pronation so that the palm of the hand faced the body.  Stabilization was 
applied to the scapula to prevent elevation and anterior tipping.  The participant was 
asked to “lift your arm up to the ceiling until you cannot go any further without 
substituting”.  The participant held this position while the digital inclinometer was placed 
parallel to the long axis of the posterior humerus displaying the extension angle as shown 
in Figure 11.   
3.4.4 Shoulder Girdle Strength 
Participant’s shoulder girdle strength was assessed for scapula abduction and 
upward rotation, scapula depression and adduction, shoulder flexion, shoulder adduction, 
shoulder internal and external rotation, and scaption, with the order of these strength 
testing positions randomized.  Randomization occurred by having each participant choose 
7 pieces of numbered papers, one at a time, out of a cup.  Participants practiced each 
testing position sub maximally one time before measures were recorded.  Each 
measurement was taken three times and the average was used for data analysis.  The 
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participant were asked to “push as hard as you can against my force without moving your 
arm” for a five second count that both began and ended with a beep.  During the 5 second 
push, participants received verbal cues of “push, push, push”, and then “relax” after the 
stopping beep.  Thirty seconds rest occurred between each trial.  A 1 minute rest period 
occurred between each extremity and testing position.  Scapula abduction and upward 
rotation and scapula depression and adduction were performed according to Kendall et 
al.239 and the test positions of humeral flexion, scaption, and adduction were performed 
according to Hislop and Montgomery.151  Intratester reliability has been established 
during pilot data for shoulder girdle strength (ICC2,1 .72 – .99 ) and is displayed in Table 
2.   
Scapula abduction and upward rotation  
The participant was seated without their back supported with their feet flat on the 
ground.  The participant’s arm was placed in 120 to 130 of flexion with the elbow 
straight and the upper extremity fully internally rotated so the thumb is pointing towards 
the ground.  Flexion of 120 to 130 was verified using a standard goniometer.  Pressure 
was applied against the dorsal surface of the arm between the shoulder and elbow in the 
direction of extension as demonstrated in Figure 12.  The primary muscle tested in this 
position is the serratus anterior.  
Scapula depression and adduction   
 The participant was positioned in prone with their head turned toward the test side 
and the shoulder that is being tested at the edge of the table.  The arm was positioned at 
90 of horizontal abduction and 135 of coronal abduction, with arm fully externally 
rotated so that their thumb faces the ceiling.  Coronal abduction of 135 was verified 
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using a standard goniometer.  Figure 13 shows how the pressure was applied against the 
proximal portion of the humerus in a downward direction toward the table.  The primary 
muscle tested in this position is the lower trapezius.   
 
Shoulder flexion  
The participant was seated without their back supported with their feet flat on the 
ground.  The arm was positioned at 90 of coronal abduction and at 0 of horizontal 
abduction with the elbow extended and the forearm pronated so that the palm was facing 
the floor.  Pressure was over the distal humerus just above the elbow in the downward 
direction of extension toward the floor as shown in Figure 14.  The primary muscles 
tested in this position are the anterior deltoid and coracobrachialis.   
Shoulder external rotation  
The participant was seated without their back supported with their feet flat on the 
ground.  The elbow was flexed to 90 with the arm in 0 of horizontal abduction and the 
forearm in a neutral position so that the thumb was pointing up towards the ceiling. 
Figure 15 depicts how the pressure was applied to the ventral surface of the distal 
forearm in the direction of internal rotation.  The primary muscles tested in this position 
are the infraspinatus and teres minor 
Shoulder internal rotation  
The participant was seated without their back supported with their feet flat on the 
ground.  The elbow was flexed to 90 with the arm in 0 of horizontal abduction and the 
forearm in a neutral position so that the thumb was pointing up towards the ceiling.  
Pressure was applied to the dorsum of the distal forearm in the direction of external 
81 
 
rotation as shown in Figure 16.  The primary muscle tested in this position is the 
subscapulais.   
 
 
Shoulder scaption  
The participant was seated without their back supported with their feet flat on the 
ground.  The arm was positioned halfway between flexion and abduction (30 anterior to 
the frontal plane of the thorax) with the forearm in a neutral position so that the thumb 
was pointing toward the ceiling.  Figure 17 demonstrates how the pressure was applied 
just above the elbow in a downward direction of extension toward the floor.  The primary 
muscles tested in this position are the anterior deltoid, middle deltoid, and supraspinatus.   
Shoulder horizontal adduction  
The participant was seated without their back supported with their feet flat on the 
ground.  The arm was positioned at 90 of coronal abduction and at 10 of horizontal 
adduction with the arm fully internally rotated.  Pressure was applied on the medial 
surface of the proximal humerus into the direction of horizontal abduction as displayed in 
Figure 18.  The primary muscle tested in this position is the pectoralis major.   
3.4.5 Cervical active ROM 
 Participants cervical AROM was measured using the CROM.  Measures of 
cervical flexion, extension, left side bending, right side bending, left rotation, and right 
rotation were measured in this order while the participant was standing in an erect posture 
with their hand relaxed at their sides.  Each measurement was taken three times and the 
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average was used for data analysis.  Intratester reliability has been established during 
pilot data for cervical active ROM (ICC2,1 .87 – .99 ) and is shown in Table 3.   
Flexion 
Participants were instructed to “bring your chin down to your chest, as if you are 
nodding, as far as you can while keeping your back straight” as depicted in Figure 19.   
Extension 
Participants were instructed “to look up to the ceiling, as far as you can without 
bending your back” as demonstrated in Figure 20.   
Left side bending  
Participants were instructed to “keep your nose facing me while you bring your 
left ear down to your left shoulder, do not move your body, just your neck” as shown in 
Figure 21.   
Right side bending 
 Participants were asked to “keep your nose facing me and bring your right ear 
down to your right shoulder, moving your neck and not your body” as seen in Figure 22.   
Left rotation  
Participants were instructed to “keep your body facing forward while you look 
over your left shoulder as far as you can without turning your body” as depicted in Figure 
23. 
Right rotation  
Participants were asked to “keep your body facing forward while you look over 
your right shoulder as far as you can without turning your body” as demonstrated in 
Figure 24. 
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 The intratester reliability of the CROM has been assessed on 25 adult subjects 
without neck pain and 22 adults with pain (Fletcher and Bandy, 2008).  The intraclass 
coefficients (ICC3,1) for subjects without neck pain was 0.87 for forward bending, 0.90 
for backward bending, 0.92 for left and right side bending, 0.94 for left rotation, and 0.90 
for right rotation.  In those subjects who had had neck pain, the ICC3,1 were as follows: 
forward bending 0.88, backward bending 0.92, left side bending 0.89, right side bending 
0.93, left rotation 0.96, and right rotation 0.92.  Table 3 shows the within day, intratester 
reliability that was established for the active and passive ROM positions described above  
3.5 Data Reduction and Processing 
3.5.1 Kinematic Data 
Euler-angle decompositions were used to describe humeral and scapula 
orientation with respect to the thorax.  Scapula orientation was defined using three axes 
as seen in Figure 24: the x-axis describes the vector from thoracic spine to acromial 
angle, the y-axis describes the vector perpendicular to the plane of  the thoracic spine, 
acromial angle and inferior angle of scapula and the z-axis is defined as the vector 
perpendicular to the x and y axes.  Humeral orientation was determined as rotation about 
the y-axis of the humerus (plane of elevation), rotation about the z-axis of the humerus 
(elevation), and rotation about the y-axis of the humerus (axial rotation).  When a 
participant stood in the anatomical position, the coordinate system for each segment was 
vertical (y-axis, describing the motion of internal/external rotation), horizontal to the 
right (x-axis, anterior/posterior tipping), and posterior (z-axis, describing 
upward/downward rotation).  The clavicle attaches the scapula to the thorax and is 
considered a rigid body with a fixed length.  Because of this, scapula position can be 
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described as the orientation of the vector extending from the sternoclavicular joint to the 
acromial angle in regard to the thorax.  This vector extending from the sternoclavicular 
joint to the acromial angle is thought to closely represent the orientation of the clavicle.  
Therefore, the scapula elevation/depression angle was calculated as the angle formed 
between this vector and the transverse plane of the thorax.  Whereas, the scapula 
protraction/retraction angle was estimated as the angle formed between this vector 
extending from the sternoclavicular joint to the acromial angle and the frontal plane of 
the thorax.  These coordinates system have been used previously and has been chosen 
based on the recommendations of the International Shoulder Group.136  The Euler-angle 
sequences were used to most closely represent clinical definitions of movements and to 
decrease mathematical inconsistencies.136 
3.6 Data Processing 
3.6.1 Reduction for Scapula Kinematics 
 The average of trials 3 – 7 of each humeral elevation task was used for the 
assessment of mean scapula angles.  The three rotations of scapula upward/downward 
rotation, internal/external rotation, anterior/posterior tipping, along with the two scapula 
translations of elevation/depression, and protraction/retraction were selected using a 
custom MATLAB (Mathworks, Natick, MA) code to identify angles at 0 º, 30 º, 60,  
and 90 of humeral elevation during the ascending phase of humeral elevation in the 
frontal plane, and elevation in the scapula plane (30 anterior to the frontal plane of the 
thorax) tasks.  Scapula angles were identified for 0 º, 30 º, 60, and max of the reaching 
task.  Kinematic data were smoothed through a Butterworth low pass 
digital-filter (4th order, recursive, zero phase lag) at an estimated optimum cutoff 
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frequency of 3.5 Hz. 
 Several breast cancer survivors had difficulty performing the humeral elevation 
tasks in the frontal and scapula plane above 100 consistently for all of the 10 trials.  
Therefore, 90 was the final angle assessed in this study during the two humeral elevation 
tasks in the frontal and scapula planes.  A similar problem was discovered with the 
reaching task and the final angle assessed in this study during that task was the maximum 
available humeral elevation angle for the breast cancer survivors.  This maximal humeral 
elevation angle was then matched for the healthy, controls.  
3.6.2  Missing Data 
3.6.2a. Function Data 
One breast cancer survivor did not complete the DASH or PSS.  A second breast 
cancer survivor’s PSS was unable to be scored due to missing data.  Because of this, 
corresponding matched controls were dropped from analysis of function on the DASH 
and PSS.  Therefore analysis of the PSS included a total of 22 breast cancer survivors and 
22 matched controls.  Analysis of the DASH included a total of 23 breast cancer 
survivors and 23 matched controls.   
3.6.2b. ROM and Strength Data 
One breast cancer survivor was unable to lie prone to complete passive and active 
extension ROM measures as well as the prone strength measure of scapula depression 
and adduction.  Because of this, the matched control was also dropped from the data 
analysis.  Therefore, a total of 23 breast cancer survivors and 23 matched controls were 
used in the analysis for the ROM and strength data.  There was no loss of cervical spine 
data for either group. 
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3.6.2c. Kinematic Data 
Two participants kinematic data was not able to be analyzed during all 3 elevation 
tasks due to data collection errors for the rotational motions of anterior/posterior tipping, 
upward/downward rotation, and internal/external rotation, as well as the translational 
motions of elevation/depression and protraction retraction.  Because of these errors the 
matched controls were dropped from the analysis.  Therefore, for the scapula motions of 
anterior/posterior tipping, upward/downward rotation, and internal/external rotation a 
total of 22 breast cancer survivors and 22 matched controls were analyzed during all three 
of the elevation tasks.   
For the analysis of the translation motions of elevation/depression and 
protraction/retraction during the flexion, 9 breast cancer survivors who had cancer on the 
left side were lost due to errors with the preference file setup. As a result, for analysis of 
the scapula translations of elevation/depression and protraction/retraction a total of 15 
breast cancer survivors and 15 matched controls were analyzed during the flexion task.   
During the scaption and reaching tasks, two additional participants had errors 
during data collection and the translation motions of elevation/depression and 
protraction/retraction were dropped from the analysis.  Therefore, for the scapula 
translation of elevation/depression and protraction/retraction a total of 13 breast cancer 
survivors and 13 matched controls were analyzed during the scaption and reaching tasks. 
3.7 Statistical Analysis 
3.7.1 Study Power 
 A-priori power calculations were based on previous literature comparing group 
(impaired versus unimpaired) or side (affected versus unaffected) differences, as well as 
87 
 
pilot data for the dependent variables.  Effect sizes, references, and sample size required 
to obtain a power of .80 in this study are provided in Tables 4 - 7.  Based on these 
estimates, it is proposed that this study contain 20 – 25 participants in each group (BCS 
and CON).  Although not every dependent variable meets this sample size, it is believed 
that the majority of the dependent variables of interest are included.   
3.7.2 Analysis Plan 
 Means and standard deviations were calculated for the demographic data of the 
two groups, including age, height, weight, and BMI.  The analysis plan for each research 
question was as follows: 
RQ1. Are there significant differences between breast cancer survivors and matched 
controls on shoulder function (DASH and PSS)? 
Analysis: A one-way analysis of variance (ANOVA) was conducted to evaluate 
the functional outcome measure scores on the DASH and PSS between the breast 
cancer survivors and healthy, matched controls.  The independent variable was 
group, while the dependent variables were the scores on the DASH and PSS. 
Means, standard deviations (SD), 95% confidence intervals (CI), p-values, and 
effect sizes are reported.  
RQ2. Are there significant differences between breast cancer survivors and matched 
controls for shoulder active ROM, shoulder passive ROM, shoulder girdle strength, 
cervical active ROM, and scapula and clavicle kinematics? 
Analysis:  A one-way multivariate analysis of variance (MANOVA) was 
conducted to determine if differences existed between the two groups, breast 
cancer survivors and controls, on the dependent variables of affected shoulder 
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girdle active shoulder ROM, affected shoulder girdle passive shoulder ROM, 
affected shoulder girdle strength, and cervical spine active ROM.  Analyses of 
variance (ANOVA) on each of the dependent variables were conducted as follow-
up tests to the MANOVA.  Means, standard deviations (SD), 95% confidence 
intervals (CI), p-values, and effect sizes are reported. 
Five mixed model 2x4 ANOVAs (group x angle) were performed to 
examine changes in scapula (3 variables) and clavicle (2 variables) position for 
each of the three elevation tasks (flexion, scaption, and reaching).  Post-hoc 
testing using Bonferroni post-hoc adjusted t-tests (adjusted α=0.0125) were 
performed for significant findings from the ANOVAs.  F-values, p-values, partial 
eta2, and power are reported. 
RQ3. Is shoulder active shoulder ROM, passive shoulder ROM, shoulder girdle strength, 
or active cervical ROM correlated to scores on the DASH in breast cancer survivors? 
Pearson Product Moment correlation coefficients were computed to assess the 
relationship between each dependent variable with scores on the DASH.  P-values 
and r-values are reported. 
RQ4. Is shoulder active shoulder ROM, passive shoulder ROM, shoulder girdle strength, 
or active cervical ROM correlated to scores on the PSS in breast cancer survivors?  
Pearson Product Moment correlation coefficients were computed to assess the 
relationship between each dependent variable with scores on the PSS.  P-values 
and r-values are reported. 
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SPSS® statistical software (version 16.0, SPSS Inc., Chicago, IL) was used to 
analyze all data.  Statistical significance levels for all comparisons was set at an a priori 
of alpha = 0.05. 
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CHAPTER IV 
 
RESULTS 
 
Introduction 
The results from this study are summarized below and organized by each research 
question.  To explain differences between the two groups, F-values, p-values, 95% 
confidence intervals, and effect sizes are presented.  Additionally, with kinematic 
variables, eta2, and power are presented.  To demonstrate relationships that existed 
between variables, Pearson Product Moment Correlation Coefficients are described and 
p-values and r-values are presented. 
4.1.  Participants 
   Volunteers were recruited from the university population and the surrounding 
Chapel Hill community through word of mouth.  A total of 24 female breast cancer 
survivors aged 50.8 ± 9.51 years and 24 healthy female matched controls aged 50.4 ± 
9.97 years participated in this study.  Eight of the breast cancer survivors underwent a 
lumpectomy while the other 16 received a mastectomy.  The breast cancer survivor group 
was matched to the healthy controls by gender and BMI.  Table 8 shows the means for 
the subject descriptive data.   
4.2  Research Questions 
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4.2.1  Research Question 1 
Are there significant differences between breast cancer survivors and matched controls 
on shoulder function (DASH and PSS)? 
The results of the ANOVA revealed a statistical significant difference between 
groups for the DASH (F1,45 = 27.90, p < .001) and PSS (F1,44  = 30.54, p < .001) as shown 
in Table 9 with the breast cancer survivor group displaying significantly greater shoulder 
disability compared to the control group on both outcome measures. Twenty three breast 
cancer survivors and twenty three matched controls completed the DASH. 
A higher score on the DASH reflects greater disability.  The average score for the 
breast cancer survivors was 19.35, whereas the control group averaged 1.16. With the 
PSS, a lower score reveals greater disability.  Breast cancer survivors averaged a 77.12 
while the control group averaged 97.46 on the PSS.  The PSS subscale means can be 
visualized in Table 10.  There was a statistically significant difference found between all 
3 subscales (pain, satisfaction, and function) between the two groups.  These results 
demonstrate the importance of utilizing an outcome measure like the DASH and PSS 
during rehabilitation that can offer an objective measure to provide a baseline for 
function in a patient, as well as monitor progress. 
4.2.2  Research Question 2 
Are there significant differences between breast cancer survivors and matched controls 
on shoulder active ROM, shoulder passive ROM, shoulder girdle strength, cervical active 
ROM, 3D kinematics? 
 A one-way multivariate analysis of variance (MANOVA) was conducted to 
determine if differences existed between the two groups, breast cancer survivors and 
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controls, on the dependent variables of affected shoulder girdle active and passive 
shoulder ROM.  ROM was assessed on twenty three breast cancer survivors and twenty 
three matched controls.  Significant differences were found between the groups on the 
dependent measures, Wilks’s Λ = .57 (F10,35 = 2.67, p= .015).  A one-way analysis of 
variance (ANOVA) on each of the dependent variables for active and passive shoulder 
ROM was conducted as follow-up tests to the MANOVA and results can be seen in 
Tables 11 and 12.  Both active (F1,46 = 20.95, p < .001), and passive (F1,46 = 18.06, p < 
.001) shoulder flexion were significantly decreased in the BCS group.  It was also found 
that both active (F1,46 = 5.79, p = .020) and passive (F1,46 = 6.84, p = .012) 90° ER were 
significantly decreased in the BCS group.  The last ROM measure found to be 
significantly decreased in the BCS group when compared to the healthy control group 
was active extension (F1,46 = 9.90, p = .004).  
A one-way MANOVA was conducted to determine if differences existed between 
the two groups, breast cancer survivors and controls, on the dependent variables of 
cervical spine active ROM and results can be viewed in Table 13.  Cervical spine active 
ROM was analyzed on twenty four breast cancer survivors and twenty four matched 
controls.  No significant differences were found on the dependent variables, Wilks’s Λ = 
.91 (F6,41 = .67, p = .67) between the two groups.  
A one-way MANOVA was conducted to determine if differences existed between 
the two groups, breast cancer survivors and controls, on the dependent variables of 
affected shoulder girdle strength with the results displayed in Table 14.  Shoulder girdle 
strength was measured on twenty three breast cancer survivors and twenty three matched 
controls.  Significant differences were found between the groups on the dependent 
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measures, Wilks’s Λ = .60 (F7,40 = 3.81, p = .003) revealing decreased upper extremity 
strength in the breast cancer survivor group when compared to the control group.  
Analyses of variance on each of the dependent variables for affected shoulder girdle 
strength were conducted as follow-up tests to the MANOVA.  All seven of the shoulder 
girdle strength measures were significant, abduction and upward rotation (F1,46 = 8.45, p 
= .006), depression and adduction (F1,46 = 9.20, p = .001), flexion (F1,46 = 19.37, p < 
.001), external rotation (F1,46 = 12.05, p = .004), internal rotation (F1,46 = 9.91, p = .001), 
scaption (F1,46 = 15.07, p < .001), and adduction (F1,46 = 20.55, p < .001).  These results 
illustrate the importance of assessing shoulder girdle strength for abduction and upward 
rotation, depression and adduction, flexion, ER, internal rotation, scaption, and adduction 
in breast cancer survivors. 
 A summary of the repeated measures ANOVA (angle x group) for the scapula 
kinematic variables during the flexion task is shown in Table 15.  Twenty two breast 
cancer survivors and twenty two matched controls were assessed for the kinematic 
variables of anterior/posterior tipping, up/down rotation, and internal/external rotation 
during the flexion task.  During the flexion task, there was no group x angle interaction 
(F3,126 = .04, p = .990) and no main effect for group (F1,42 = 2.15, p = .150) for the scapula 
motion of anterior/posterior tipping.  Analysis of scapula internal/external rotation 
demonstrated no group x angle interaction (F3,126 = 1.16, p = .326) and no main effect for 
group (F1,42 = 1.13, p = .294).  There was also no group x angle interaction (F3,126 = .132, 
p = .941) and no main effect for group (F1,42 = 2.18, p = .147) during upward/downward 
rotation.  A one-way ANOVA revealed no significant differences between the groups for 
humeral elevation maximum angle as shown in Table 21 (F1,42 = 4.02, p = .051).  Means, 
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standard deviations, 95% confidence intervals, and effect sizes for the scapula rotations 
and translations are reported in Table 16 for the flexion task.   Figures 26 - 30 shows the 
mean scapula rotations and translations during the flexion task.    
 The scapula kinematic results from the repeated measures ANOVA (angle x 
group) performed on the scaption task is shown in Table 16.  Twenty two breast cancer 
survivors and twenty two matched controls were assessed for the kinematic variables of 
anterior/posterior tipping, up/down rotation, and internal/external rotation during the 
scaption task.  Analysis of scapula anterior/posterior tipping demonstrated no group x 
angle interaction (F3,126 = .25, p = .861) and no main effect for group (F1,42 = 3.57, p = 
.066).  There was no group x angle interaction (F3,126 = .13, p = .942) and no main effect 
for group (F1,42 = 1.45, p = .235) for the scapula motion of upward/downward rotation.  
For the scapula variable of internal/external rotation, there was no group x angle 
interaction (F3,126 = .03, p = .994) and no main effect for group (F1,42 = .29, p = .597). 
There was no significant difference found between the two groups for maximal humeral 
flexion angle (F1,42 = 1.27, p = .266).    Means, standard deviations, 95% confidence 
intervals, and effect sizes for the scapula rotations and translations are reported in Table 
17 for the scaption task.   Figures 31 - 35 shows the mean scapula rotations and 
translations during the scaption task.    
Analysis of scapula motion during the reaching task also was performed using 
repeated measures ANOVA (angle x group) with the results shown in Table 18.  Twenty 
two breast cancer survivors and twenty two matched controls were assessed for the 
kinematic variables of anterior/posterior tipping, up/down rotation, and internal/external 
rotation during the reaching task.  For anterior/posterior tipping no group x angle 
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interaction (F3,126 = .52, p = .678) and no main effect for group (F1,42 = 3.07, p = .087) 
was found.  There was also no group x angle interaction (F3,126 = .090, p = .966) and no 
main effect for group (F1,42 = .89, p = .352) during upward/downward rotation.  A group 
x angle interaction was found for internal/external rotation (F3,126 = 2.95, p = .035) 
although there was no main effect for group (F1,42 = .483, p = .491).  Bonferonni post-hoc 
testing (adjusted α=0.0125) found no significant differences for angle within the two 
groups (breast cancer survivor and control) for scapula internal/external rotation.  Means, 
standard deviations, 95% confidence intervals, and effect sizes for the scapula rotations 
and translations are reported in Table 19 for the reaching task.   Figures 36 - 40 shows the 
mean scapula rotations and translations during the reaching task.    
 A repeated measures ANOVA (angle x group) was also performed on the scapula 
translations of elevation/depression and protraction/retraction for all three tasks of 
flexion, scaption, and reaching as depicted in Table 15.  Fifteen breast cancer survivors 
and fifteen matched controls were assessed for the kinematic variables of 
elevation/depression and protraction/retraction during the flexion task.  For the flexion 
task there was no group x angle interaction (F3,84 = 5.41, p = .842) and no main effect for 
group (F1,28 = 1.36, p = .254) for the scapula translation of elevation/depression.  There 
was also no group x angle interaction (F3,84 = 5.39, p = .918) and no main effect for group 
(F1,28 = .340, p = .564) during protraction/retraction.  Thirteen breast cancer survivors and 
thirteen matched controls were assessed for the kinematic variables of 
elevation/depression and protraction/retraction for the scpation task.  During the scaption 
task, a repeated measures ANOVA (Table 16) revealed no group x angle interaction (F3,84 
= .040, p = .989) and no main effect for group (F1,24 = .309, p = .583) for the scapula 
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translation of elevation/depression as shown in Table 17.  During protraction/retraction, 
there was no main effect for angle (F3,84 = .171, p = .915), however there was a main 
effect for group (F1,24 = 5.183, p = .032).  Thirteen breast cancer survivors and thirteen 
matched controls were assessed for the kinematic variables of elevation/depression and 
protraction/retraction for the reaching task.  During the reaching task, analysis of 
elevation/depression found no group x angle interaction (F3,72 = .264, p = .851) or main 
effect for group (F1,24 = .358, p = .555) as seen in Table 19.  Also, no group x angle 
interaction (F3,72 = .2.40, p = .075) or main effect for group (F3,72 = .212, p = .649) was 
found during the reaching task for protraction/retraction. 
4.2.3  Research Question 3 
Is shoulder active shoulder ROM, passive shoulder ROM, shoulder girdle strength, or 
active cervical ROM correlated to scores on the DASH in breast cancer survivors? 
 Twenty three breast cancer survivors completed the DASH and were analyzed for 
this correlation.  Five active shoulder ROM measures were analyzed and from these 
measures correlation coefficients were calculated.  The results of the correlational 
analyses presented in Table 22 show that 2 of the 5 correlations were statistically 
significant and were greater than or equal to -.615.  The results of this correlation suggest 
there is a relationship with active shoulder ROM measures of flexion as seen in Figures 
41 and 42 with the DASH.  Revealing that limitations in these motions may result in a 
higher score on the DASH reflecting greater disability. 
 Five different positions of passive shoulder ROM were analyzed and relationships 
were calculated using correlation coefficients. The results of the correlational analyses 
presented in Table 23 show that 2 of the 5 correlations were statistically significant and 
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were greater than or equal to -.544.  In general, the results illustrate a relationship with 
the DASH and shoulder ROM measures of flexion and 90°ER as shown in Figures 43 
and 44.  More specifically, where limited passive shoulder ROM may result in a higher 
score on the DASH reflecting greater disability. 
 Correlation coefficients were computed among the seven shoulder girdle strength 
measures.  The results of the correlational analyses presented in Table 24 show that 6 of 
the 7 correlations were statistically significant and were greater than or equal to -.477.  
The results of this correlation suggest that decreased shoulder girdle strength of abduction 
and upward rotation (Figure 45), depression and adduction (Figure 46), flexion (Figure 
47), internal rotation (Figure 48), scaption (Figure 49), and adduction (Figure 50) 
demonstrate a relationship with the DASH.  Decreased shoulder girdle strength may 
result in a higher score on the DASH reflecting greater disability. 
.  Six different measures of cervical spine active ROM was assessed and the 
resultant correlation coefficients were evaluated. The results of the correlation analyses 
presented in Table 25 show that only 1 of the 6 correlations were statistically significant 
demonstrating a moderate relationship r = -.476.  The results of this correlation suggest a 
relationship between the DASH and cervical spine active ROM measure of left rotation 
(Figure 51).  Limitations in this motion may result in a higher score on the DASH 
reflecting greater disability. 
The variables that were not significantly correlated to the DASH were:  active 
0°ER, active 90°IR, active extension, passive 0°ER, passive 90°IR, passive extension, 
external rotation strength, cervical flexion, cervical extension, cervical left sidebending, 
cervical right sidebending, and cervical right rotation. 
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4.2.4  Research Question 4 
Is shoulder active shoulder ROM, passive shoulder ROM, shoulder girdle strength, or 
active cervical ROM correlated to scores on the PSS in breast cancer survivors?  
Twenty two breast cancer survivors completed the PSS and were analyzed for this 
correlation.  Correlation coefficients were computed among the five active shoulder 
ROM measures.  The results of the correlational analyses presented in Table 26 shows 
that only 1 of the 5 correlations were statistically significant demonstrating a moderate 
relationship r - .588.  The results of this correlation suggest that decreased active shoulder 
ROM measure of flexion, as seen in Figure 52, will result in a lower score on the PSS 
reflecting greater disability. 
 Five passive shoulder ROM measures were assessed and the resultant correlation 
coefficients were calculated.  The results of the correlational analyses presented in Table 
27 shows that 2 of the 5 correlations were statistically significant and were greater than or 
equal to .424.  In general, the results suggest that there is a relationship between 
decreased passive shoulder ROM measures of flexion (Figure 53) and 90°ER (Figure 54) 
and the PSS which may result in a lower score on the PSS reflecting greater disability. 
 Shoulder girdle strength was measured in seven different positions and the 
correlation coefficients were computed.  The results of the correlational analyses 
presented in Table 28 show that 4 of the 7 correlations were statistically significant and 
were greater than or equal to .436.  The results of this correlation suggest that decreased 
shoulder girdle strength of flexion (Figure 55), internal rotation (Figure 66), scaption 
(Figure 57), and adduction (Figure 58) have a relationship with scores on the PSS and 
may result in a lower score on the PSS reflecting greater disability. 
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.  Correlation coefficients were calculated for the six cervical spine active ROM 
measures.  The results of the correlational analyses presented in Table 29 shows that 3 of 
the 6 correlations were statistically significant and were greater than or equal to .449.  
The results of this correlation demonstrate a relationship with cervical spine measures of 
left sidebending, left rotation, and right rotation, and limitations in these ROM measures 
may result in a lower score on the PSS reflecting greater disability as seen in Figures 59 - 
61. 
The variables that were not significantly correlated to the PSS were:  active 0°ER, 
active 90°ER, active 90°IR, active extension, passive 0°ER, passive 90°IR, passive 
extension, abduction and upward rotation strength, depression and adduction strength, 
external rotation strength, cervical flexion, cervical extension, and cervical right side 
bending. 
  
100 
 
 
 
CHAPTER V 
DISCUSSION 
Purpose 
The purpose of this study was to compare affected active and passive shoulder 
ROM, affected shoulder girdle strength, cervical active ROM, upper extremity function, 
and 3D scapula kinematics between breast cancer survivors and healthy, matched 
controls.  The secondary goal of this study was to assess if relationships exist in the 
breast cancer survivor population between functional scores on the DASH and PSS with 
affected active shoulder ROM, affected passive shoulder ROM, cervical active ROM, and 
affected shoulder girdle strength.  This is the first study known to the authors to compare 
breast cancer survivors affected side to a healthy age, matched population for these 
variables, as well as assess relationships between function and a number of clinical 
variables.  Several significant differences were found between the two groups in this 
study, as well as relationships between function and clinical measures.  This discussion 
will be divided into three main sections: 1) outcome measures of shoulder function from 
the DASH and PSS, 2) clinical measures of active and passive shoulder ROM, affected 
shoulder girdle strength, and cervical ROM, including what is driving differences in 
function, and 3) scapula kinematics. 
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5.1  Outcome measures 
Significant differences were found between the two groups with regards to upper 
extremity outcome measures for both the DASH and PSS, supporting our hypotheses. 
The results from this study showed that the average score on the DASH for the breast 
cancer survivor group was 19.35, while the healthy matched controls averaged 1.56.  The 
DASH is a validated measure and has been utilized in one previous study to objectively 
assess upper extremity function in breast cancer survivors.  Hayes et al. conducted a 
study on 258 women six months after treatment for unilateral breast cancer.86  Results 
from this study revealed an average DASH score of 10.8, with a wide range from 0.00 to 
17.7.86  The average of 10.8 is much less than the 19.35 average found on the DASH 
found in our study.  Although the Hayes et al. study and our study have similar means for 
age and time since receiving breast cancer treatment, comparisons of the DASH score 
between these two studies may be difficult to make due differences in surgery type.   
Only 28% of the breast cancer survivors in the Hayes et al. study received a mastectomy, 
whereas 67% received a mastectomy in our study.86  Further analysis of the 8 breast 
cancer survivors in this present study who received a lumpectomy scored an average of 
9.88 on the DASH compared to the average of 24.40 for those who received a 
mastectomy.  It is believed that the type of breast cancer surgery may affect upper 
extremity function.  Future research should be conducted to assess whether those who 
receive a mastectomy demonstrate a greater loss of upper extremity function, such as 
scores on the DASH, when compared with those who received a lumpectomy. 
Another study utilizing the DASH to assess upper extremity function in sixty-six 
breast cancer survivors was conducted by Gordon and colleagues.  This study revealed 
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the breast cancer survivors scored an average of 15.2 on the DASH, which falls in 
between what was found in the Hayes et al. study of 10.8 and our study’s findings of 
19.35.  It is difficult to make comparisons with the results from our study to the results 
from our study because there was no explanation as to how long ago the women in the 
Gordon et al. study completed their breast cancer treatment.   
There are relatively few studies that utilize the DASH to assess upper extremity 
function in breast cancer survivors making comparisons with the results from this study 
difficult.  To gain a better understanding of the meaningfulness of the average score of 
19.35 found on the DASH in this study, comparisons with other shoulder pathologies are 
needed.  The DASH has been used to assess upper extremity function in several other 
shoulder pathologies including rotator cuff tears, impingement, and adhesive capsulitis.  
A recent study conducted by Colegate-Stone et al., assessed 123 persons who were to 
undergo a rotator cuff repair.240  Individuals who had a rotator cuff tear <30 mm scored 
an average of 52 on the DASH, whereas those who had a tear >30mm scored an average 
of 68 prior to their surgery.240  These average scores of 52 and 68 are significantly higher 
than the average score on the DASH found in the breast cancer survivors in this study.  It 
is important to note that all of these individuals were surgical candidates, and pain 
descriptors were not utilized, which may explain the high DASH score.  Also, the authors 
did not indicate how long these individuals have been affected by the rotator cuff 
pathology making comparisons difficult since the breast cancer survivors in our study had 
very recently completed their treatment.  Fifty-eight individuals who were waiting to 
begin physical therapy for suspected shoulder impingement syndrome completed the 
DASH in a study conducted by Ardic et al.172  The average score on the DASH was 58.3 
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for these individuals.172  These individuals also complained of 7.5/10 shoulder pain, 
whereas the average shoulder pain found in the breast cancer survivor group was 
2.2/10.172  These individuals with impingement stated their shoulder pain had been 
bothering them for ~12 months.172  This duration and intensity of pain also makes 
comparing their DASH scores to the breast cancer survivors difficult.   A study was 
conducted on 63 individuals to test the efficacy of low-power laser therapy in persons 
with adhesive capsulitis.241  These individuals completed the DASH prior to treatment 
and revealed an average score of 46.241  The subjects with adhesive capsulitis 
demonstrated a higher score on the DASH when compared to the breast cancer survivors 
in this study.241   However, once again, comparisons of the DASH scores between those 
who have been diagnosed with adhesive capsulitis and the breast cancer survivors in our 
study are difficult to make because the study conducted by Stergioulas did not report 
patient demographics such as average age and time of onset of pain, although the 
individuals did rate their pain an average of 7/10.241  The results of the above studies 
reveal that it is very difficult to compare breast cancer survivors’ function on an 
assessment like the DASH with other shoulder pathologies such as rotator cuff tears, 
impingement, and adhesive capsulitis.  This appears to be due to a large amount of 
variability in the patient demographics and the different nature of these shoulder 
pathologies when comparing the effects of shoulder function in breast cancer survivors.  
One similar finding in all three of the shoulder pathologies discussed above is the higher 
subjective rating of pain when compared to the breast cancer survivors in our study which 
may also explain the difficulty in comparing DASH scores.   
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While the level of dysfunction as represented on the DASH in the breast cancer 
survivors for this study is not as great as that associated with shoulder impingement of 
rotator cuff tears, there is still an important difference in function between BCS and 
control subjects as evidenced by the large effect size of 1.08.  The comparison to the 
other shoulder pathologies gives a sense of the relative level of dysfunction in 
comparison to several shoulder pathologies.  The significant differences on scores of the 
DASH found between the breast cancer survivors and healthy, matched controls, along 
with the large effect sizes found illustrate that this is still an important decrease in 
function that is statistically and clinically important.  As such, clinicians need to better 
understand this dysfunction in order to identify those breast cancer survivors who have a 
loss of shoulder function to develop the appropriate rehabilitation programs for these 
individuals 
Assessing the clinical significance on scores of the DASH can be difficult. There 
is no set standard or cutoff on the DASH to represent a score for disability, although it 
has been suggested that scoring a 20 or higher may represent a significant loss of 
function.242  The average score on the DASH for the breast cancer survivors in this study 
of 19.35 is just slightly below this average.  However, further analysis reveals 11 of the 
23 breast cancer survivors scored greater than a 20 with an average score of 32.6.    Thus, 
while the average DASH score in breast cancer survivors is slightly below the cut score 
of 20 for displaying a significant loss of function our findings indicate that many 
individuals score well above this cut score and do display significant function loss.  
Because of this further analysis, it is recommended further research be conducted 
regarding outcome measures assessing function in breast cancer survivors to evaluate if 
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there is a subgroup of women who are affected adversely by their breast cancer treatment.  
A second way to assess whether the 19.35 average score found in our study is clinically 
meaningful is to examine the minimal clinically important difference (MCID).  Schmitt 
and DiFabio have suggested the MCID for the DASH to be 10.2.243  When comparing the 
averages between the two groups in this study, breast cancer survivors (19.35) and 
healthy matched controls (1.56), the average difference is 17.79, therefore reflecting a 
clinically important difference between groups. 
One limitation found on the DASH in this study is the wide range of scores from 
0.86 to 71.3.  Several factors may have contributed to the wide range in scores found in 
this study such as: stage of breast cancer, type of surgery (mastectomy or lumpectomy), 
reconstruction, and systemic treatment such as chemotherapy and/or radiation.  Although 
these variables were recorded but not separately analyzed in this study due to a small 
sample size, it is recommended that these factors are examined in future research 
involving breast cancer survivors.   
Although the DASH provides clinicians with an overall score reflecting function, 
it may be important to analyze each question individually when working with a breast 
cancer survivor to identify specific deficits for that individual.  This is because; the 
DASH is not a specific outcome measure of function for breast cancer itself, and as 
discussed above, it can be used for a variety of upper extremity pathologies.  Further 
analysis of each individual item on the DASH found that almost half of the breast cancer 
survivors in this study agreed or strongly agreed with feeling less capable, less confident 
or less useful because of their arm, shoulder or hand problem (question #30).  
Approximately half of the breast cancer respondents in this study reported moderate to 
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severe difficulty, or the inability to perform recreational activities (golf, hammering, 
tennis, etc) which take some force or impact through the arm, shoulder, or hand (question 
#18).  The breast cancer survivors in this study also reported difficulty with performing 
question 19, recreational activities in which the arm is moved freely (Frisbee, badminton, 
etc).  While the average disability found on the DASH in this study for the breast cancer 
survivors was 19.35, assessing the response of each item on the DASH could help better 
guide an individual rehabilitation program for the specific function of each breast cancer 
survivor. 
This is the first study known to the authors that utilized the PSS to analyze upper 
extremity function in a group of breast cancer survivors.  With the PSS, a lower score 
reveals greater disability.  In this study, breast cancer survivors averaged a 77.12 (out of 
100) while the control group averaged 97.46 on the PSS.  A wide range of variability can 
be seen in this study with the PSS scores for the breast cancer survivors ranging from 35 
– 100.  However, little variability existed with regards to PSS scores for the healthy, 
matched controls ranging from 88 – 100 with 11 of the 24 women scoring a 100.  As 
described previously with the DASH, the large range in scores for the breast cancer 
survivors may be due to a variety of factors such as: stage of breast cancer, type of 
surgery (mastectomy or lumpectomy), reconstruction, and systemic treatment such as 
chemotherapy and/or radiation.  These variables were recorded but not separately 
analyzed in this study due to a small sample size.  It is recommended that variables such 
as these are examined in future studies investigating upper extremity function in breast 
cancer survivors.   
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Understanding what is clinically important can be difficult when analyzing the 
PSS.  Unlike the DASH, there has been no recommended cutoff to delineate disability 
when analyzing the PSS.  Furthermore, there has been no minimally important clinical 
difference established for the PSS.  Therefore, comparisons must be made between breast 
cancer survivors’ upper extremity function with other shoulder pathologies such as 
rotator cuff tears and impingement.  Sauerbrey and colleagues conducted a retrospective 
comparative study on 54 individuals who were to undergo a rotator cuff repair.244  The 
overall PSS score for these individuals prior to surgery was roughly 47 (out of 100) 
considerably lower than the average of 77 found for the breast cancer survivors in our 
study.244  Another study utilized the PSS to assess shoulder function in 39 individuals 
who were diagnosed with shoulder impingement.194  The average total score on the PSS 
for these individuals was 63.3, once again lower than the average score of 77 for the 
breast cancer survivors in this study.194  
The PSS can be subdivided into three subscales: function, pain, and satisfaction.  
The average found for the function subscale in this study was 46.6 (out of 60, a higher 
number reflects greater function) for the breast cancer survivors and 58.6 for the healthy, 
matched controls.  Similar to the findings above regarding the overall score on the PSS, 
differences are seen when trying to compare the breast cancer survivors in our study to 
individuals with other shoulder pathologies such as rotator cuff tears and impingement.  
These same studies discussed previously revealed the function subscale score to average 
30.0 (out of 60, a higher number reflects greater function) and 42.7 for those with rotator 
cuff tears and shoulder impingement, respectively.194, 244   Differences in group 
comparisons for pain were also observed.  In the study conducted by Sauerbrev on 
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individuals with rotator cuff tears, the average pain score was 15 (out of 30, a higher 
number reflects less pain) whereas the average pain score was 16.9 for those with 
shoulder impingement in the study conducted by McClure et al.194, 244  These pain 
subscales averages are significantly lower, compared to the 25 average found in our study 
for the breast cancer survivors. 
A unique feature of the PSS is the satisfaction subscale, which asks “how satisfied 
are you with the current level of function of your shoulder”.  To our knowledge, no other 
upper extremity outcome assessment tool asks individuals about their satisfaction 
regarding current shoulder function.  The satisfaction subscale on the PSS is based on a 
score of 10, where a higher number reflects greater satisfaction.   The average satisfaction 
score for the breast cancer survivors in this study was a 5.7.  Shoulder pathologies such as 
individuals with rotator cuff tears and impingement have reported scores of 2.5 and 3.7 
respectively.  These satisfaction scores appear to reflect not as large of a magnitude of 
difference between the breast cancer survivors and other shoulder pathologies.  There 
appears to be a trend when comparing the breast cancer survivors in our study with other 
shoulder pathologies. It appears that overall, the breast cancer survivors in our study 
tended to have better overall function, decreased pain, and are more satisfied than others 
with such shoulder pathologies as rotator cuff tears and shoulder impingement.   
As with the DASH, it appears comparing the total outcome score as well as each 
subscale on the PSS for breast cancer survivors in our study with those individuals who 
suffer from other shoulder pathologies such as rotator cuff tears and impingement may 
not be an appropriate comparison.  Onset of injury may be one area that could explain the 
differences in scores observed between the breast cancers survivors and those with other 
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shoulder pathologies. The breast cancer survivors were no more than 6 months out from 
their last systemic and/or surgical treatment.  In contrast, 50% of those individuals who 
were diagnosed with shoulder impingement had an average duration of injury of 6 
months or greater.  Unfortunately, the study conducted by Sauerbrey et al. does not 
mention the duration of injury before these individuals proceeded with their rotator cuff 
repair.  One limitation of our study is the relatively small sample size of breast cancer 
survivors (n = 22) when compared to other research studies utilizing the PSS with other 
shoulder pathologies194, 244  A second limitation with our study is the variability in 
treatment received in our breast cancer survivor cohort including type of surgery 
(mastectomy or lumpectomy) as well as type and duration of systemic treatment 
(chemotherapy and/or radiation).  These factors were not analyzed separately due to the 
small sample size, but should be considered in the research design and subject 
recruitment during future research involving breast cancer survivors and shoulder 
function.  Despite these limitations, while the level of dysfunction is not as large as that 
associated with other shoulder pathologies, there is still an important difference in 
function between the breast cancer survivors and control subjects as evidenced by the 
large effect size of 1.15 found in this study for the PSS.  Similar to the DASH, the 
significant difference between the breast cancer survivors and the healthy, matched 
controls along with the large effect sizes reveal that the scores on the PSS demonstrates 
an important decrease in function that is both statistically and clinically important 
Pain appears to be a significant factor affecting function when analyzing the PSS.  
Significant differences are evident when examining the pain subscale in those with 
rotator cuff tears and shoulder impingement compared to the breast cancer survivors’ 
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scores.  Pain is a subjective measure and is interpreted and described differently person to 
person.  Two significant factors may be causing “better” scores for pain on the PSS in the 
breast cancer survivor group.  First, as mentioned above, they have only recently 
completed their primary treatment and many have stated they have not been able to return 
to their previous activity lifestyle due to a variety of factors including fatigue and 
uncertainty of what they can do regarding movement with their surgical side.  Secondly, 
breast cancer survivors may report pain in a different manner when compared to other 
individuals who have not gone through such a life threatening diagnosis as cancer.  
Future research should be conducted within the breast cancer population to further assess 
their perception of pain in order to make comparisons to other pathologic populations. 
The results from this study utilizing the DASH and PSS demonstrate breast cancer 
survivors who have recently completed their primary breast cancer treatment display a 
decrease in upper extremity function when compared to matched, healthy controls.  The 
level of average functional loss in breast cancer survivors does not appear to be as great 
as other shoulder pathologies, such as rotator cuff tears and shoulder impingement; 
however, breast cancer survivors do suffer from significant loss of function as well as a 
low level of satisfaction with the use of the shoulder as indicated by the DASH and PSS 
scores.  It is important to note a wide range of scores was observed in this study for both 
the DASH and PSS and should be further examined.  Future research investigating upper 
extremity function in breast cancer survivors should utilize a larger sample size, take into 
account other factors such as surgical and systemic treatment, and consider examining 
women who have finished their primary treatment greater than six months ago.  As 
Isaksson and Feuk found, breast cancer survivors continue to have pain, weakness, and 
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restricted movements two years postoperatively.9  This study does begin to provide 
insight regarding upper extremity function and breast cancer survivors and shows 
function can be significantly affected in this cohort.  Utilizing quality, outcome tools such 
as the DASH and PSS could provide clinicians with important information regarding 
upper extremity function in order to help each breast cancer survivor resume a high 
quality of function in their lives.  These findings also indicate that shoulder function is 
diminished in breast cancer survivors.  To improve function in these individuals it is 
important to understand whether physical characteristics, such as strength and ROM are 
also affected in these women.  This information may provide insight into factors which 
may need to be addressed during rehabilitation of breast cancer survivors 
5.2  Clinical measures  
Several clinical measures were examined in this study to quantify differences that 
may exist between breast cancer survivors and healthy, matched controls.  These clinical 
measures included: active and passive shoulder ROM, shoulder girdle strength, and 
cervical spine active ROM.  This is the first known study to compare breast cancer 
survivors’ active and passive shoulder ROM to healthy, matched controls.  Five active 
and passive shoulder ROM movements were assessed in this study.  Of those, active and 
passive flexion and 90° ER, and active extension demonstrated significant differences 
between the two groups, partially supporting our hypotheses.   
Research has shown that normative values for active shoulder flexion in females 
average approximately 176°.245  The average active and passive shoulder flexion ROM 
found in this study for the breast cancer survivors was 156.5º and 160.5º compared to the 
164.8º and 171.9º averages for the healthy, matched controls.  This difference was 
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statistically significant and represents an average difference of 8.29 º and 11.34º between 
the two groups for active and passive shoulder flexion respectively. 
Shoulder flexion appears to be the most commonly studied motion in the breast 
cancer survivor population and has been recently examined by several different 
researchers.  Hayes et al. found limitations in active shoulder flexion in 214 breast cancer 
survivors with a mean of 143°.86  Other studies have revealed average active shoulder 
flexion in breast cancer survivors to be 155°,246 163°,55 163°,247 and 168°.55  Caution 
needs to be utilized when comparing the results of these studies amongst each other, as 
well as against the results of flexion ROM found in this study.  This is because several 
different testing methodologies were incorporated in these studies.  These include 
differing length of time since diagnosis of breast cancer, a wide range of ages, various 
treatments (systemic and surgical) for the breast cancer, and differing testing positions 
utilized (standing, seated, and supine) during the measurements of shoulder flexion.   
To further understand the clinical significance regarding the limitations in flexion 
ROM found in the breast cancer survivor population, comparisons can be examined 
between the breast cancer population and other shoulder pathologies such as rotator cuff 
disease, shoulder impingement, and adhesive capsulitis.  A recent study examined 85 
Canadian postal workers who had symptoms lasting >6 weeks for rotator cuff 
tendinitis.248  Results showed these individuals demonstrated 122° of active and 124° of 
passive shoulder flexion.248  One limitation making comparisons difficult with this study 
to ours is that there is no description of how the subjects were positioned (seated, 
standing, or supine) during the testing measures of flexion ROM.  Vermuelen et al, 
analyzed ten individuals who were diagnosed with adhesive capsulitis.207  Results from 
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this study demonstrated active and passive shoulder flexion to average 156° and 167°, 
which are very similar to the flexion ROM limitations found in the breast cancer 
population examined in our study.207  In another study, 58 individuals who were 
diagnosed with shoulder impingement and waiting to begin physical therapy had a variety 
of clinical measures recorded.172  Results revealed active shoulder flexion to average 
139.2°.172  A study performed by Lombardi et al. analyzed flexion active ROM in 60 
patients who had impingement.249   Interestingly, the results demonstrated greater deficits 
in active flexion ROM , 119.5°.  The authors do state the measurement in standing was 
“performed against the pull of gravity”.249  This positioning of the patient may explain 
the differences in flexion ROM found when comparing the results from our study, and 
those like Ardic’s with the study by Lombardi.   Despite these factors limiting 
comparisons between other shoulder pathologies with our results, the results illustrate 
deficits do exist with regards to shoulder flexion ROM on the affected extremity in the 
breast cancer survivor population.  Similar deficits in shoulder flexion ROM are observed 
between breast cancer survivors and other shoulder pathologies and breast cancer 
survivors.  Thus, these appear to be clinically important differences in shoulder flexion 
ROM.      
The average active flexion ROM found in this study was 156.5º for the breast 
cancer survivors and was significantly different when compared to the healthy, matched 
controls.  What proves difficult is interpreting the clinical relevance of observed changes 
between these two groups.  Some researchers recommend a clinical significant ROM 
difference be compared between the involved and uninvolved extremity.75  It is believed 
when these measures differ by >10° between extremities, a clinical significance exists.75 
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Because comparison measures between extremities were not recorded in this study, 
analysis between the breast cancer survivors and control group flexion ROM reveals a 
difference of 8.3º  for active ROM and 10.5º for passive ROM.  To further explain the 
clinical significance of these findings, effect sizes can be examined to further emphasize 
the clinical importance of the flexion active and passive ROM differences found between 
the breast cancer survivors and healthy, matched controls.   In this study, the effect sizes 
for active and passive flexion ROM were 1.14 and 1.05 respectively.  These large effect 
sizes, the 8.3º and 10.5º differences between groups for this measure of flexion ROM, 
along with the statistical significance found in this study helps to demonstrate a 
meaningful clinical difference seems to exist for active and passive shoulder flexion 
ROM between breast cancer survivors and healthy, matched controls. 
Although shoulder active and passive flexion ROM appears to be the most often 
studied shoulder motion in the breast cancer survivor population, results from this study 
demonstrate a necessity for clinicians to also examine active and passive ROM for 90° 
ER.  Significant differences were found for both the active and passive ROM measures at 
90° ER in this study.  Outcomes for this measure demonstrated breast cancer survivors 
averaged 87.64° and 91.64°, whereas the healthy, matched controls averaged 98.36° and 
102.17° respectively for the active and passive ROM measures.   
Several other studies complement the results from this study reporting limitations 
of active ROM for 90° ER in breast cancer survivors to range from 80°,250 82°,247 and 
86°.55   To further demonstrate the significance of deficits for this motion in breast cancer 
survivors, examining other shoulder pathologies may provide further insight into the 
clinical meaningfulness of the statistical differences found in this study.  Lombardi and 
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colleagues examined shoulder active ROM for 90° ER in 60 patients diagnosed with 
shoulder impingement syndrome.249  These individuals with shoulder impingement 
demonstrated an average of 71.6° for active 90° ER.249  There was one significant 
difference regarding methodology making comparisons between this measure of ROM 
with our measures is that the individuals with impingement were standing when active 
ROM was recorded.  One hundred and seventy individuals who were about to undergo 
rotator cuff surgery had baseline measures of active and passive ROM for 90° ER 
assessed.251  Averages for 90° ER active ROM was 50°, whereas passive ROM averaged 
64°.251  Although these averages are several degrees less than what was found for the 
breast cancer survivors in this study, it is important to note that these individuals reported 
an average duration of symptoms for 45 months, significantly longer than the time since 
the breast cancer survivors in this study were diagnosed.  This large difference in 
duration since onset and assessment of these ROM measures should cause some concern 
when making comparisons.   
Comparing breast cancer shoulder ROM measures to other pathologies such as 
impingement and rotator cuff dysfunction may provide limited understanding of clinical 
significance due to differences in methodology and length of time since injury.  
Reviewing normative data for active shoulder ROM at 90° ER reveals an average of 101° 
for healthy females.245  This is approximately 13° greater than the averages found in this 
study for the breast cancer survivor population.  When utilizing the minimal clinically 
important difference of  >10º to demonstrate clinical significance, as suggested by 
MacLean and colleagues, differences between the two groups in this study reveal a 10.7° 
difference for active ROM and 10.5° difference for passive ROM measures.75  
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Furthermore, examining the effect sizes of 0.56 for active and 0.62 passive ROM 
demonstrates a possible clinical meaningful difference for the measure of 90° ER in the 
breast cancer survivor population.  Although this effect size is moderate, clinicians who 
rehabilitate women who have recently undergone treatment for breast cancer should 
monitor this particular ROM especially if deficits exist when compared to the unaffected 
extremity and/or normative data.   
The final ROM that was found to significantly differ between the breast cancer 
survivors and the healthy, matched controls was active extension.  This motion averaged 
25.78° for the breast cancer survivors compared to the average of 31.53° measured in the 
healthy, matched controls.  Therefore, there was an average difference of 5.75° between 
the breast cancer survivors and healthy, matched controls when assessing active 
extension.  The difference of 5.75° may not seem large; however, when this difference is 
converted into a percentage, a difference of 18% is evident between the two groups.  To 
try and further explain the significance of this measure between the two groups in this 
study a large effect size of 0.82 was calculated. 
Only a few studies have examined active extension in the breast cancer survivor 
population.  Cho et al. examined fifty-five women who had completed their breast cancer 
treatment approximately 1 year from the time of the study and found active extension to 
average 41°.250  One of the difficulties in making comparisons to this study and a 
significant limitation is that the authors did not discuss the methodology regarding how 
the ROM was measured.  Another study assessed active extension in sixty-five breast 
cancer survivors and found this motion to average 45° seven months after the primary 
surgical procedure.246  A large difference in the methodology of this study making 
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comparisons difficult was that Box et al. chose to analyze active extension in the seated 
position, whereas the present study chose to measure active extension in the prone 
position.  These methodological differences between studies may explain the 15° – 20° 
difference found between our study and those conducted by Box et al and Cho et al. 
In trying to further understand whether the average active extension ROM of 
25.78° in the breast cancer survivor group is clinically meaningful, comparisons with 
other shoulder pathologies can be analyzed.  The average extension active ROM in 65 
individuals with diagnosed rotator cuff tendinitis was 37.7°, although there was no 
explanation as to the positioning of these individuals during the recording of this 
measure.248  Lombardi and colleagues measured standing active extension ROM in 60 
individuals who were diagnosed with shoulder impingement.249  Active extension ROM 
measured 45.9° in these individuals.  These measures are much greater than the average 
found in our study for the breast cancer survivors and could be explained in the 
variability of positioning the individuals when measuring active extension.  As noted 
previously with other ROM findings, it seems to be difficult to make comparisons for 
measures of ROM between breast cancer survivors and other shoulder pathologies due to 
differences in methodology and duration of injury symptoms.   
Interestingly, passive extension did not differ between the two groups.  This might 
be explained by the positioning of the individual when recording this measure.  
Individuals were required to lie prone and perform extension against gravity in this study.  
Of importance to note is two of the breast cancer survivors were unable to assume the 
prone position due to pain.  These differences in passive and active ROM may provide 
evidence that perhaps it is not just a ROM deficit that exists with extension in breast 
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cancer survivors, but also a strength deficit may exist as well.  In future studies, a 
modification of this position, such as having the patient seated or standing, could be used 
to eliminate performing this motion entirely against gravity to gain a better understanding 
of whether this ROM is truly limited.  
Several measures were found to not be statistically significant between the two 
groups in this study; these included active and passive 0° ER, 90° IR, and passive 
extension ROM.  It is difficult to explain why there were no significant differences 
between the groups for the measures of active and passive 0° ER since no normative data 
could be found for this measure.  Furthermore, there appears to be no literature on this 
measure for breast cancer survivors and other shoulder pathologies such as impingement, 
adhesive capsulitis, or rotator cuff pathology.   This study revealed averages for active 
and passive ROM at 90° IR to be 60.71° and 65.09° respectively.  In comparison, 
normative values report active ROM for healthy females to average 51.0°, whereas 
passive ROM average 61.45° and 60.25°.245, 252  The active ROM measure of 90° IR has 
been examined in breast cancer survivors in three previous studies.55, 247, 250  The results 
from these studies show that the 90° IR active ROM measure to average 78.56°, 51.4°, 
and 56.9°.  Our results seem to correspond with two of these three studies; however 
caution must be used when making these comparisons as the measure for 90° IR was 
measured in the seated position in one study, whereas this study obtained this measure in 
the supine position. Other shoulder pathologies have revealed 90° IR ROM to average 
50.7° in subjects with impingement172 and only 3° in those with adhesive capsulitis.253  
The results of this study demonstrate the clinical importance of assessing active 
and passive shoulder ROM when evaluating a breast cancer survivor.  Several ROM 
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measures were shown to be significantly less in the breast cancer survivors when 
compared to the healthy, matched controls.  Having adequate ROM is pertinent in order 
to perform activities of daily living.  Activities of daily living (ADLs) can be defined as 
activities that describe the functional capacity of patients.87  ADL’s are essential for 
maintaining independent living, returning to work, and for general quality of life.87  In 
daily life, having the ability to achieve functional active flexion is imperative for a large 
number of different ADL’s such as combing hair, reaching, washing the upper back, 
shampooing hair, and performing other overhead tasks.87  If the active and passive 
motions of shoulder flexion, ER at 90°, and extension are not addressed in this population 
within the first 6 months of finishing their primary treatment, these women may 
experience upper extremity functional deficits, affecting ADL’s,  in the future as 
evidenced by the results of this study.  Limitations in shoulder ROM could possibly lead 
to a variety of future problems including decreased function, difficulty completing 
ADL’s, the development of adhesive capsulitis, rotator cuff pathology, and shoulder 
impingement.   
Although subjectively, is has been reported that breast cancer survivors have 
decreased muscle strength on the affected extremity, very few studies have quantified 
these actual deficits.101  Shamley and colleagues were one of the first to demonstrate a 
decrease in muscle activity of the upper trapezius, rhomboids, and serratus anterior 
during arm elevation in the plane of the scapula in breast cancer survivors when their 
affected extremity was compared to their unaffected extremity.254  This was the first 
known study to compare strength measures between breast cancer survivors and healthy, 
matched controls.  Results from this study illustrated that all of the shoulder girdle 
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strength measures of scapula abduction and upward rotation, scapula depression and 
adduction, humeral flexion, humeral external rotation, humeral internal rotation, scaption, 
and horizontal adduction were significantly different between the breast cancer survivors 
and matched healthy controls supporting our hypotheses.   
There have been very few studies conducted that assess upper extremity strength 
in the breast cancer survivor population.  Lee et al. conducted a study to examine upper 
extremity strength in sixty-four breast cancer survivors.72  Although MVIC’s were 
utilized to assess strength using a digital dynamometer, the results of the study were 
reported in Newtons and did not appear to be normalized to body weight for the subjects.  
Along with not normalizing the strength measures, different testing positions were also 
used in this study.  Therefore, it is difficult to make comparisons between the results of 
our study with those from Lee et al.  Another study evaluated upper extremity strength in 
forty women who had completed all of their treatment for breast with an average of 28 
months since initial treatment.101  Dynamic concentric strength was measured using a 1-
repetition maximum (RM) comparing the affected side to the unaffected side.  Significant 
differences were found for the 1RM measures between sides for the shoulder protractors, 
retractors, and extensors.  Comparisons again are difficult to make regarding the results 
from this study to the study conducted by Merchant et al. because of the different method 
utilized to assess strength, dissimilar muscles assessed, and a significant longer period, 22 
months versus 6 months, since initial treatment. 
To gain a better understanding of the observed differences in strength between the 
breast cancer survivors and healthy, matched controls in this study, comparisons can be 
made with other shoulder pathologies regarding strength measures.  Razmjou and 
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colleagues examined 170 individuals who were candidates for rotator cuff repair 
surgery.251  Strength measures were recorded in the scapular plane using an unsecured 
tensiometer.251  Results revealed a statistically significant difference between the affected 
(2.89 lbs) and unaffected (7.81 lbs) sides, explaining a 73% difference between sides.251  
This is a very large difference between the sides and may not be a representative 
comparison with our study.  This is because, the subjects with rotator cuff pathology were 
not only surgical candidates, but had reported symptoms for an average of 45 months.   
Forty-five subjects with impingement syndrome were compared with 45 subjects without 
known pathology or impairments at the shoulder in a recent study.19  Measures of force 
were assessed using the “break test method” for external rotation, internal rotation and 
scaption.19  Results showed all strength measures were statistically significant between 
the two groups for all three of these strength measures.19  Further analysis shows a 35% 
difference in strength measures between the groups for scaption, 23% for external 
rotation, and an 18% difference for the strength measure of internal rotation.19  Jurgel and 
colleagues examined 10 individuals with adhesive capsulitis and compared several 
measures of isometric maximal force with 10 healthy, matched controls.255  Isometric 
maximal force of the shoulder was measured by a hand-held dynamometer in a variety of 
positions including flexion, adduction, internal rotation, and external rotation.255  Of these 
measures, there was a statistically significant difference, reflecting a decrease in upper 
extremity strength when comparing those with adhesive capsulitis to the matched 
controls for the strength measures of shoulder flexors (33%), adductors (25%), and 
external rotators (33%).255  The above studies help to demonstrate strength differences 
exist in several different shoulder pathologies.   
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No other study has compared upper extremity strength in the breast cancer 
survivor population with healthy controls making comparisons of this measure difficult.  
Furthermore, understanding the clinical significance of strength deficits proves difficult.  
To gain a better appreciation of the differences that were found for strength measures in 
this study, percent deficits can be calculated for all of the statistically significant strength 
measures between the two groups.  Of all the strength measures that demonstrated 
significant differences between the breast cancer survivor population and the healthy, 
matched controls, the percent deficit is greatest for scapula depression and adduction at 
31%, followed by both scaption and adduction at 28%, internal rotation at 26%, external 
rotation at 25%, flexion at 24%, and scapula abduction and upward rotation at 20%.  The 
percentage of difference for strength measures in the shoulder pathologies discussed 
above including impingement syndrome and adhesive capsulitis range from 18% to 33%, 
similar to the findings in this study, further demonstrating the importance of strength 
measure deficits in the breast cancer survivor population.  To continue to emphasize not 
only the statistical significance of these differences, but also the clinical significance, 
effect sizes can be examined.  For all of the above significant strength measures between 
the breast cancer survivors and healthy, matched controls, the effect sizes ranged from 
0.82 – 1.29, reflecting a large difference for these measures between the two groups.   
Decreases in strength will often affect function, the ability to perform ADL’s, and 
affect overall quality of life. It is evident that strength is an important clinical measure 
that needs to be evaluated in the breast cancer survivor population.  Results from this 
study showed clinically meaningful differences in strength measures of scapula abduction 
and upward rotation, scapula depression and adduction, humeral flexion, humeral 
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external rotation, humeral internal rotation, scaption, and horizontal adduction between 
the two groups.  Clinicians should focus on assessing these strength measures in the 
breast cancer survivor population, as large deficits are present in this group. 
Researchers believe that impairments of the cervical spine may contribute to 
shoulder pain and disability.173  It is also thought that movement of the shoulder can 
cause direct or indirect secondary movement of the cervical spine.256  Because of this, it 
is important to assess cervical spine ROM in those presenting with an upper extremity 
dysfunction.  This is the first study known to the authors to assess cervical spine active 
ROM in the breast cancer population.  No significant differences were found between the 
two groups for cervical spine measures of cervical flexion, extension, left side bending, 
right side bending, left rotation, and right rotation.  Further analysis was conducted to 
determine if rotating or side bending away from the affected extremity demonstrated any 
differences between groups. This analysis was performed because these two motions 
would cause the pectoralis, a muscle often compromised in breast cancer treatment to be 
lengthened.  Again, no statistically significant difference was found for these measures.  
There is limited research investigating the relationship between cervical spine ROM and 
shoulder pathologies.   
In order to try and better understand the relationships between functional 
outcomes and physical characteristics in breast cancer survivors correlation analyses were 
performed.  This study examined the relationship between two self report outcome 
measures for the shoulder, the DASH and PSS, and the following dependent variables; 
affected active and passive shoulder ROM, affected shoulder girdle strength, and cervical 
active ROM.   Several negative relationships were found between the DASH and the 
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aforementioned variables analyzed in this study which was partially in agreement with 
our hypotheses.  The DASH is a 30 item self report questionnaire asking the subject to 
rate his/her difficulty performing a wide variety of tasks that involve the use of the upper 
extremity.257  A higher score on the DASH reflects greater disability.  Therefore, negative 
correlations would represent decreased measures on the dependent variable relating to 
higher scores on the DASH.    
Two of the five active shoulder ROM measures examined in this study showed 
marked correlations with the DASH, flexion (r = -0.62) and 90° ER (r = -0.65).  The 
same passive ROM measures also illustrated marked correlations with the DASH, flexion 
(r = -0.54) and 90° ER (r = -0.64).  These findings indicate that decreased shoulder 
flexion and 90° ER ROM were associated with decreased shoulder function as measured 
by the DASH.  The first 21 of the 30 questions on the DASH ask the respondent to “rate 
their ability to do the following activities within the past week”.  The Likert scale used in 
the DASH is as follows: 1 = no difficulty, 2 = mild difficulty, 3 = moderate difficulty, 4 = 
severe difficulty, and 5 = unable.  When analyzing each question on the DASH 
independently, approximately 17 of the first 21 questions require the motion of shoulder 
flexion. (Table 28)  Some of the 17 tasks on the DASH that requires active flexion 
include: “prepare a meal”, “push a heavy door”, “place an object on a shelf above your 
head”, and “change a light bulb overhead”.  External rotation ROM was also markedly 
correlated to scores on the DASH.  Approximately 10 of the first 21 questions on the 
DASH require external rotation to complete effectively.  Some of the questions on the 
DASH that require active external rotation include: “opening a tight or new jar”, “turning 
a key”, “wash or blow dry your hair”, and “washing your back”.  Surprisingly, internal 
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rotation measures were not correlated with DASH scores, even though approximately 14 
of the first 21 questions appear to require internal rotation motion such as “opening a 
tight or new jar”, “preparing a meal”, “doing heavy household chores such as washing the 
floor”,  and “making your bed” to name a few.  Perhaps this is because; anecdotally many 
people tend to hold their arms close to their body in an internally rotated position after 
receiving treatment on their upper extremities.  It should also be noted that there was not 
a statistically significant difference between the breast cancer survivors and healthy, 
matched controls regarding internal rotation active ROM. 
Six of the seven strength measures displayed correlations with the DASH:  
scapula abduction and upward rotation (r = -0.48), scapula depression and adduction (r = 
-0.64), humeral flexion (r = -0.51), humeral internal rotation (r = -0.52), scaption (r = -
0.56), and adduction (r = -0.60).   Clinically, these findings indicate that decreased 
strength of scapula abduction and upward rotation, scapula depression and adduction, 
humeral flexion, humeral internal rotation scaption, and adduction were associated with 
decreased shoulder function as measured by the DASH.  Scapula depression and 
adduction, the highest correlated strength measure in this study with the DASH, is needed 
to complete approximately 8 of the 21 questions on the DASH.  The second strength 
measures to show a marked correlation with the DASH was adduction.  Only 
approximately 5 of the 21 questions on the DASH require the use of adductor strength.  
The next correlated strength measure, scaption, is needed to perform 10 of the 21 tasks on 
the DASH.  With the remaining correlations found to be significant, roughly, 12 of the 21 
tasks involve internal rotation strength, 16 require flexion strength, and approximately 3 
tasks call for use of abduction and upward rotation. 
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To our knowledge, there have been no studies assessing ROM or strength 
relationships with the DASH in any population with shoulder dysfunction.  However, 
there has been one recent study that assessed the relationship between arm morbidity and 
disability in 347 breast cancer survivors who were 6-12 months after surgery.75 In this 
study, lymphedema, pain, and ROM were assessed to determine if these were associated 
with disability as measured by the DASH.75  Pearson correlation coefficients revealed 
that of those measures, abduction ROM was the strongest correlation with scores on the 
DASH.75  Although this study utilized different measures than our study, it demonstrates 
an association between ROM and disability, similar to what was found in our study.  
Since both ROM and strength variables appear to be correlated to DASH scores, 
the results from this study could be used to assist clinicians when treating a breast cancer 
survivor.  Specifically, the ROM measures of flexion and 90 of ERº were shown to 
correlate with DASH scores.  This provides some initial evidence to suggest that 
clinicians should address these ROM deficits when treating breast cancer survivors who 
have a loss of function and/or deficits in the shoulder region.  Along with ROM, strength 
measures of scapula abduction and upward rotation, scapula depression and adduction, 
humeral flexion, humeral internal rotation, scaption, and adduction were also shown to 
correlate with the DASH.  Once again, results from this study provide preliminary 
support to suggest that clinicians should focus on these specific strength measures when 
working with breast cancer survivors who have recently completed their primary 
treatment of surgery, chemotherapy, and radiation. 
Several positive relationships were found between the PSS and the dependent 
variables of affected active shoulder ROM, affected passive shoulder ROM, affected 
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shoulder girdle strength, and cervical active ROM which was partially in agreement with 
our hypotheses.  The PSS is a self report measure that has 3 subjective portions assessing 
function, pain, and satisfaction with a lower score reflecting greater disability.  The 
function portion on the PSS contains 20 questions with a four category Likert scale.  The 
Likert scale ranges from “no difficulty”, “some difficulty”, “much difficulty”, and “can’t 
do at all”.   Positive correlations would represent decreased measures on a dependent 
variable relating to lower scores on the PSS.    
Of the five active ROM measures, flexion (r = 0.59) was the only significant 
relationship found for the breast cancer survivors and scores on the PSS.  When 
analyzing each functional question on the PSS, 14 of these 20 questions require an 
individual to move their arm into flexion.  Some of these tasks include:  “washing the 
back of your opposite shoulder”, “combing hair”, “dressing, including pulling a shirt off 
overhead”, “placing a soup can at shoulder level”, and “placing a gallon jug at shoulder 
level”.  Similar to the DASH, no relationship was found between the PSS and active 
internal rotation ROM even though approximately 8 of the 20 questions on the PSS 
require internal rotation.  However, as mentioned above, there was no statistical 
significant difference between the breast cancer survivors and controls for active internal 
rotation.  Also, internal rotation tends to be the static position held by those who have had 
shoulder pain and dysfunction, possibly many of the functional tasks that these people 
perform are conducted in this internally rotated position. 
Two of the five passive ROM measures demonstrated moderate relationships with 
the PSS: shoulder flexion (r = 0.60) and ER at 90° (r = 0.42).  As mentioned previously, 
14 of the 20 function questions on the PSS require flexion.  However, it remains unclear 
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to the authors of this study, why active ER at 90° did not correlate to the PSS, although 
passive ER at 90° did.  Approximately 7 of the 20 questions on the PSS require the 
motion external rotation.  These questions include: “placing your hand behind your head 
with your elbow straight out to the side”, “performing a usual hobby”, “cooking”, and 
“performing overhead/swim/overhand racquet sport”.   
Four of the shoulder girdle muscle strength measures were found to be moderately 
correlated to the PSS:  shoulder flexion (r = 0.46), internal rotation (r = 0.44), scaption (r 
= 0.44), and adduction (r = 0.45).  When analyzing each question on the PSS for strength 
requirements, approximately 13 of the 20 functional questions require flexion strength to 
complete effectively.  Scaption strength is needed for 50% of the tasks, whereas both 
internal rotation and adduction strength are utilized in approximately 25% and 15% of the 
tasks respectively. 
To the authors’ knowledge, this is the first study to examine the relationship 
between impairment measures (ROM and strength) with scores on the PSS in breast 
cancer survivors.  There has been one recent study that examined the relationship 
between impairment measures in persons who had recently undergone arthroscopic repair 
for rotator cuff tears with scores on the SPADI and PSS.16  Strength measures were 
assessed in three positions: external rotation, internal rotation, and scaption with internal 
rotation.  Range of motion measures were taken in standing for flexion, external rotation 
at 0 and 90 of abduction, and internal rotation measured by spinal level.  Strength and 
ROM measures were compared to the uninvolved side and were reported as percentage 
scores.  A pearson product moment correlation was conducted and found the relationship 
for the strength, (internal rotation, external rotation, and scaption) (r = 0.44) and ROM 
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(humeral flexion, humeral 0º of ER, 90 º of ER, and IR using the thumb up the back) (r = 
0.50) measures showed a moderate correlations.  Although the two percentage scores for 
strength and ROM in this study seemed to demonstrate moderate correlations with the 
DASH, the authors concluded that there was a large amount of variance in the study’s 
population self-reported function scores to be unexplained by impairment scores.16  
Of interest when reviewing both the DASH and PSS correlations in this study 
requires discussion of the presence of 2 outliers in the group of breast cancer survivors.  
These two subjects were the same outliers for both the DASH and PSS.  These outliers 
scored a 71.3 and 43.1 on the DASH and a 41.6 and 57.6 on the PSS.  A separate analysis 
was performed excluding these two subjects, and although there continues to be a 
statistically significant difference in scores on both the DASH and PSS between the 
breast cancer survivors and healthy, matched controls, a different picture is presented for 
the correlation analysis. With this new analysis, there were no clinical measures that 
demonstrated relationships with scores on the DASH.  Of all of the ROM measures, the 
clinical measures that demonstrated the highest relationship with the DASH, although not 
significant were 90° ER active (r = -0.32) and passive (r = -0.34) measures. Again, with 
this new analysis, none of the strength measures demonstrated a relationship with scores 
on the DASH.  The highest correlation strength measure with the removal of these two 
outliers on the DASH was adduction (r = 0.35).  When these two outliers were removed 
for analysis of the PSS, there was only one marked relationship that was shown, this was 
the measure of passive flexion (r = 0.45).  Removal of these 2 outliers presents a very 
different picture when trying to assess what relationships exist between clinical measures 
and scores on the DASH and PSS.   
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Due to the small sample size, and covariates such as type of treatment (systemic 
and surgical), as well as stage of breast cancer that were not separately analyzed in this 
study, caution should be used when trying to interpret the clinical significance of these 
results.  Regardless, findings from the above correlation analyses suggest that more 
research is needed to understand what physical characteristics are influencing functional 
outcomes.  The results from this study suggest that shoulder external rotation and flexion 
ROM combined with other strength measures are associated with shoulder function as 
measured by the DASH and PSS.  These findings suggest that clinicians may need to pay 
particular attention when addressing these physical characteristics to achieve optional 
functional outcomes when rehabilitating an individual recovering from breast cancer.  
Future research investigating interventions aimed specifically at addressing these 
physical characteristics is needed to better understand whether rehabilitation programs 
targeting these physical deficits facilitate better functional outcomes. 
5.3  Scapular Kinematics  
This is the first known study to compare scapular kinematics on the affected side 
in a breast cancer survivor population with healthy, matched controls.  A significant 
limitation occurred during the kinematic data collection in this study.  The breast cancer 
survivor cohort had difficulty in consistently elevating their humerus above 90 degrees in 
all three of the tasks.  The kinematic data was originally planned to be analyzed at 30 
degree increments beginning from the starting position up to 120 degrees.  However, we 
learned that this was not feasible as the breast cancer survivors were not consistently 
reaching this point.  Because of this, the kinematic analysis was altered.  As a result the 
data for the tasks of flexion and scaption were analyzed at start, 30°, 60°, and 90 degrees.  
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Because the breast cancer survivors had difficulty consistently elevating up to 90 degrees 
during the reaching task, the kinematic analyses was performed at start, 30°, 60°, and 
maximal humeral elevation angle.  A further explanation of why the breast cancer 
survivors had difficulty elevating above 90° and how this may have impacted the study’s 
findings will be discussed below. 
Scapula kinematics were analyzed during three tasks of flexion, scaption, and 
reaching.  Analyses revealed a main effect for group for the translation of 
protraction/retraction during the scaption task.  The results showed that the breast cancer 
survivors demonstrated greater protraction when compared to the healthy, matched 
controls.  More specifically, the breast cancer survivor cohort demonstrated 4 – 5 degrees 
greater protraction throughout the scaption motion when compared to the healthy, 
matched controls regardless of humeral angle.  An interaction effect for group x angle 
was found during the reaching task for internal/external rotation.  Post hoc testing did not 
reveal a statistically significant difference for the interaction effect of internal/external 
rotation during the reaching task.  No other significant differences were found between 
the breast cancer survivors and healthy, matched controls for the scapula rotations of 
anterior/posterior tipping, upward/downward rotation, and internal/external rotation 
during the tasks of flexion, scaption, and reaching.  Similarly, no other significant 
differences were found between the two groups for the translations of 
elevation/depression and retraction/protraction during these three tasks.  
Modest differences in scapula kinematics, all less than 5 degrees were found 
between the two groups during all three tasks.  Because of these small differences, the 
clinical significance is difficult to assess.  Some researchers believe that a 4 - 5 degree 
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difference in scapula and clavicular joint position between groups is clinically 
meaningful.18, 254  During flexion only small effect sizes were observed in this study for 
all of the scapula rotations and translations throughout humeral elevation.  While there 
have been no studies examining kinematics during flexion for the breast cancer survivor 
population, other shoulder pathologies have investigated these motion patterns.  A study 
conducted by McClure and colleagues examined 45 individuals with impingement 
syndrome and compared 3D kinematics during three cycles of active flexion with 45 
healthy, matched controls.19  Small differences (less than 5 degrees) in kinematics were 
demonstrated between groups.19  Specifically, during flexion the individuals with 
impingement syndrome showed a pattern of slightly greater posterior tipping, greater 
internal rotation, greater upward rotation, increased elevation and decreased protraction 
when compared to the healthy controls.19  The only statistically significant differences 
between those with impingement and those without were increases in upward rotation 
and elevation at 90° and 120° of flexion.19  The average difference between these two 
groups during the flexion task was 4.9° for upward rotation and 2.9° for elevation.19  It is 
difficult to make comparisons with our study since the breast cancer survivors had 
difficulty consistently elevating greater than 90°.  However, the average differences 
found in our study between the breast cancer survivors and healthy matched controls was 
3.8° at 90° of  elevation, just slightly less than what was found in the study conducted by 
McClure and colleagues.  As seen in the study by McClure and colleagues, differences 
found between the two groups occurred when elevating above 90°.  Bagg and Forrest 
described motion between 80° – 140° of elevation to be the middle phase.184  It is 
believed that this phase is the most stressful on the upper extremity during arm 
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elevation.184, 186  Because the breast cancer survivors were unable to consistently reach 
this middle range during our study, important differences in scapula kinematics may not 
have been identified.   
A recent study conducted by Fayad and colleagues demonstrated similar 
difficulties with consistently elevating the affected upper extremity greater than 90° in 
individuals with shoulder dysfunction.197  Thirty-two individuals with a diagnosis of 
glenohumeral osteoarthritis or adhesive capsulitis performed two repetitions of flexion.  
Individuals with glenohumeral arthritis demonstrated an average of 95.7° for maximal 
humeral elevation, whereas those with adhesive capsulitis averaged 66.4°.197  Despite this 
difficulty in elevating above 90°, statistically significant differences were observed for 
external rotation in both groups and protraction in those with frozen shoulder.197  
Specifically, individuals with osteoarthritis demonstrated increased external rotation, 
whereas those with adhesive capsulitis showed not only increased internal rotation, but 
decreased protraction when compared to the unaffected extremity.197  These differences 
in kinematics are dissimilar from the results of this study.  It may not be appropriate to 
compare the variables analyzed in our study with individuals who have shoulder 
pathologies such as impingement syndrome, osteoarthritis, or adhesive capsulitis. The 
methods and subject characteristics in the study conducted by Fayad and colleagues 
differs significantly from those in the present study.  The average age of the individuals 
in the study conducted by Fayad and colleagues of 60.6 years was much higher than the 
average age of individuals in our study at 50.6 years.197  The average duration of 
symptoms was much greater, 35.2 months, compared to the duration since the breast 
cancer survivors completed their treatment of no greater than 6 months.197  The different 
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results obtained in our study may also be attributable to differences in measurement 
methods.  In the study conducted by Fayad and colleagues, the thorax sensor was 
mounted on the sternum and the humeral sensor was attached just below the insertion of 
the deltoid.197  During flexion, it appears scapula motion is highly variable, as evidenced 
by large standard deviations,  in individuals with shoulder dysfunction and multiple 
studies have found only modest (<5°) differences between a pathologic and healthy 
controls.  Further research should be conducted to gain a more clear understanding of 
scapula movement patterns in individuals with shoulder pathology including breast 
cancer survivors. 
Scapula plane elevation is one of the most common studied motions for kinematic 
analysis. The results found in this study revealed a main effect for group during scaption 
for the translation of protraction/retraction with the breast cancer survivor cohort 
demonstrating 4 – 5 degrees greater protraction throughout the scaption motion when 
compared to the healthy, matched controls regardless of humeral angle.  There has been 
one recent study that examined a group of breast cancer survivors’ three-dimensional 
scapulothoracic motion.254  In this study conducted by Shamley and colleagues, 152 
women treated for unilateral carcinoma of the breast were included.254   Only one task, 
scaption, was analyzed, and only 3 repetitions were performed.254  Results revealed a 
statistically significant difference when comparing the affected side to the unaffected side 
for all kinematic motions analyzed in the study.254  Shamley and colleagues found 
increased protraction on breast cancer survivors who were affected on their left side.258  
Our study found an average difference between the two groups for the protraction 
measure to range from 4.9° – 5.5° during elevation.  The average difference found in the 
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study conducted by Shamley in colleagues was ~2.5°.  Also, we observed a significant 
group by angle interaction for internal/external rotation, although post hoc analysis was 
not able to detect significant differences between groups.  This does suggest that our 
findings are in partial agreement with Shamley and colleagues.  The study conducted by 
Shamley and colleagues had a large sample, 131 breast cancer survivors, thus our study 
may have been underpowered to show statistical significance.   
Some caution should be exercised when comparing our study as variations existed 
in methodology.  Specifically the “control” used in the study by Shamley and colleagues 
was the unaffected side of the breast cancer survivor, not a healthy, matched control as 
utilized in our study.  Using the unaffected side of a breast cancer survivor might not be a 
true representation of a “healthy” side due to the systemic effects of treatments such as 
chemotherapy and radiation.  Also, all of the breast cancer survivors examined in the 
study conducted by Shamley and colleagues had mastectomies and had a greater duration 
since surgery (~3 years) compared to no more than 6 months for the breast cancer 
survivors in our study.254  It is believed that the type of breast cancer surgery may affect 
upper extremity function reflecting differences in outcome measures, although more 
research is needed to further explain this phenomenon. Three repetitions were used in the 
study by Shamley and colleagues, compared to 10 repetitions performed in our study.  As 
mentioned previously, all of the seven strength measures were significantly weaker when 
compared to the healthy controls.  Performing 10 repetitions, for three different tasks is a 
significant amount of work required, and although we did not record rate of perceived 
exertion, it is hypothesized that the breast cancer survivors fatigued easily due to 
decreases in strength, therefore causing difficulty in performing the tasks consistently 
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above 90°.  Finally, a significant difference existed between our study and theirs with 
regards to subjects receiving chemotherapy.  Only 16.6% of the breast cancer survivors in 
the study conducted by Shamley and colleagues received chemotherapy, compared to 
87.5% in our study.254  Although further research is needed to elaborate on this 
hypothesis, researchers believe chemotherapy might affect a breast cancer survivor 
differently when compared to those who did not receive chemotherapy.259  Another factor 
affecting comparisons between the two studies is the low sample size used in our study (n 
= 22), compared to the large sample size analyzed in the study by Shamley and 
colleagues (n = 152) for the scapula rotations of anterior/posterior tipping, 
upward/downward rotation, and internal/external rotation.254   
Even though several differences existed between the current study and the work 
of Shamley et al, the findings from these studies do suggest that scapula kinematics are 
altered in breast cancer survivors.  In particular, protraction was demonstrated to be 
increased in the breast cancer survivors.  The clinical implications of increased 
protraction could include the development of impingement like symptoms as protraction 
can cause a decrease in subacromial space.260   Furthermore,  the pectoral muscles and 
anterior shoulder girdle soft tissue are largely affected with breast cancer treatments and 
could be contributing to restricting shoulder motion as evidenced with decreased shoulder 
flexion and 90 ER observed in this study.   Although this was not directly measured in 
this study, it should be considered in future research with breast cancer survivors.  As a 
result the scapula may be forced to move into a more protracted position to compensate 
for these tissue changes.  Research has shown that increased scapula protraction could be 
related to scapula dyskinesis.261  Although this was not analyzed in our study, future 
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investigations regarding scapula dyskinesis should be examined in the breast cancer 
survivor population. 
Kinematic analysis of scaption has been assessed in several different studies in 
individuals with impingement syndrome.  A study conducted by Lukasiewicz and 
colleagues examined scapula kinematics during 2 trials of upper extremity elevation in 
the scapula plane in 17 individuals with impingement syndrome and 20 individuals 
without shoulder pathology.18  The subjects did not move continuously through their 
available range but held 3 static positions: rest, 90°, and maximum elevation for 30 
seconds each.18  Results revealed statistically significant differences at 90° and maximum 
elevation for the scapula measures of posterior tilting.18  Individuals with impingement 
demonstrated significantly less posterior tilt that differed from those who did not have 
shoulder pathology by approximately 8 and 9 degrees.18  It is difficult to compare our 
study to the study conducted by Lukasiewicz and colleagues because static positions were 
studied rather than continuous motion.  The study mentioned above conducted by 
McClure and colleagues also examined motion in the scapular plane in those 45 
individuals with and without impingement syndrome.19  During elevation in the scapular 
plane individuals with impingement syndrome demonstrated greater posterior tilt, upward 
rotation, external rotation, elevation, and clavicular retraction.19  Statistically significant 
differences were found in this study at 90° for upward rotation and at 120° for posterior 
tilting and retraction.19  The results showed a substantial amount of variability among 
subjects and although statistical significant differences were found, these differences 
between groups were all less than 4°.19  As mentioned previously, it is difficult to make 
comparisons with our study since the breast cancer survivors had difficulty consistently 
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elevating greater than 90°.  Future studies should be conducted to examine scapula 
kinematics when the humerus is above 90° in individuals who have had breast cancer to 
examine if alterations in scapula kinematics exist as it does appear to in individuals with 
other shoulder pathologies such as impingement syndrome.   
Reaching is a relatively new motion that is being examined using three 
dimensional analyses.  A group x angle interaction effect was found during the reaching 
task for internal/external rotation, although post hoc analysis revealed no statistically 
significant differences between groups.  Statistical results demonstrate the breast cancer 
survivor cohort and control groups were different and only small effect sizes were shown, 
as this difference was dependent upon the angular position, specifically at maximal 
humeral elevation during reaching.  Although a group x angle interaction was found 
during internal/external rotation, the effect sizes were small for all of the four humeral 
positions examined.  This could be attributed to our study being underpowered.  Similar 
to the elevation tasks described above, the small changes found during the reaching tasks, 
all less than 5 degrees between the two groups, afford difficulty in assessing clinical 
significance.  Moderate effect sizes ranging from .45 - .53 were found for the scapula 
variable of anterior/posterior tipping.  All other scapula motions analyzed during the 
reaching task revealed only small effect sizes.  One explanation for a lack of larger 
differences in scapula kinematics is perhaps only a small subset of women who have 
recently undergone treatment for breast cancer truly have abnormal scapula motion.  
Breast cancer treatment varies greatly from person to person, and because of this, future 
research is needed to further investigate whether a subset of women exist who present 
with scapular movement abnormalities. 
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As previously indicated we believe that the inability for breast cancer survivors to 
consistently elevate beyond 90-degrees may have limited our ability to observe 
significant differences in scapula and clavicle kinematics.  Thus, it is important to 
understand factors that may have influenced the ability to study kinematic differences 
above 90-degrees of humeral flexion.  The mean (±SD) maximal active humeral flexion 
angle in those with breast cancer during the flexion task was 122.5° (13.92), while not 
statistically significant (p = 0.051) when compared to 130.1° (10.84) in the healthy, 
matched controls the difference in maximal humeral flexion during the flexion task may 
have affected the results.  However, the observed difference of approximately 8-degrees 
may be important as it was associated with a moderate effect size of .55.  Differences in 
humeral elevation were not close to reaching statistical significance during scaption (p = 
0.27) as there was approximately a 5 degree difference between the groups for this 
measure: 122.3° (13.14) for the breast cancer survivors and 127.14° (15.19) for the 
control group with a small effect size of .32. During the reaching task, the breast cancer 
survivors revealed 96.54° (13.43) whereas the controls demonstrated 104.4° (12.14) for 
maximal humeral elevation, which was statistically significant (p = .05) .  The different in 
humeral elevation during reaching was approximately 8-degrees and was associated with 
a moderate effect size of .66.  When comparing the active shoulder flexion ROM values 
to the maximal humeral elevation values achieved during kinematics testing, differences 
are apparent as breast cancer survivors achieve more active flexion ROM compare to 
humeral elevation during kinematics testing.  This is most likely due to the positioning of 
the subjects during each measure.  For ROM measures, the subjects were supine where 
gravity could help with the last several degrees of motion.  Kinematics were assessed 
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with the subjects in standing, where gravity would have the opposite effect on end range 
motion.  Thus, during ROM assessment gravity was able to assist humeral flexion 
whereas during kinematics testing subjects worked against gravity.  We believe that the 
inability of the breast cancer survivors to consistently achieve 90-degrees of humeral 
flexion may have been influenced by our findings of decreased shoulder girdle strength, 
and pain.  Although not specifically measured in this study, fatigue may have also been a 
factor affecting the breast cancer survivors ability to consistently move above 90 
degrees..     
During kinematics testing the subjects appeared to be able to elevate their arm 
beyond 90-degrees of elevation.  However, humeral flexion angles during kinematic 
testing did not support this visual observation.  Lack of humeral flexion during 
kinematics testing may have been influenced by landmarks used to define humeral 
flexion as well as compensatory movement patterns during humeral elevations tasks.  The 
landmarks used to define the humerus involve the shoulder joint center and the medial / 
lateral epicondyles of the humerus.  Humeral flexion was measured as the angle formed 
by the humerus relative to the thorax.  We did not measure kinematics of the forearm and 
hand segments.  Thus, individuals may have been able to elevate the forearm and hand 
segments to appropriate heights relative to the global coordinate system, but unable to 
produce greater than 90-degrees of humeral flexion relative to the thorax.  Also, 
compensatory movement patterns in breast cancer survivors may have allowed for 
sufficient elevation of the hand relative to the world, but not true humeral flexion as 
measured relative to the thorax.  Thorax motion substitutions may have occurred to 
position the forearm and hand segments in sufficient elevation relative to the global 
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coordinate system thus limiting the need for greater humeral flexion relative to the 
thorax.    These factors should be considered in future research studying breast cancer 
survivors.  It may be necessary to study scapula and clavicle kinematics as a function of 
the position of the hand relative to the global coordinate system rather than as a function 
of humeral flexion.  Also, researchers should closely monitor for compensatory motions 
of the thorax during testing or perhaps include thorax position as a variable of interest. 
Another potential factor that may have influenced our ability to identify 
differences between groups was the number of repetitions performed during testing.    
Our study required all participants to complete three separate tasks, requiring 10 
repetitions for each task.  As mentioned previously, all of the seven strength measures 
were significantly weaker when compared to the healthy controls.  Performing 10 
repetitions, for three different tasks is a significant amount of work required, and 
although we did not record rate of perceived exertion, it is hypothesized that the breast 
cancer survivors fatigued easily due to decreases in strength, therefore causing in 
performing the tasks consistently above 90°.  Perhaps the breast cancer survivors did 
consistently move greater than 90°, but through compensatory thorax motions as 
previously mentioned.  Visually and verified using a goniometer, the breast cancer 
survivors appeared to achieve elevation consistently greater than 120°.  Compensatory 
mechanisms occurring at the humerus and thorax may have occurred causing the breast 
cancer survivors to appear to move above 90°.  Ludewig and Cook found that the 
humeral laterally rotates relative to the scapula throughout most of scaption.17  
Unfortunately, these kinematic variables were not assessed in this study.  Finally, a data 
collection error occurred causing the removal of 11 participants, along with their matched 
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counterparts, reducing the total number of subjects in each group to 15 for kinematic 
analysis, therefore decreasing the sample size and power in our study. 
5.4  Future Research 
Understanding upper extremity deficits in the breast cancer survivor population 
continues to garner attention and the research to explain why these deficits occur has just 
begun.  It is also important for clinicians to have a better understanding about the 
relationship between shoulder dysfunction and quality of life when working with breast 
cancer survivors.  At the present time, there has been minimal research conducted 
examining outcome measures and quality of life in the breast cancer survivor population.  
Future research is needed to try and explain the relationships between a domain specific 
measure such as the DASH and PSS with clinical measures such as ROM and strength.  It 
is also important to continue to explore the relationships that may exist between quality 
of life with clinical measures and functional outcome measures.  Based on the ROM, 
strength and functional deficits revealed in this study, future research should be 
conducted to further examine the best rehabilitation practices needed in order to decrease 
functional deficits and impairments in this population.  Research should continue to try 
and better understand what factors of breast cancer treatment (ie: surgical and systemic 
treatment) impact on upper extremity function.  Finally, future research utilized to 
examine scapula kinematics in the breast cancer survivor population should be aware of 
the effects of fatigue, and perform the minimal amount of repetitive motion, as well as 
examine any compensatory mechanism that may be occurring in this group of women in 
order to understand if abnormalities in motion exist. 
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5.5  Clinical Significance 
 There are several clinical implications that can be taken from the findings found 
in this study.  Specifically the, ROM measures of humeral flexion and humeral ER at 90º 
appear to be affected in the breast cancer survivor population.  All seven of the strength 
measures assessed in this study were found to be decreased in the breast cancer survivor 
cohort.  Finally, increased scapula protraction is another key finding.  The results from 
this study provide preliminary evidence to suggest that clinicians focus on these 
particular ROM and strength measures when treating a breast cancer survivor who has 
recently completed their primary treatment. 
Women who have recently completed their primary breast cancer treatment 
appear to have function deficits as revealed in this study when using outcome measures 
such as the DASH and PSS.  Results from this study help to lay preliminary ground work 
describing functional limitations as well as impairments women may experience who 
have recently completed their primary breast cancer treatment of surgery, chemotherapy, 
and/or radiation.  Outcomes from this study could be used to further develop evidenced 
based guidelines to provide the most effective treatment when rehabilitating breast cancer 
survivors.   
5.6  Conclusions 
 In conclusion, this is a novel study that provides valuable information to the 
rehabilitation profession regarding shoulder active and passive ROM, upper extremity 
strength, and function for breast cancer survivors who have recently (within the past 6 
months) completed their primary surgical and systemic treatments.  The results of this 
study may help to guide clinicians in the appropriate direction when treating a breast 
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cancer survivor who is experiencing decreased function of the affected upper extremity.  
In summary, clinicians should utilize self-report functional assessments such as the 
DASH and PSS, as well as pay special attention to the shoulder ROM measures of 
flexion and 90° ER.  Furthermore, upper extremity strength measures need to be 
examined in the breast cancer survivor population as the results from this study revealed 
weaknesses in the following shoulder girdle strength measures: abduction and upward 
rotation, depression and adduction, flexion, external rotation, internal rotation, scaption, 
and horizontal adduction.  Finally, clinicians should examine scapula protraction during 
scapular plane movements in breast cancer survivors. 
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Table 1. Upper extremity active ROM and passive ROM ICC’s 
 
 
 
Glenohumeral Joint Active & Passive ROM ICC
AROM PROM AROM PROM
Flexion 0.98 1.00 1.37 0.52
0° External Rotation 1.00 0.99 0.77 0.90
90° External Rotation 0.99 0.99 1.34 12.9
90° Internal Rotation 0.99 0.97 1.21 1.89
Extension 0.98 0.97 1.48 1.74
Affected Affected
ICC SEM
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Table 2.  Shoulder Girdle Strength ICC’s 
 
 
 
Affected SEM
0.99 0.79
0.77 2.01
0.99 0.90
0.91 0.76
0.97 0.80
0.99 0.65
0.87 1.48
Strength ICC
Scapular Abduction & upward Rotation
Scapular Depression & Adduction
Humeral Flexion
Humeral External Rotation
Humeral Internal Rotation
Shoulder Scaption
Shoulder Horizontal Adducation
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Table 3.  Cervical active ROM ICC’s 
 
 
 
ICC SEM
Flexion 0.97 2.22
Extension 0.97 1.68
Left Side Bending 0.87 1.93
Right Side Bending 0.98 1.32
Left Rotation 0.87 6.82
Right Rotation 0.99 1.90
Cervical Active ROM ICC
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Table 4.  Shoulder active ROM power calculation 
 
 
 
 
Affected Unaffected Affected Unaffected
Flexion 0.98 1.89 13 9
External Rotation - 0° 0.05 0.42 1237 78
External Rotation -90° 1.75 0.35 7 108
Internal Rotation - 90° 0.002 2.51 1237 7
Extension 1.05 1.14 13 13
Effect Size # of subject for .80 power
Shoulder AROM
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Table 5.  Shoulder strength power calculation 
 
 
 
Affected Unaffected Affected Unaffected
Scapular Abduction & Upward Rotation 0.27 0.28 138 138
Scapular Depression & Adduction 1.47 2.43 7 7
Shoulder Flexion 0.56 0.69 35 26
Shoulder Internal Rotation 0.28 0.51 138 50
Shoulder External Rotation 1.21 0.96 9 13
Shoulder Scaption 0.57 0.23 35 310
Shoulder Horizontal Adduction 1.08 0.53 13 50
Shoulder Strength
Effect Size # of subject for .80 power
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Table 6.  Cervical spine active ROM power calculation 
 
 
 
Effect Size # of subject for .80 power
Flexion 0.38 78
Extension 0.85 20
Left Side Bending 3.26 7
Right Side Bending 0.64 35
Left Rotation 0.36 78
Right Rotation 0.18 310
Cervical Spine AROM
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Table 7.  Scapula kinematics power calculation 
 
 
 
Article Plane Population Scapular Motion Effect Size # of subject for .80 power
Rundquist 2007 Scapular Upward/ Downward Rotation 0.23 310
Internal/ External Rotation 0.78 20
Anterior/ Posterior Tipping 0.42 78
Fayad et al 2008 Frontal Osteoarthritis Upward/ Downward Rotation 0.99 13
Internal/ External Rotation 0.69 26
Anterior/ Posterior Tipping 0.09 1237
Fayad et al 2008 Frontal Frozen Shoulder Upward/ Downward Rotation 0.57 35
Internal/ External Rotation 0.93 13
Anterior/ Posterior Tipping 0.05 1237
Fayad et al 2008 Sagittal Osteoarthritis Upward/ Downward Rotation 1.10 11
Internal/ External Rotation 0.48 50
Anterior/ Posterior Tipping 0.17 310
Fayad et al 2008 Sagittal Frozen Shoulder Upward/ Downward Rotation 0.78 20
Internal/ External Rotation 1.10 11
Anterior/ Posterior Tipping 0.52 50
Scapular Position Based on Maximum Humeral Elevation
                
Idiopathoathic loss of 
Shoulder ROM
152 
 
Table 8.  Subject Descriptive Data 
 
 
 
 
 
Breast Cancer 
Survivor Control
Age (years) 50.8 ± 9.51 50.4 ± 9.97
Height (cm) 65.2 ± 2.71 65.2 ± 2.94
Weight (kg) 75.6 ± 15.1 73.2 ± 15.1
BMI (kg/m2) 27.6 ± 5.49 26.9 ± 5.47 
Subject Descriptive Data
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Table 9.  Mean, SD, 95% CI, p value, and effect size for the DASH and PSS 
 
 
 
 
 
Mean SD 95%CI Mean SD 95%CI P ES
DASH 19.4      
(n = 23)
16.79 14.4, 
24.3
1.56        
(n = 23)
1.71 -3.07, 
6.01
<0.001* 1.08
PSS 77.1        
( n = 22)
17.7 71.8, 
82.5
97.5     
(n = 22)
3.37 92.3, 
102.6
<0.001* 1.15
* Significant differences
Breast Cancer Survivor Control
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Table 10.  Mean, SD, 95% CI, p value, and effect size for subscales of PSS (scores) 
 
 
 
Mean SD 95%CI Mean SD 95%CI P ES
Pain 25 5.11 23.5, 27.8 29.4 1.19 27.8, 30.9 0.000* 0.84
Satisfaction 5.74 2.88 4.80, 6.68 9.39 1.35 8.45, 10.3 0.000* 1.27
Function 0.78 0.23 0.71, 0.85 0.98 0.03 0.91, 1.05 0.000* 0.87
* Significant differences
Breast Cancer Survivor (n = 22) Control (n = 22)
155 
 
Table 11.  Mean, SD, 95% CI, p value, and effect size for active shoulder ROM (degrees) 
 
 
 
Mean SD 95%CI Mean SD 95%CI P ES
Flexion 156.5 10.28 153.1, 160.0 168.2 5.950 164.8, 
171.7
<0.001* 1.138
0° External Rotation 75.69 15.68 70.40, 80.99 77.72 9.307 72.43, 
83.02
0.588 0.129
90° Exrnal Rotation 87.64 19.25 81.30, 93.98 98.36 10.28 92.02, 
104.7
0.020* 0.557
90° Internal Rotation 60.71 11.51 55.96, 65.46 66.40 11.61 61.65, 
71.15
0.095 0.49
Extension 25.78 6.65 23.09, 28.48 31.53 6.177 28.89, 
34.17
0.004* 0.864
* Significant differences
Breast Cancer Survivor (n = 23) Control (n = 23)
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Table 12.  Mean, SD, 95% CI, p value, and effect size for passive shoulder ROM 
 
 
 
 
Mean SD 95%CI Mean SD 95%CI P ES
Flexion 160.5 10.79 157.0, 164.0 171.9 5.270 168.4, 175.3 <0.001* 1.057
0° External 
Rotation
78.85 14.68 74.06, 83.63 80.53 7.473 75.74, 85.31 0.620 0.114
90° External 
Rotation
91.64 16.92 85.91, 97.37 102.2 10.14 96.44, 107.9 0.012* 0.624
90° Internal 
Rotation
65.09 10.21 60.80, 69.39 70.10 10.69 65.80, 74.39 0.104 0.469
Extension 32.38 16.48 24.24, 40.52 40.49 21.88 32.35, 48.63 0.162 0.370
* Significant differences
Breast Cancer Survivor (n = 23) Control (n = 23)
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Table 13.  Mean, SD, 95% CI, p value, and effect size for cervical spine active ROM 
 
 
 
Mean SD 95%CI Mean SD 95%CI P ES
Flexion 47.5 7.88 44.0, 50.9 46.7 8.95 43.2, 50.2 0.75 0.09
Extension 60.6 7.25 56.8, 64.5 64.8 11.0 61.0, 68.6 0.13 0.38
Left 
Sidebending
33.8 8.82 32.1, 38.3 36.3 8.06 33.2, 39.5 0.61 0.28
Right 
Sidebending
35.2 7.1 30.3, 37.4 35.3 8.58 31.7, 38.9 0.56 0.01
Left 
Rotation
66.5 10.8 62.5, 70.1 69.6 8.61 65.6, 73.6 0.29 0.29
Right 
Rotation
67.6 9.94 63.9, 71.3 71.3 7.73 63.9, 71.3 0.16 0.37
* Significant relationship
Breast Cancer Survivor (n = 24) Control (n = 24)
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Table 14.  Mean, SD, 95% CI, p value, and effect size for shoulder girdle strength 
(normalized to body weight)   
 
 
 
Mean SD 95%CI Mean SD 95%CI P ES
Abduction and Upward 
Rotation
0.12 0.04 0.10, 0.13 0.15 0.04 0.13, 
0.17
0.006* 0.82
Depression and 
Adduction
0.11 0.05 0.09, 0.13 0.16 0.03 0.14, 
0.18
<0.001* 1.10
Flexion 0.13 0.04 0.12, 0.15 0.17 0.04 0.15, 
0.18
0.004* 0.82
External Rotation 0.09 0.02 0.08, 0.10 0.12 0.03 0.11, 
0.13
0.001* 0.88
Internal Rotation 0.14 0.04 0.13, 0.16 0.19 0.05 0.17, 
0.21
0.003* 0.87
Scaption 0.13 0.04 0.12, 0.15 0.18 0.05 0.16, 
0.19
<0.001* 1.02
Adduction 0.13 0.04 0.12, 0.15 0.18 0.04 0.17, 
0.20
< 0.001* 1.29
* Significant relationship
Breast Cancer Survivor (n = 23) Control (n = 23)
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Table 15.  Summary of scapula kinematic ANOVA analyses.  F-values, p-values, partial 
eta-squared (eta2), and observed power for the flexion task analyses. 
 
 
 
 
Variable Comparison F-Value P-Value Eta2 Power
anterior/posterior 
tipping
Group 2.145 0.150 0.049 0.299
Angle 44.75 <0.001 0.516 1.000
Group x Angle 0.380 0.990 0.001 0.057
Upward/downward 
rotation
Group 2.183 0.147 0.049 0.303
Angle 142.8 <0.001 0.773 1.000
Group x Angle 0.132 0.941 0.003 0.074
Internal/external 
rotation
Group 1.129 0.294 0.026 0.180
Angle 88.87 <0.001 0.679 1.000
Group x Angle 1.164 0.326 0.027 0.307
Elevation/depression Group 1.357 0.354 0.046 0.203
Angle 202.2 <0.001 0.878 1.000
Group x Angle 0.842 0.475 0.029 0.226
Protraction/Retraction Group 0.340 0.564 0.012 0.087
Angle 55.19 <0.001 0.663 1.000
Group x Angle 0.918 0.436 0.032 0.244
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Table 16.  Mean, SD, 95% CI, and effect size for scapula kinematics (degrees) during the 
flexion task 
 
 
  
Mean SD 95%CI Mean SD 95%CI ES
anterior/posterior 
tipping
Start -11.1 7.00  -14.3, -7.91 -14.6 7.79  -17.8, -11.5 0.45
30 º -11.3 8.02  -14.8, -7.79 -14.9 8.19  -18.4, -11.4 0.45
60 º -15.4 9.73  -19.4, -11.3 -19.4 9.10  -23.5, -15.4 0.42
90º -19.0 10.9  -23.8, -14.3 -22.8 11.3  -27.6, -18.0 0.33
upward/downward 
rotation
Start 7.14 7.25 4.17, 10.1 3.62 6.56 0.64, 6.59 0.49
30 º 11.3 5.38 8.46, 14.2 8.98 7.74 6.12, 11.9 0.30
60 º 21.3 6.72 18.0, 24.7 18.6 8.70 15.3, 22.0 0.31
90º 32.1 12.4 26.8, 37.4 28.3 12.2 23.0, 33.7 0.30
internal/external 
rotation
Start 34.3 14 29.4, 39.2 37.8 8.02 32.9, 42.7 0.25
30 º 38.8 16.4 33.3, 44.4 42 8.58 36.4, 47.6 0.2
60 º 43.2 18.7 36.7, 49.6 48.2 9.99 41.7, 54.6 0.27
90º 45.6 21.0 38.5, 52.8 51.6 10.76 44.4. 58.7 0.29
elevation/depression# Start 14 5.22 11.0, 17.0 16 6.16 13.0, 19.0 0.32
30 º 16.2 5.36 12.9, 19.5 18.1 6.89 14.9, 21.4 0.26
60 º 21.4 6.24 17.9, 25.0 24.5 7.10 20.9, 28.0 0.43
90º 27.9 6.23 23.8, 31.8 31.5 8.78 27.5, 35.5 0.41
protraction/retraction# Start -22.1 13.1  -27.5, -16.7 -18.8 6.08  -24.2, -13.4 0.25
30 º -22.0 13.5  -27.6, -16.4 -19.4 6.44  -25.1, -13.8 0.19
60 º -23.4 14.6  -29.6, -17.3 -21.2 7.41  -27.3, -15.0 0.16
90º -28.2 16.8  -34.9, -21.4 -26.9 6.44  -33.6, -20.2 0.08
# (n = 15) for each group
Breast Cancer Survivor (n = 22) Control (n = 22)
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Table 17.  Summary of scapula kinematic ANOVA analyses.  F-values, p-values, partial 
eta-squared (eta2), and observed power for the scaption task analyses. 
 
 
 
Variable Comparison F-Value P-Value Eta2 Power
anterior/posterior 
tipping
Group 3.568 0.066 0.078 0.455
Angle 19.69 <0.001 0.319 1.000
Group x Angle 0.251 0.861 0.006 0.097
Upward/downward 
rotation
Group 1.454 0.235 0.033 0.218
Angle 133.4 <0.001 0.761 1.000
Group x Angle 0.130 0.942 0.003 0.073
Internal/external 
rotation
Group 0.285 0.597 0.007 0.082
Angle 49.45 <0.001 0.541 1.000
Group x Angle 0.026 0.994 0.001 0.054
Elevation/depression Group 0.309 0.583 0.013 0.083
Angle 215.6 <0.001 0.900 1.000
Group x Angle 0.040 0.989 0.002 0.057
Protraction/Retraction Group 5.153 0.032* 0.177 0.587
Angle 96.87 <0.001 0.801 1.000
Group x Angle 0.171 0.915 0.007 0.080
* Significant relationship
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Table 18.  Mean, SD, 95% CI, and effect size for scapula kinematics during the scaption 
task.  
 
 
 
Mean SD 95%CI Mean SD 95%CI ES
anterior/posterior 
tipping
Start -10.3 6.74 -13.5,   -7.08 -14.8 8.10 -18.0,   -11.6 0.55
30 º -10.1 7.60 -13.4,   -6.74 -14.9 7.82 -18.3,   -11.6 0.62
60 º -12.6 9.87 -16.5,   -8.71 -17.8 8.33 -21.7,   -13.9 0.52
90º -16.6 11.3 -21.1,   -12.1 -20.3 9.59 -24.8,   -15.8 0.33
upward/downward 
rotation
Start 6.37 8.31 3.00, 9.74 2.52 7.32 -0.85, 5.89 0.46
30 º 10.8 6.96 7.60, 13.9 7.64 7.74 4.47, 10.8 0.40
60 º 19.5 9.07 15.6, 23.4 16.9 9.24 12.9, 20.8 0.28
90º 29.8 13.8 24.0, 35.6 27.5 13.2 21.7, 33.3 0.17
internal/external 
rotation
Start 33.7 10.6 29.3, 37.6 35.7 7.18 31.8, 39.6 0.19
30 º 37.4 12.0 32.8, 41.5 38.7 7.64 34.3, 43.0 0.11
60 º 41.1 14.1 36.0, 46.1 42.9 8.60 37.9, 47.9 0.13
90º 44.2 18.3 37.7, 50.7 46.0 10.9 39.5, 52.5 0.1
elevation/depression# Start 14.1 5.54 10.7, 17.5 15.7 6.32 12.3, 19.1 0.26
30 º 17.1 5.99 13.3, 20.8 18.4 7.15 14.6, 2.1 0.18
60 º 22.5 6.68 18.5, 26.6 23.8 7.60 19.7, 27.9 0.17
90º 28.5 6.00 24.4, 32.6 29.9 8.08 25.8, 34.0 0.17
protraction/retraction# Start -25.6 5.67 -28,9,   -22.7 -20.1 5.96 -23.5,   -16.8 0.92
30 º -26.2 5.67 -29.5,   -22.7 -21.1 6.14 -24.5,   -17.7 0.81
60 º -27.9 6.18 -31.3,   -24.5 -23 5.64 -26.4,   -19.7 0.79
90º -32.6 6.38 -36.0,   -29.3 -27.6 5.38 -31.0,  -24.2 0.79
# (n = 13) for each group
Breast Cancer Survivor (n = 22) Control (n = 22)
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Table 19.  Summary of scapula kinematic ANOVA analyses.  F-values, p-values, partial 
eta-squared (eta2), and observed power for the reaching task analyses 
 
 
 
Variable Comparison F-Value P-Value Eta2 Power
anterior/posterior tipping Group 3.067 0.087 0.068 0.402
Angle 33.23 <0.001 0.442 1.000
Group x Angle 0.507 0.678 0.012 0.151
Upward/downward 
rotation
Group 0.885 0.352 0.021 0.151
Angle 113.5 <0.001 0.730 1.000
Group x Angle 0.090 0.966 0.002 0.066
Internal/external rotation Group 0.483 0.491 0.011 0.104
Angle 125.1 <0.001 0.749 1.000
Group x Angle 2.953 0.035* 0.066 0.669
Elevation/depression Group 0.358 0.555 0.015 0.089
Angle 93.01 <0.001 0.795 1.000
Group x Angle 0.264 0.851 0.011 0.098
Protraction/Retraction Group 0.212 0.649 0.009 0.073
Angle 8.419 <0.001 0.260 0.991
Group x Angle 2.400 0.075 0.091 0.577
* Significant relationship
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Table 20.  Mean, SD, 95% CI, and effect size for scapula kinematics (degrees) during the 
reaching task.  
 
 
  
Mean SD 95%CI Mean SD 95%CI ES
anterior/posterior tipping Start -12.6 6.69 -15.7,    -9.47 -16.1 7.73 -19.2,    -12.9 0.45
30 º -12.8 7.78 -16.2,    -9.43 -17 7.95 -20.4,    -13.6 0.53
60 º -15.7 9.55 -19.9,  -11.6 -20.7 9.72 -24.8,    -16.6 0.51
Max -19.7 12.5 -25.0,    -14.5 -25.3 12.00 -30.6,    -20.1 0.45
upward/downward 
rotation
Start 6.04 7.47 3.09, 8.98 4.23 6.17 1.28, 7.18 0.24
30 º 12.1 6.80 9.21, 15.0 9.76 6.61 6.87, 12.7 0.34
60 º 21.2 8.29 17.6, 24.9 19.5 8.66 15.9, 23.2 0.19
Max 31.6 15.7 25.3, 38.0 28.6 13.8 22.2, 34.9 0.19
internal/external rotation Start 34.4 10.7 30.7, 38.3 35.1 6.54 31.3, 39.0 0.07
30 º 37.8 12.0 33.4, 42.1 38.5 7.87 34.2, 42.9 0.06
60 º 43.5 14.3 38.3, 48.7 45.5 9.40 40.3, 50.7 0.14
Max 50.2 19.5 43.4, 56.9 56.1 10.5 49.4, 62.9 0.31
elevation/depression# Start 15.7 5.58 12.6, 19.2 16.5 6.5 13.0, 20.0 0.12
30 º 18.9 5.46 15.4, 22.3 20.1 6.57 16.6, 23.5 0.19
60 º 23.9 5.59 20.3, 27.4 25.8 6.74 22.2, 29.3 0.28
Max 26.9 8.03 22.3, 31.5 28.9 8.03 24.3, 33.5 0.24
protraction/retraction# Start -20.6 16.6 -27.3,    -13.8 -21.7 3.30 -28.6,    -14.9 0.07
30 º -21.4 16.9 -28.4,    -14.4 -22.7 3.04 -29.7,    -15.8 0.08
60 º -22.1 18.2 -29.6,    -14.6 -24.4 3.37 -31.9,    -16.9 0.13
Max -22.2 20.3 -30.6,    -13.9 -26.7 3.02 -35.0,    -18.4 0.22
# (n = 13) for each group
Breast Cancer Survivor (n = 22) Control (n = 22)
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Table 21.  Mean, SD, 95% CI, p value, and effect size for maximum humeral elevation 
angle during the tasks (flexion, scaption, and reaching) 
 
 
Mean SD 95%CI Mean SD 95%CI P ES
Flexion 122.5 13.92 117.2, 127.9 130.1 10.84 124.7, 135.4 0.051 0.546
Scaption 122.3 13.14 116.2, 128.4 127.1 15.19 121.0, 133.2 0.266 0.316
Reaching 95.54 13.43 91.03, 102.0 104.4 12.14 98.86, 109.9 0.049* 0.660
* Significant differences
Breast Cancer Survivor Control
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Table 22.  Correlations among the DASH and active shoulder ROM 
 
 
r p
Flexion -0.615 0.002*
0° External Rotation -0.133 0.544
90° External Rotation -0.653 0.001*
90° Internal Rotation -0.271 0.211
Extension -0.294 0.184
*Significant relationship
Breast Cancer 
Survivor
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Table 23.  Correlations among the DASH and passive shoulder ROM   
 
 
r p
Flexion -0.544 0.007*
0°External Rotation -0.013 0.954
90°External Rotation -0.637 0.001*
90° Internal Rotation -0.165 0.451
Extension 0.091 0.686
*Significant relationship
Breast Cancer 
Survivor
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Table 24.  Correlations among the DASH and shoulder girdle strength    
 
 
r p
Abduction and 
Upward Rotation
-0.477 0.021*
Depression and 
Adduction
-0.635 0.001*
Flexion -0.507 0.014*
External Rotation -0.350 0.102
Internal Rotation -0.523 0.010*
Scaption -0.558 0.006*
Adduction -0.603 0.002*
*Significant relationship
Breast Cancer 
Survivor
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Table 25.  Correlations among the DASH and active cervical spine  
 
 
r p
Flexion -0.073 0.741
Extension -0.363 0.089
Left 
Sidebending
-0.269 0.215
Right 
Sidebending
-0.135 0.540
Left 
Rotation
-0.476 0.022*
Right 
Rotation
-0.213 0.330
*Significant relationship
Breast Cancer 
Survivor
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Table 26.  Correlations among the PSS and active shoulder ROM 
 
 
r p
Flexion 0.615 0.004*
0° External Rotation 0.086 0.704
90° External Rotation 0.416 0.054
0° Internal Rotation -0.004 0.985
Extension 0.292 0.199
*Significant relationship
Breast Cancer 
Survivor
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Table 27.  Correlations among the PSS and passive shoulder ROM  
 
 
r p
Flexion 0.600 0.003*
0° External Rotation 0.003 0.989
90° External Rotation 0.424 0.049*
90 °Internal Rotation -0.101 0.656
Extension -0.077 0.738
*Significant relationship
Breast Cancer 
Survivor
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Table 28.  Correlations among the PSS and shoulder girdle strength    
 
 
r p
Abduction and 
Upward Rotation
0.393 0.070
Depression and 
Adduction
0.377 0.084
Flexion 0.458 0.032*
External Rotation 0.300 0.176
Internal Rotation 0.441 0.043*
Scaption 0.436 0.043*
Adduction 0.449 0.036*
*Significant relationship
Breast Cancer 
Survivor
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Table 29.  Correlations among the PSS and active cervical spine ROM   
 
 
r p
Flexion 0.324 0.142
Extension 0.408 0.059
Left 
Sidebending 0.449 0.036*
Right 
Sidebending 0.303 0.171
Left Rotation 0.517 0.014*
Right 
Rotation 0.542 0.009*
*Significant Relationship
Breast Cancer 
Survivor
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Table 30.  Item analysis of the DASH 
 
 
ROM Fexion 1,2,4,5,6,7,8,9,12,13,15,16,17,18,19,20,21
External Rotation at 0° 6,12
External Rotation at 90° 1,3,7,8,9,12,13,14,16,17,18,19,20
Internal Rotation 1,2,4,7,8,912,13,14,16,17,18,19,20
Extension -
Strength Scapular Abducation & Upward Rotation 5,6,7
Scapular Depression & Adduction 1,3,5,6,10,11,18,19
Humeral Flexion 1,3,4,5,6,7,8,9,11,12,13,15,18,19,20,21
Humeral External Rotation 1,3,6,7,8,10,12,13,14,15,18,19
Humeral Internal Rotation 1,3,7,8,9,10,11,12,13,14,15,18,19
Shoulder Scaption 4,5,6,7,8,9,11,12,13,15
Shoulder Horizontal Adduction 1,7,8,11,18
DASH
Corresponding Items
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Table 31.  Item analysis of the PSS 
 
 
ROM Fexion 3,4,5,6,7,9,12,13,14,15,16,17,18,19
External Rotation at 0° -
External Rotation at 90° 3,6,7,16,17,18,19
Internal Rotation 1,2,3,4,5,17,18,19
Extension 1,2,3
Strength Scapular Abducation & Upward Rotation 9,16,18
Scapular Depression & Adduction 11,16
Humeral Flexion 4,5,6,7,9,12,13,14,15,16,17,18,19
Humeral External Rotation 5,6,7,11,15,16,17,18,19
Humeral Internal Rotation 4,5,11,17,18
Shoulder Scaption 5,6,7,9,12,13,14,15,16,18
Shoulder Horizontal Adduction 4,17,18
PSS
Corresponding Items
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Figure 1.  Electromagnetic tracking sensor placement 
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Figure 2  Reaching task demonstration 1 
 
 
Figure 3.  Reaching task demonstration 2 
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Figure 4   Humeral elevation task in the sagittal plane demonstration 1 
 
 
Figure 5  Humeral elevation task in the sagittal plane demonstration 2 
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Figure 6.  Humeral elevation task in the scapula plane 
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Figure 7.  Supine flexion ROM 
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Figure 8.  Supine ER at 0° ROM 
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Figure 9.  Supine ER at 90° ROM 
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Figure 10.  Supine IR at 90° ROM 
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Figure 11.  Prone extension ROM 
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Figure 12.  Scapula abduction and upward rotation strength assessment 
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Figure 13.  Scapula depression and adduction strength assessment 
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Figure 14.  Shoulder flexion strength assessment 
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Figure 15.  Shoulder external rotation strength assessment 
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Figure 16.  Shoulder internal rotation strength assessment 
 
 
 
190 
 
Figure 17.  Shoulder scaption strength assessment 
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Figure 18.  Shoulder horizontal adduction strength assessment 
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Figure 19.  Cervical flexion ROM 
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Figure 20.  Cervical extension ROM 
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Figure 21.  Cervical left side bending ROM 
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Figure 22.  Cervical right side bending ROM 
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Figure 23.  Cervical left rotation ROM 
 
 
197 
 
Figure 24.  Cervical right rotation ROM 
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Figure 25.  Scapula orientation and axes 
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Figure 26. Mean scapula posterior tipping during the flexion task 
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Figure 27. Mean scapula upward rotation during the flexion task 
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Figure 28. Mean scapula external rotation during the flexion task 
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Figure 29. Mean scapula elevation during the flexion task 
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Figure 30. Mean scapula protraction during the flexion task 
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Figure 31. Mean scapula posterior tipping during scaption task 
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Figure 32. Mean scapula upward rotation during the scaption task 
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Figure 33. Mean scapula external rotation during the scaption task 
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Figure 34.  Mean scapula elevation during the scaption task 
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Figure 35.  Mean scapula protraction during the scaption task 
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Figure 36. Mean scapula posterior tipping during the reaching task 
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Figure 37. Mean scapula upward rotation during the reaching task 
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Figure 38. Mean scapula external rotation during the reaching task 
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Figure 39. Mean scapula elevation during the reaching task 
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Figure 40. Mean scapula protraction during the reaching task 
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Figure 41. Scatterplot for correlation between the DASH and active flexion ROM 
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Figure 42. Scatterplot for correlation between DASH and active 90° external rotation 
ROM 
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Figure 43. Scatterplot for correlation between the DASH and passive flexion ROM 
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Figure 44. Scatterplot for correlation between the DASH and passive 90° external 
rotation ROM 
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Figure 45. Scatterplot for correlation between the DASH and scapula abduction and 
upward rotation strength 
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Figure 46. Scatterplot for correlation between the DASH and scapula depression and 
adduction strength 
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Figure 47. Scatterplot for correlation between the DASH and flexion strength 
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Figure 48. Scatterplot for correlation between the DASH and internal rotation strength 
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Figure 49. Scatterplot for correlation between the DASH and scaption strength 
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Figure 50. Scatterplot for correlation between the DASH and adduction strength 
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Figure 51. Scatterplot for correlation between the DASH and cervical left rotation 
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Figure 52. Scatterplot for correlation between the PSS and active flexion ROM 
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Figure 53. Scatterplot for correlation between PSS and passive flexion ROM 
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Figure 54. Scatterplot for correlation between the PSS and passive 90° external rotation 
ROM 
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Figure 55. Scatterplot for correlation between the PSS and flexion strength 
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Figure 56. Scatterplot for correlation between the PSS and internal rotation strength 
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Figure 57. Scatterplot for correlation between the PSS and scaption strength 
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Figure 58. Scatterplot for correlation between the PSS and adduction strength 
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Figure 59. Scatterplot for correlation between the PSS and cervical left side bending 
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Figure 60. Scatterplot for correlation between the PSS and cervical left rotation 
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Figure 61. Scatterplot for correlation between the PSS and cervical right rotation 
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Appendix I: 
Functional Questionnaire 1 - DASH 
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Functional Questionnaire 1 – DASH (continued) 
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Appendix II: 
Functional Questionnaire 2, Part 1, PSS 
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Functional Questionnaire 2, Part 2, PSS 
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